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  Breast cancer is the most common cancer afflicting women globally, 
and its progression is the result of complex genetic and molecular processes. 
Once breast cancer acquires metastatic features, no effective cure is available, 
and treatments are meant for palliative purposes. Hence, a search of molecular 
biomarkers for the diagnosis and treatment of breast cancer holds great 
importance. One such molecule is the complement component 1, q 
subcomponent binding protein (C1QBP), which has been reported to play 
important roles in cancer development, including proliferation and metastasis. 
Although much work has been done on C1QBP and its role in cancer, the 
mechanistic role of C1QBP in breast cancer has not been fully elucidated. 
Therefore, the current study aims to determine the effect of C1QBP on breast 
cancer progression, and elucidate the underlying molecular pathways, to 
provide a better understanding of the roles of C1QBP in breast cancer.  
 Immunohistochemical analysis of C1QBP in tissue microarrays 
(TMAs) of breast cancer, revealed significant associations with age, tumor 
size and lymph node spread. Furthermore, in progesterone receptor-positive 
patients, C1QBP was found to be an independent predictor of tumor size, after 
performing multivariate analysis. Immunostaining of C1QBP in breast cancer 
TMAs appeared granular in nature and predominantly localized to the 
cytoplasm. In MDA-MB-231 and T47D breast cancer cell lines, 
immunofluorescence staining of C1QBP indicated that it was mainly localized 
to the mitochondria. The depletion of C1QBP in a progesterone receptor-
positive breast cancer cell line, T47D, diminished cell proliferation, 
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substantiating the data from the TMAs. In addition, depletion of C1QBP in 
MDA-MB-231 breast cancer cells, a metastatic cell line, decreased cell 
proliferation and cell migration, but not cell invasion, while overexpression of 
C1QBP in MDA-MB-231 cells increased cell proliferation, migration and 
invasion. Further evaluation into the cell cycle profile after overexpression of 
C1QBP, showed an elevated G1 to S progression, accompanied by changes in 
Cyclin D1 and CDK6 expression. Chemoresistance studies showed that 
C1QBP affects chemosensitivity to Doxorubicin hydrochloride treatment. 
Furthermore, constitutively higher levels of C1QBP were observed in 
Doxorubicin hydrochloride-resistant MCF7 cells compared to its parental 
counterpart.  
 Using gene microarray analysis and an antibody array, C1QBP was 
found to be involved in the regulation of p-STAT3 (Y705) and the ERK1/2 
signalling pathways. Overexpression of C1QBP increased p-ERK1/2 and p-
MEK1/2, both of which are main regulators of the ERK1/2 pathways. In 
addition, C1QBP also affected the downstream targets of p-STAT3 (Y705), 
such as Bcl2, Mcl1 and p53. These are cell survival signals, and could 
contribute to the increase of cell survival seen in C1QBP-overexpressing cells. 
Additionally, the p-STAT3 and ERK1/2 pathways are also known to be 
upstream regulators of Cyclin D1, and hence, could indirectly affect cell 
proliferation. Cell migration and cell invasion have also been reported to be 
potentially regulated by these two pathways. The antibody array also revealed 




 SILAC-immunoprecipitation quantitative proteomics was carried out 
to determine C1QBP’s interactome, and YB-1 was identified as one of its 
interacting partners. Further studies revealed that this interaction is partially 
involved in cell proliferation, migration and invasion, and other factors may 
also influence these functions. Taken together, the findings provided a further 
understanding of the role of C1QBP in breast cancer, and may be useful for 
future development of a molecular target in breast cancer.  
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1.1 Breast cancer 
1.1.1 Epidemiology of breast cancer 
The breast or mammary gland contains milk-secreting lobules, which 
drain into ducts that coalesce into the larger lactiferous ducts, which empty 
into the nipple (Marieb et al., 2014). The breast is only functional in lactating 
females when milk is produced to nourish the infant. Breast cancer has been 
reported to be the 2
nd
 most common cancer and ranked 5
th
 as the cause of 
cancer deaths worldwide. In the global female population, an estimated 1.7 
million breast cancer cases and 521,900 breast cancer deaths have been 
recorded, making it the most frequently diagnosed type of cancer and leading 
cause of cancer death among females (Ferlay, 2013).  Incidence rates of breast 
cancer vary across the world, where slightly more cases are seen in less 
developed countries compared to developed countries. The differences in rates 
reflect the accessibility of early intervention and risk factors (Torre et al., 
2015). Breast cancer death rates have seen a plateau or decline in Northern 
America and developed European countries, mainly due to advanced 
treatments and early detection via mammography (Bosetti et al., 2012). On the 
contrary, breast cancer incidence is increasing in the South America, Africa 
and Asia region, most likely caused by westernized lifestyles and lack of 
facilities for diagnosis and treatment (Youlden et al., 2012).   
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The Singapore Cancer Registry Interim Annual Report released in May 
2015, indicated that breast cancer is the most common cancer among female 
residents of Singapore from the year 2010 to 2014 (Figure 1.1). 
 
Figure 1.1. Percentages of 10 most frequent cancers in Singapore females, 
2010-2014. (Used with permission from National Registry of Diseases Office, 
Health Promotion Board) 
 Likewise, the mortality rate for breast cancer is the highest among 
other cancer deaths in Singapore’s female population. It was also noted that 
the age-standardized incidence rate of newly diagnosed breast cancer has been 
increasing drastically over the years from 23.8 per 100000 in 1975-1979 to 
64.7 per 100000 in 2010-2014. 
 
Figure 1.2. Age-standardized incidence rates for Singapore female breast 
cancer, 1975-2014. (Used with permission from National Registry of Diseases 




 The incidence rate is highest in Chinese females, followed by Malay 
and Indian females. There is also a steep increase of incidence rate in the 30-
39 age group onwards with the highest incidence rate recorded in the 60-69 
age group. On a more positive note, survival rates of breast cancer patients 
were slightly increased for all ethnicities and age group (except for the 65-74 
age group) in the years 2010-2014 compared to 2005-2009 (NRDO, 2015). 
1.1.2 Risk factors of breast cancer 
Breast cancer predisposition is not the same among women. Several 
risk factors have been identified to increase the chances of breast cancer 
development. These include biological factors, hormonal factors and lifestyle 
choices.  
1.1.2.1 Biological factors – family history, age and breast conditions 
Risk factors such as family history, age and breast conditions are 
biological risk factors for breast cancer. Epidemiological studies have shown 
that individuals with predisposing gene mutations, have a 50-85% chance of 
having breast cancer (Evans, 2013). In addition, it was estimated that women 
with a first degree relative having a history of breast cancer, have a higher risk 
of developing cancer, compared to women without such history (Dumalaon-
Canaria et al., 2014). The likelihood is increased if the first degree relatives 
were affected by breast cancer, when they are below 40 years of age (Claus et 
al., 1994). Inheritable gene mutations, such as BRCA1 and BRCA2 mutations, 
have been associated with a cumulative lifetime risks of 85% for breast cancer 
(Evans et al., 2008).  
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Age has also been identified as a significant risk factor of breast 
cancer. Approximately 75% of breast cancer cases happen in postmenopausal 
women. The risk of breast cancer for women in their 70s is 1 to 30, which is 
about 8 fold higher than women in their 30s (NBOCC, 2009).  
Physically, an individual’s breast density is a risk factor of breast 
cancer. It has been estimated that women with breast density of more than 
75%, are 4 times more likely to develop breast cancer, than women with less 
dense breast (Dumalaon-Canaria et al., 2014). 
1.1.2.2 Hormonal factors 
The hormonal environment of breast tissue has been associated with 
increased risk factor of breast cancer. Cumulative exposure to estrogen 
influenced by early menarche, late menopause, late first pregnancy, not having 
children and not breastfeeding has been associated with a higher risk of breast 
cancer (Evans, 2013; Dumalaon-Canaria et al., 2014). A meta-analysis of over 
100 epidemiological studies, showed that the risk of breast cancer is increased 
by 5% per year for every younger year of menarche. Additionally, the use of 
oral contraceptive pill has been associated with a 20% increase of breast 
cancer risk, which persists for 10 years after use (Evans, 2013).  The strongest 
association between these reproductive factors and breast cancer risks, exist 
for hormone receptor-positive breast cancer (Anderson et al., 2014).  
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1.1.2.3 Lifestyle factors – physical activity, diet, body size and alcohol 
consumption 
Physical activity, diet, body size and alcohol consumption have been 
associated with the development of breast cancer. There is convincing 
evidence that breast cancer risk is inversely related to physical activity. 
Constant physical activity from adolescence to adulthood has been shown to 
reduce the risk of breast cancer by approximately 30% (Maruti et al., 2008; 
Colditz et al., 2014). Nine percent of breast cancer death has been attributed to 
obesity. In addition, weight gain and abdominal fat accumulation have been 
associated with higher risk of breast cancer in postmenopausal women 
(Dumalaon-Canaria et al., 2014). Dietary factors, such as high cholesterol and 
triglycerides intake, have also been shown to increase the risk of breast cancer 
while diets high in fibres, fruits and vegetable, have been shown to be 
protective against breast cancer (Rossi et al., 2014).  Also, intake of alcohol is 
considered a risk factor for breast cancer. Alcohol has been classified by the 
International Agency for Research on Cancer (IARC) as ‘carcinogenic to 
human’ with alcohol being attributed to 5% of breast cancer-related death 
(Colditz et al., 2014; Dumalaon-Canaria et al., 2014). 
1.1.3 Symptoms of breast cancer 
The most common presentation of breast cancer is a painless lump in 
the breast. Other symptoms are changes in the size and shape of the breast, 
nipple discharge and changes, breast pain and breast skin changes. These 
symptoms are usually evaluated in terms of their duration, persistence and 
variation with the menstrual cycle (Morrow, 2014). However, it should also be 
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noted that not all breast lumps are malignant (Bleicher, 2014). In addition, 
some early stage breast cancers are asymptomatic. Therapeutic intervention at 
an earlier stage of malignancy will greatly increase survival chances (Benson, 
2013). Thus, regular breast examination and screening, are important for early 
detection of breast cancer. In agreement, trials have shown that in women over 
50 years old, breast screening reduced the mortality rate of breast cancer by 25 
to 30% (Benson, 2013). 
1.1.4 Diagnosis of breast cancer 
Diagnosis of breast cancer is done based on triple assessment, which is 
a combination of clinical assessment, radiological assessment and pathological 
assessment. Clinical assessment includes clinical breast examination, while 
radiological and pathological assessments, are based on imaging techniques 
and biopsy, respectively. Each assessment will be categorised as either 
normal, benign, indeterminate, suspicious or malignant. The ‘worse’ 
conclusion from the clinical and radiological assessment, must be used to 
interpret the pathological assessment (Mathew and Cheung, 2013).  
1.1.4.1 Breast examination 
Breast examination can be divided into breast self-examination, or 
clinical breast examination. As the name suggests, breast self-examination can 
be perform by women themselves, to detect any presence of lumps or changes 
in the appearance of the breasts. It is recommended to be done monthly, a 
week after menstruation. Although the effectiveness of breast self-examination 
in reducing breast cancer mortality seemed weak, it has been shown to assist 
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in the early detection of breast cancer (Kamproh and Fungpong, 2008; Lee and 
Elmore, 2014).  
Clinical breast examination is done by a certified health professional. 
Several studies have assessed the effectiveness of clinical breast examination, 
combined with mammography, in reducing breast cancer mortality. The final 
conclusion of its effectiveness is still in debate, where some argued that higher 
false negative or false positive rates are observed with clinical breast 
examination (Chiarelli et al., 2009; Lee and Elmore, 2014). Nonetheless, it 
was also reported that the quality of clinical breast examination, can be greatly 
improve and beneficial, when it is done by highly trained personnel (Chiarelli 
et al., 2009; Lee and Elmore, 2014). 
1.1.4.2 Radiological assessment – mammography, ultrasonography, 
magnetic resonance imaging and radionuclide breast imaging 
Mammography is the mainstay of breast cancer screening. 
Randomized clinical trials conducted have shown that breast screening using 
mammography, reduced mortality rate by 30% (Lewin, 2011). Women at the 
age of 40 and above, are recommended to attend yearly mammography 
screenings. Screening should start about 7 to 10 years earlier for women with 
higher risk of breast cancer, such as for women with family history or prior 
chest radiation therapy (Jochelson, 2014). A weakness of traditional film 
mammography, is its reduced sensitivity with dense breast tissue. Digital 
mammography has largely replaced film mammography and improved 
sensitivities in this situation (Lewin, 2011; Jochelson, 2014). In addition, 
several advancements have been made such as digital breast tomosynthesis 
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and contrast-enhanced mammography, which could improve accuracy and 
sensitivity of digital mammography (Jochelson, 2014).  
Ultrasonography is another widely used method to aid diagnosis of 
breast cancer. Apart from differentiating cystic and solid mass in the breast, 
ultrasonography can be used to distinguish benign and malignant 
characteristics of the tumor (Lewin, 2011; Jochelson, 2014). It is also used to 
confirm negative mammograms of palpable mass in the breast. Additionally, 
this method is also applied for guiding core needle biopsies (Lewin, 2011).  A 
pitfall of the ultrasonography method compared to mammography, is its 
inefficiency of detecting ductal carcinoma in situ and microcalcifications 
(Jochelson, 2014). The reproducibility of this technique is also highly 
dependent on the operator of the ultrasound transducer, thus, reproducibility is 
sub-optimal (Sedgwick, 2014). Nevertheless, the development of Automated 
Whole Breast Ultrasound, reduces dependency on the operators and increases 
reproducibility of the results (Jochelson, 2014). 
Magnetic resonance imaging (MRI) is a breast cancer detection 
technique, that uses gadolinium contrast medium with no radiation exposure 
(Weinstein and Roth, 2014). Unlike mammography and ultrasonography, the 
use of MRI enabled the determination of tumor size, and presence of 
multifocal and multicentric tumors. Furthermore, the detection of contralateral 
disease of the breast and lymph node spread are possible with MRI (Lewin, 
2011). Although the sensitivity of MRI in detecting invasive breast cancer 
reaches almost a 100%, its specificity is low resulting in more false-positive 
results (Pointon and Down, 2013; Weinstein and Roth, 2014). The MRI is 
especially useful for screening of high-risk younger women – below 50 years 
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old – where repeated radiation exposure is of concern, or screening by 
mammography alone is not satisfactory. With a combination of both MRI and 
mammography, the sensitivity and specificity of cancer detection are increased 
(Pointon and Down, 2013). Other ways being develop to improve the 
specificity of MRI are the addition of Diffusion-Weighted Imaging and MR 
spectroscopy to conventional MRI (Jochelson, 2014). 
Radionucleotide breast imaging detects abnormalities based on the 
physiology of the breast, and it is not affected by breast densities (Jochelson, 
2014). In this technique, low-level radioactive compounds will be introduced 
into the body or specific sites for subsequent detection. The commonly used 
traces are sestamibi and 18F-fluorodeoxyglucose (18F-FDG) (Jochelson, 
2014). Sestamibi imaging is usually indicated for evaluating the extent of 
breast cancer in known patients, and in patients where MRI cannot be 
performed. Specificity and sensitivity of breast cancer detection using 
sestamibi, are greatly improved using detector systems, such as the breast-
specific gamma imaging system. Though, it is to be noted that sestamibi 
imaging is dependent on patients’ hormone status (Jochelson, 2014). On the 
other hand, 18F-FDG is not dependent on both breast density and hormone 
status. It is widely utilized for whole body Positron Emission Tomography 
(PET) to determine the stage and progression of lymphoma and solid tumors. 
However, the sensitivity for primary breast tumor detection is very low 
(Jochelson, 2014). Positron Emission Mammography (PEM) using 18F-FDG 
was developed for improved breast imaging, and its specificity seemed to be 
better than that of MRI (Berg et al., 2011).  In addition, PEM could also direct 
biopsy of the lesion (Jochelson, 2014). However, usage of radionucleotide 
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imaging methods need to be limited, due to their radiation dose (Jochelson, 
2014). 
1.1.4.3 Pathological assessment – fine needle aspiration cytology and 
needle core and surgical biopsy 
A simple and fast technique: fine-needle aspiration (FNA) is a low-
cost, relatively comfortable procedure, that can be helpful in diagnosis of 
malignancy (Prier, 2011). Despite that, the use of FNA has been markedly 
limited due to frequent poor sampling, inability to distinguish ductal 
carcinoma in situ and invasive carcinoma, difficulty in characterizing receptor 
status, and most importantly, FNA has a high false positive rate with low 
accuracy (Prier, 2011; Sung and Comstock, 2014). Consequently, FNA is 
routinely used for sampling of axillary nodes or lesions which are not suitable 
for biopsy (Sung and Comstock, 2014).  
Core needle biopsy is usually done using an automated or vacuum-
assisted 14-gauge needle, to obtain breast tissue samples for analysis. The 
method is superior to that of FNA as sufficient samples are obtained, for more 
accurate histological diagnosis and immunohistochemical analysis. 
Additionally, it is also possible to discriminate between in situ and invasive 
cancer (Prier, 2011). Core needle biopsy is further enhanced by assistance 
from imaging procedures, such as ultrasound and MRI. Ultrasound-guided 
core biopsy is less invasive, accurate and permits better access to lesions 
which are difficult to reach (Sung and Comstock, 2014).  
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1.1.5 Breast cancer classification 
Breast cancer development arises from a complex series of molecular 
events, that oversee the progression of breast cells from normal cells to in situ 
carcinoma, and eventually invasive and metastatic disease (Simpson et al., 
2005; Bombonati and Sgroi, 2011). Since development of breast cancer entails 
the disease with altered pathological and clinical features at different stages, 
classification of breast cancer is important for diagnosis and treatment of the 
disease. Breast cancer can be classified using a few methods. Staging of breast 
cancer according to the American Joint Committee on Cancer (AJCC) remains 
the mainstay in evaluating prognosis and treatment of a breast cancer patient 
(Yalcin, 2013). The World Health Organization (WHO) classification of 
breast cancer, is mostly a histopathological classification of breast cancer, 
which is based on morphological characteristics of the cells (Viale, 2012). 
Another way to categorize breast cancer is the grouping of the disease based 
on its molecular features. 
1.1.5.1 American Joint Committee on Cancer (AJCC) staging system 
The AJCC staging system uses TNM classification where T defines the 
size and extent of the primary breast tumor, N defines the spread to 
neighbouring lymph nodes, and M defines the presence of distant metastases 
(Harris, 2014). Based on this features, the staging of breast cancer is as 
follows: 
Stage 0 : Carcinoma in situ 
Stage I : Primary tumor of 2 cm or less with no lymph node metastasis 
Stage IIA : Primary tumor not detected with lymph node spread in axillary 
lymph nodes; or primary tumor of 2 cm or less with lymph 
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node spread in axillary lymph nodes; or primary tumor larger 
than 2 cm but smaller than 5 cm without lymph node spread 
Stage IIB : Primary tumor of more than 2 cm but less than 5 cm with 
axillary lymph node spread; or primary tumor size is larger than 
5 cm without lymph node spread 
Stage IIIA : Primary tumor not detected but presence of fixed or matted 
axillary lymph node metastasis or metastasis to internal 
mammary nodes; or tumor size of less than 5 cm with fixed or 
matted axillary lymph node metastasis or metastasis to internal 
mammary nodes; or tumor size of more than 5 cm with axillary 
lymph node spread; or tumor size of more than 5 cm with fixed 
or matted axillary lymph node spread or internal mammary 
nodes spread  
Stage IIIB : Primary tumor of any size that extent to chest wall or skin 
without lymph node spread or with axillary lymph node spread 
or internal mammary nodes spread 
Stage IIIC : Primary tumor of any size with metastasis in ipsilateral 
infraclavicular or both axillary lymph nodes and internal 
mammary nodes or supraclavicular lymph nodes 
Stage IV : Primary tumor of any size with any lymph node spread status 
and the presence of distant metastasis 
 Although still important, more emphasis is given to the rapidly 
growing molecular classifications of breast cancer, which will be discussed 
later. Nonetheless, these newer methods are used complementarily with 
staging of breast cancer for therapeutic decisions (Harris, 2014). 
1.1.5.2 World Health Organization (WHO) classification 
The WHO classification, which has been primarily based on 
morphological aspects of breast cancer, has been updated to include some 
molecular expression of the tumors (Sinn and Kreipe, 2013; Austreid et al., 
2014). Among others, it includes classification of precursor lesions, benign 
epithelial proliferations, fibroepithelial, epithelial tumors and invasive breast 
carcinoma. Several subtypes are included in invasive breast carcinoma, 
including invasive breast carcinoma of no special type, invasive lobular 
carcinoma, tubular carcinoma and so on. A majority of breast cancer falls 
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under the invasive breast carcinoma of no special type category. This 
constitutes the group of breast cancers, which do not belong to other breast 
cancer categories, and it is  previously known as invasive ductal carcinoma 
(Sinn and Kreipe, 2013).  
1.1.5.3 Breast cancer molecular subtype 
Traditionally, breast cancer has also been classified according to the 
presence of hormone receptors, and human epidermal growth factor receptor 2 
(HER2) status, in order to assess the use of adjuvant systemic therapy 
(Goldhirsch et al., 2009; Viale, 2012). In the advent of gene expression 
profiling, more detailed breast cancer subtypes have since been unveiled. The 
luminal breast cancer subtypes, consisting of luminal A and luminal B 
subtypes, have been identified as subtypes with positive hormone receptors 
while HER2-enriched, basal-like and claudin-low groups are under the 
hormone receptors-negative group (Schnitt, 2010).  
The luminal A subtype is generally enriched with estrogen receptors 
(ER), progesterone receptors (PR) and genes associated with ER activation. In 
addition, this subtype contains low levels of proliferation gene clusters, mainly 
Ki67 (Schnitt, 2010; Carey et al., 2014; Sonnenblick et al., 2014). On the other 
hand, the luminal B breast cancer subtype, has relatively less ER-gene clusters 
although still positive for ER and/or PR and high Ki67 expression. In addition, 
variable HER2 expression is present (Schnitt, 2010; Sonnenblick et al., 2014). 
The HER2-enriched group contains elevated HER2 gene cluster expression, 
accompanied by low levels of luminal and basal-like gene cluster. Apart from 
that, this subtype also exhibits high proliferation clusters, with TP53 mutations 
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commonly detected (Carey et al., 2014). The basal-like breast cancer subtype 
has low levels of luminal characteristics and HER2 expression, with high 
expression of proliferation genes. In addition, what makes this subtype unique, 
is the greater presence of the basal gene clusters which consists of basal 
epithelial cytokeratins, such as CK5, 6, epidermal growth factor receptor, c-
Kit, vimentin, P-Cadherin and αB-crystallin (Schnitt, 2010; Carey et al., 
2014). Claudin-low subtype is similar to basal-like breast cancer subtype, in 
that, it has low luminal genes and HER2 expression. However, the claudin-low 
subtypes differ from the basal-like breast cancer, in terms of their low level of 
proliferation genes and cell-cell adhesion proteins. Additionally, claudin-low 
subtypes also contain elevated immune system response genes, such as 
interleukin-6 and CD4 (Carey et al., 2014).  
Although much has been done to elucidate the molecular subtypes of 
breast cancer, the use of molecular subtypes alone, is not enough for decisions 
on staging, treatment and follow-up of breast cancer (Sonnenblick et al., 
2014). However, several ongoing clinical trials based on gene expression 
signatures, such as the Amsterdam 70-gene prognostic profile (Agendia 
Mammaprint®), and Treatment for Positive Node, Endocrine Responsive 
Breast cancer (RxPONDER) trial, are being conducted to determine the 
prognostic and therapeutic value of these classifications (Carey et al., 2014; 
Sonnenblick et al., 2014). 
1.1.6 Treatment of breast cancer 
There are several options for treatment of breast cancer, and these are 
dependent on the staging and spread of the cancer, hormone receptor status, 
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patient’s menopausal status, age and also patient’s choices (Maughan et al., 
2010). Basically, breast cancer treatment options ranged from surgery, 
systemic therapy to targeted therapy.  
1.1.6.1 Surgery 
Generally, breast conserving surgery is done for patients with early-
stage disease, and smaller tumor size (<5cm) in relation to breast size. Tumor-
to-breast size is important to ensure clear resection of tumor, while preserving 
the breast appearance (Harris and Morrow, 2014). Breast conserving surgery is 
usually followed by radiation therapy, and this has been shown to reduce local 
recurrence, and at the same time, improve long-term survival of patients 
(Clarke et al., 2005). Another form of surgical therapy for breast cancer is the 
removal of whole breast or mastectomy. The procedure applies to breast 
cancer patients who are unable to undergo breast conserving surgery. This 
could be due to the inability to reduce the tumor burden, and inability for 
patients to receive safe radiation therapy. Simple mastectomy involves the 
removal of the whole breast, without the removal of axillary lymph nodes, 
while modified radical mastectomy involves the removal of breast, plus 
axillary lymph nodes (Morrow and Golshan, 2014). 
1.1.6.2 Radiation therapy 
Radiation therapy utilizes ionizing radiation to kill cancerous cells. 
Whole breast irradiation includes radiation of the chest wall and the 
supraclavicular lymph nodes. This is usually done after surgery to remove 
residual local disease, and reduce the chances of local recurrence (Khan and 
Haffty, 2014). In addition, radiation therapy may also be administered before 
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surgery to reduce the size of tumor, so that, breast conserving surgery can be 
performed (Harris and Morrow, 2014).  
1.1.6.3 Chemotherapy 
Chemotherapy is administered to breast cancer patients, as a 
neoadjuvant or adjuvant treatment. Preoperative chemotherapy or neoadjuvant 
chemotherapy, is used to downstage tumors, enabling the removal of 
previously unresectable tumors (Bardia and Baselga, 2014). Adjuvant 
chemotherapy after surgical resection, is done to remove remaining malignant 
cells, and is based on histological parameters and the molecular subtypes 
(Dang and Hudis, 2014). Both preoperative and adjuvant chemotherapy, have 
shown good clinical outcomes in the treatment of breast cancer (Bardia and 
Baselga, 2014; Dang and Hudis, 2014). Some examples of chemotherapeutic 
drugs, are Doxorubicin hydrochloride, Epirubicin hydrochloride and 5-
Fluorouracil (Eisner and Luoh, 2011). 
1.1.6.4 Targeted therapy 
A deeper understanding of the molecular signatures of breast cancer, 
has led to the development of targeted therapy, where treatments are directed 
to specific molecules of cancer cells. One of the earliest forms of targeted 
therapy is the endocrine therapy, which is recommended for breast cancer 
patients whose tumors have high levels of ERs. An example of such drug is 
tamoxifen (Lumachi et al., 2011; Rimawi and Osborne, 2014). Aside from 
targeting ERs, trastuzumab which is a monoclonal antibody targeting the 
HER2 receptor, is fundamental in the development of targeted therapies 
(Munagala et al., 2011). In addition, due to the advancements of tumor 
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genetics, many new targeted therapies are being developed, which includes 
phosphatidylinositol-3 kinase/protein kinase B (PI3K/AKT) inhibitors, cyclin-
dependent kinase inhibitors, mitogen-activated protein/extracellular signal-
regulated kinase (MEK) inhibitors and matrix metalloproteinases inhibitors 
(Munagala et al., 2011).  
1.1.6.5 Challenges associated with current breast cancer treatment 
Although advancements in breast cancer treatment have improved the 
prognosis of breast cancer patients, 15% of patients still develop distant 
metastasis, for which there is no cure (Austreid et al., 2014). Chemoresistance 
and drug resistance remain the main issues in the treatment of breast cancer 
(Austreid et al., 2014). In addition, patients undergoing breast cancer 
treatment, often face acute and chronic adverse side effects, such as cardiac 
toxicity and neurotoxicity (Odle, 2014). Chemotherapeutic drugs in 
combination with targeted therapies, such as anti-HER2, have been shown to 
counteract drug resistance (Austreid et al., 2014). However, the efficacy of 
combination therapy of new drugs, such as mTOR inhibitors, CDK inhibitors 
and so on, have given mixed results or are not yet established (Austreid et al., 
2014; Ziauddin et al., 2014). Yet, the development of targeted therapies are 
still widely pursued, because of their potential use to battle drug resistance, 
and at the same time, reduce toxicity of treatment due to their specificity to 
malignant cells (Austreid et al., 2014; Odle, 2014; Ziauddin et al., 2014). 
Hence, it is important to continually unearth potential biomarkers, to develop 
therapeutic and prognostic targets for breast cancer. 
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1.2 Complement component 1, q subcomponent binding protein 
(C1QBP) 
Complement component 1, q subcomponent binding protein (C1QBP) 
is a protein known by many names, such as receptor for the globular head of 
C1q (gC1qR), hyaluronan-binding protein 1 (HABP1), Y-box protein-
associated acidic protein (YBAP1) and mitochondrial matrix protein p32 
(p32). Initially purified from Raji cells, it was found to bind to globular heads 
of C1q molecules (Ghebrehiwet et al., 1994). The C1QBP gene originates 
from chromosome 17p13.3, spanning 6055 bp of DNA (Ghebrehiwet and 
Peerschke, 1998; Tye et al., 2001). The gene contains 6 exons and 5 introns, 
encoding a pre-pro protein of 282 amino acid residues, which is eventually 
cleaved to form the mature protein of 209 amino acid residues, beginning on 
the 74
th
 (Leu) amino acid residue (Ghebrehiwet et al., 1994; Ghebrehiwet and 
Peerschke, 1998). The cleaved section contains the mitochondrial localization 
signal necessary for mitochondrial localization of C1QBP (Muta et al., 1997; 
Dedio et al., 1998). In addition, C1QBP has also been found to be present in 
the cell nucleus and cell surface (Dedio et al., 1998; Ghebrehiwet and 
Peerschke, 1998; Soltys et al., 2000; Brokstad et al., 2001). Due to its high 
charge, the mature C1QBP protein is very acidic with a pI value of 4.15 
(Ghebrehiwet and Peerschke, 1998). The crystal structure of C1QBP revealed 
that C1QBP exists as a trimeric doughnut-shaped quarternary complex, with 
assymetrical charge distribution (Jiang et al., 1999). Although predicted to be 
a 24.3 kDa protein, the C1QBP protein appears as a 33 kDa protein on SDS-
PAGE (Ghebrehiwet et al., 1994; Ghebrehiwet and Peerschke, 1998). 
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1.2.1 Physiological functions of C1QBP 
C1QBP is a multifunctional protein, evident from its interaction with 
diverse proteins of different functions. One of the early discoveries of 
C1QBP’s functions, is its role in infection and inflammation (Peerschke and 
Ghebrehiwet, 2007). C1QBP contributes to infection by facilitating binding to 
antigens from microbes, such as Listeria monocytogenes, Hepatitic C virus 
and Staphylococcus aureus (Ghebrehiwet and Peerschke, 1998; Peerschke and 
Ghebrehiwet, 2007). For example, persistent infection of hepatitis C virus due 
to T cell suppression is mediated by C1QBP, through its interaction with the 
hepatitis C virus core protein. This blocks the G1 to S phase progression of T 
cell and thus, inhibits proliferation (Yao et al., 2003). C1QBP also modulates 
the classical complement pathway, contributing to inflammation. In 
atheroscelerotic lesions, C1QBP facilitated inflammation by binding to C1q 
and influencing the kinin systems (Peerschke et al., 2004). 
Apart from that, C1QBP has also been shown to be involved in 
transcription. It has been reported to interact with proteins involved in 
transcription regulation, such as CCAAT-binding factor- B subunit and human 
immunodeficiency virus type 1 Tat transactivator, as well as, transcription 
factor II B (TFIIB) (Yu et al., 1995; Chattopadhyay et al., 2004). In addition, 
C1QBP influences the pre-mRNA splicing process, by deterring the functions 
of serine/arginine-rich splicing factor 1 (ASF/SF2), an important protein for 
this process (Petersen-Mahrt et al., 1999). ASF/SF2, functions as both splicing 
repressor and activator, depending on the site of its binding on pre-mRNA. 
C1QBP inhibits ASF/SF2 dual functions by preventing the binding of 
ASF/SF2 to RNA, thus allowing the formation of pre-spliceosome, and by 
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hindering phosphorylation of ASF/SF2, which is required for spliceosome 
assembly (Petersen-Mahrt et al., 1999). C1QBP has also been shown to 
interact with Y-box binding protein 1 (YB-1 or YBX1) and relieves the 
translational repression of YB-1, which is a multifunctional transcription 
factor (Matsumoto et al., 2005). 
The predominant localization of C1QBP in the mitochondria, indicates 
a role of C1QBP in mitochondrial-related functions. Mitochondrial C1QBP 
has been shown to be an essential factor in maintaining mitochondrial 
oxidative phosphorylation, and its depletion affects ATP synthesis (Muta et 
al., 1997). C1QBP has also been reported to be involved in apoptosis. In 
normal fibroblastic cells, the up-regulation of C1QBP increased the production 
of reactive oxygen species, leading to apoptosis via elevation of Bax 
(Meenakshi et al., 2003; Chowdhury et al., 2008).  Additionally, C1QBP also 
modulates ARF-induced p53-dependent apoptosis (Itahana and Zhang, 2008). 
However, C1QBP has also been reported to prevent cell death induced by 
oxidative stress, by inhibition of the mitochondrial permeability transition pore 
(McGee and Baines, 2011).  
The role of C1QBP also extends to the nervous system. In 
hippocampal neurons isolated from rats, C1QBP was found to interact with γ-
Aminobutyric acid type A (GABAA) receptor (Schaerer et al., 2001). 
Furthermore, studies done on the Drosophila melanogaster model, showed 
that C1QBP is located within the presynaptic mitochondria, and is important 
for synaptic transmission (Lutas et al., 2012).  
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C1QBP has also been implicated in the embryonic development and 
reproduction system. C1QBP-knockout mice displayed mid-gestation lethality, 
with severe disruption of mitochondrial DNA-encoded protein synthesis (Yagi 
et al., 2012). Placental cytotrophoblast proliferation, which is needed for 
sustenance of the fetus during pregnancy, is regulated by C1QBP, and the 
ablation of C1QBP, was highly observed in placentas with fetal growth 
restriction (Matos et al., 2014).  
In addition to all these functions, C1QBP has also been reported to be 
involved in early nucleolar ribosome biogenesis, via its interaction with 
Nop52 and fibrillarin (Yoshikawa et al., 2011). Other than that, C1QBP has 
also been shown to interact with Protein Kinase C µ (PKCµ) and lamin B 
(Simos and Georgatos, 1994; Storz et al., 2000). Altogether, these findings 
showed that C1QBP is involved in a plethora of cell processes and functions. 
1.2.2 Role of C1QBP in tumorigenesis 
Given its multifunctional role, it is not surprising that the dysregulation 
of C1QBP could give rise to tumorigenesis. The overexpression of C1QBP has 
been reported in various carcinomas, including  breast, lung, colon, thyroid, 
gastric, esophagus, pancreas, ovarian and endometrial cancers (Rubinstein et 
al., 2004; Chen et al., 2009b; Amamoto et al., 2011; Dembitzer et al., 2012; 
Yu and Wang, 2013; Zhao et al., 2015). In clinical breast cancer tissue 
samples, mRNA expression of C1QBP was correlated with lymph node 
spread, and low survival rate for breast cancer patients (Chen et al., 2009b). In 
addition, the high levels of C1QBP protein in breast cancer tissue, were also 
recently reported to be associated with distant metastasis of breast cancer 
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(Zhang et al., 2013). Overexpression of C1QBP in ovarian cancer, has been 
shown to produce poor outcomes. In a study done on stage III and stage IV 
serous ovarian cancer, C1QBP was highly expressed in cisplatin-resistant 
cases, and overexpression of C1QBP was associated with poorly differentiated 
carcinomas, residual tumor size, lymph node spread and lower overall survival 
(Yu and Wang, 2013). Moreover, the expression of C1QBP was seen to 
gradually increase from the primary lesions to metastatic lesions of epithelial 
ovarian cancer. The expression of C1QBP in this cancer, was also associated 
with peritoneal invasion and lymph node spread (Yu et al., 2013). Similarly, 
increased tumor recurrence and metastasis, were associated with high levels of 
C1QBP expression in endometrial cancer, which led to an unfavourable 
prognosis for patients with this disease (Zhao et al., 2015). In prostate cancer 
tissue samples, the expression of C1QBP showed an inverse relationship with 
survival of patients. In addition, C1QBP was associated with Gleason score, 
prostate-specific antigen (PSA) and pathological stage, all of which are 
prognostic factors for prostate cancer (Amamoto et al., 2011).  
There are several ways in which C1QBP exerts its tumorigenic 
functions. True to its physiological function, C1QBP sustains tumor growth 
and progression, by maintaining oxidative phosphorylation in tumor cells 
(Fogal et al., 2010). Depletion of C1QBP switched tumor metabolism from 
oxidative phosphorylation to glycolysis, which reduces tumor growth and 
progression (Fogal et al., 2010). This function contradicts with the well-known 
Warburg effect, where cancer cells rely on glycolysis for metabolism in the 
hypoxic environment (Dang, 2010). In liver carcinoma cells, C1QBP caused 
the maintenance of hyaluronan synthesis, and increased expression of β-
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catenin, ras and Cyclin D1, which promotes cell survival (Kaul et al., 2012). 
C1QBP mediates cell migration by regulating lamellipodia formation in lung 
carcinoma cells. It is known to be condensed in the lamellipodia protrusions 
with lamellipodial components, and aided in the lamellipodial formation, by 
regulating receptor tyrosine kinases signalling (Kim et al., 2011). The binding 
of C1QBP to matrix metallopeptidase 14 (MT1-MMP), which has roles in 
tumor invasion has also been recorded (Rozanov et al., 2002). In line with this, 
melanoma cells exposed to exogenously introduced C1QBP, led to interaction 
with αvβ3 integrin and phosphorylation of nuclear factor inducing kinase, 
which caused an increase of MT1-MMP and MMP2 expression, accompanied 
by cell migration and tumor growth (Prakash et al., 2011). In contrast to its 
tumorigenic role, C1QBP has also been shown to repress the phosphorylation 
of YB-1, which is an oncogene in renal carcinoma. It was also reported that 
high C1QBP expression and low nuclear YB-1 expression, gave a better 
prognosis for renal carcinoma patients (Wang et al., 2015).  
In breast cancer, C1QBP has been shown to positively regulate cell 
proliferation, migration and resistance to Doxorubicin hydrochloride (McGee 
et al., 2011). Although the mechanism has not been fully elucidated, the 
interaction of C1QBP with protein kinase C δ (PKCδ), has been shown to 
enhance cell polarity and migration in breast cancer (Zhang et al., 2013).  
1.3 Scope of study 
The development of breast cancer is a complex interplay of molecular 
events, which primes the breast cancer cells for survival, metastasis and 
resistance to current therapeutic interventions (Simpson et al., 2005; 
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Bombonati and Sgroi, 2011). Thus, continual investigations of potentially 
useful biomarkers for monitoring and therapeutic purposes are always in 
progress. The role of C1QBP in breast cancer progression, has been 
demonstrated in various studies. C1QBP has been associated with 
proliferation, migration and chemoresistance in breast cancer (McGee et al., 
2011). In addition, a recent study showed that distant metastasis is associated 
with C1QBP expression, and cell migration could be mediated through PKCδ 
(Zhang et al., 2013). Therefore, it is of interest to have a comprehensive look 
into the role of C1QBP in breast cancer.  
 The hypothesis of the current study is that, C1QBP promotes 
breast cancer progression by regulating fundamental processes, such as 
cell proliferation, migration and invasion. In order to prove this hypothesis, 
the following objectives were delineated:  
1. Analyse the expression of C1QBP in clinical breast cancer tissue 
samples, in association with clinicopathological parameters.  
2. Evaluate the expression of C1QBP in breast cancer cell lines, and 
determine the association of C1QBP with cell proliferation, migration, 
invasion and chemosensitivity, by manipulation of C1QBP expression 
in breast cancer cell lines.  
3. Determine the potential signalling pathways that C1QBP is involved 
in, by genome wide analysis, antibody array and stable isotope 
labelling by amino acids in cell culture (SILAC)-immunoprecipitation 















2 MATERIALS AND METHODS 
2.1 Gene expression profiling of C1QBP in breast cancer tissues 
Gene expression profile of C1QBP was determined by performing real-
time PCR on Human Breast Cancer Panel I TissueScan
TM
 qPCR Array 
(Origene, Rockville, MD, USA). The array contained 48 cDNA samples from 
normal and breast cancer tissues diagnosed at various clinical stages – 7 
samples from normal breast tissues, 13 samples from Stage IIa breast cancer, 7 
samples from Stage IIb breast cancer, 8 samples from Stage IIIa breast cancer 
and 3 samples from Stage IIIc breast cancer. Patients’ age ranged from 31 to 
82 years old. The samples were normalized using a housekeeping gene, β-
actin.  
The ABI Prism 7500 thermocycler (Applied Biosystems
®
, Carlsbad, 
CA, USA) was used for the real-time RT-PCR procedures. Prior to that, a pre-
mix solution, comprising of 750 µl of SYBR Green Master Mix, 50 µl of 
C1QBP forward primer, 50 µl of reverse primer and 650 µl of ddH2O was 
made. The sealing film from the array was removed, and 30 µl of the pre-mix 
was loaded into each well. A new adhesive cover sheet was used to seal the 
wells tightly. Any air bubbles formed were removed by gently tapping the 
plate. The plate was left on ice for 15 minutes to dissolve the dried cDNA. The 
thermal cycling program started with an activation step at 95°C for 15 
minutes, after which, a cycle, comprising of denaturation at 94°C for 15 sec, 
annealing at 60°C for 30 sec and extension at 72°C for 30 sec, was repeated 
for 40 PCR cycles.  
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2.2 Immunostaining of C1QBP in invasive ductal breast carcinoma 
tissues 
2.2.1 Tissue microarray specimens and clinicopathological parameters  
Tissue microarrays (TMAs) were constructed by the Department of 
Pathology, Singapore General Hospital. The microarrays comprised of 1 mm 
core from paraffin-embedded breast cancer specimens. These samples were 
collected from patients between the year 2004 and 2007. Ethics approval was 
granted by the Institutional Review Board of Singapore General Hospital.  
Briefly, areas of breast tumours were preselected, marked and punched 
out from ‘donor’ blocks, using a 1 mm punch. The tissue cores of 1 mm in 
diameter were sequentially arranged into ‘recipient’ blocks, by the tissue 
microarrayer. Five ‘recipient’ blocks with a total of 132 cases were used for 
this study. The recipient blocks were also prepared with control tissues of 1 
mm in diameter, which include normal lung, liver, colon, tonsil, thyroid and 
testis tissues. Sections of 4 µm from the TMA blocks were sliced and mounted 
on silane-coated glass slides (3-aminopropyltriethoxysilane; Sigma-Aldrich, 
St. Louis, MO, USA) and left to dry at 37°C, overnight.  
Clinicopathological data of the patients were recorded by the 
Department of Pathology, Singapore General Hospital. These include patients’ 
age, race, tumor size, histological grade, pathological staining, lymph node 
spread, mitotic index, extent as well as, grade of ductal carcinoma in situ, and 




2.2.2 Immunohistochemical staining of C1QBP and PCNA of invasive 
ductal breast carcinoma tissue microarrays 
The Leica BOND-MAX
TM
 System with a standard protocol F, was 
used to stain the TMA sections. Rabbit polyclonal anti-C1QBP antibody was 
used as the primary antibody, at a dilution of 1:1000. The antibody was 
produced against the recombinant C1QBP-His6 protein, and subsequently 
purified through a protein G Sepharose column (Matsumoto et al., 2005). 
Tissue sections were deparaffinised, and pre-treated with epitope retrieval 
solution 2 (EDTA buffer, pH 8.8) for 20 minutes at 90°C. The slides were 
washed thrice, and the sections were blocked for peroxidase, with Bond 
Polymer Refine Detection Kit DC9800 (Leica Biosystems Inc., Buffalo Grove, 
IL, USA) for 10 min. After washing, the tissue sections were incubated with 
primary antibody for 30 min. Excess primary antibody was removed by 
washing the tissue sections thrice. Subsequently, the tissue sections were 
incubated with polymer for 10 min and DAB-chromogen for 10 min. Each 
step was followed by washing steps. Upon completion of standard protocol F, 
hematoxylin was used to counterstain the sections, followed by three washing 
steps. After staining, the TMA sections were dehydrated with three changes of 
absolute ethanol and three changes of histoclear. The TMA sections were 
mounted with a coverslip.  The omission of primary antibody on breast cancer 
tissue was used as the negative control. Mouse monoclonal anti-proliferating 
cell nuclear antigen (PCNA) antibody (Sigma-Aldrich; 1:10000 dilution) was 




2.2.3 Scoring system of invasive ductal breast carcinoma tissue 
microarrays 
The TMAs were viewed under the light microscope, at magnifications 
of 100X and 400X. The percentage and corresponding staining intensity of 
C1QBP in malignant epithelial cells with immunopositive staining, was scored 
by assigning ‘0’ for non-detectable staining, ‘1+’ for weak staining, ‘2+’ for 
moderate staining and ‘3+’ for strong staining. The scores were validated 
independently by a researcher and a pathologist from the Department of 
Pathology, Singapore General Hospital. The weighted average index (WAI) 
score was then computed as followed: 
 AI=
∑(intensity of each staining x percentage of cells stained with each intensity)
Total percentage of immunopositive staining
 
 For analysis of PCNA, only the total percentage of PCNA staining was 
recorded.  
2.2.4 Statistical analyses of TMA samples 
Statistical analyses were carried out by the STATA version 10 
software, to determine the association of the immunohistochemical expression 
of C1QBP with patients’ clinicopathological parameters. The analysis was 
first performed by univariate analysis, using chi-square test. A P-value of less 
than 0.05 is considered as statistically significant. The correlation of the 
expression of C1QBP and PCNA was done using Pearson’s correlation. 
Multivariate analysis was subsequently done using binary logistic 
regression, to define the association between the main predictor and outcome, 
after correcting for confounders. The outcome of interest included tumor size, 
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grade of tumour, associated ductal carcinoma in situ (DCIS) grade, associated 
DCIS extent, tubule formation, pleomorphism, mitotic index and lymph node 
spread. These are categorized into binary variables as depicted in Table 3.3. 
Age, ER status, PR status and HER2 status were considered as the potential 
confounders.  
In the initial model, the potential confounders were incorporated for 
every main outcome of interest. This was followed by backward stepwise 
regression, where the potential confounder having the highest p-value (>0.05) 
was dropped from the model. The stepwise regression was repeated until all 
potential confounders retained, achieved statistical significance, or no 
confounder was left in the model. Following that, non-significant predictor 
variables will then be removed from the model until all predictors retained 
achieve statistical significance, or no predictor of interest was left in the 
model.  
2.3 Cell culture 
2.3.1 Culture conditions for breast cancer cell line 
MDA-MB-231 (HTB-26), T47D (HTB-133), ZR-75-1 (CRL-1500) 
and MCF7 (HTB-22) breast cancer cell lines, were included in this study. The 
breast cancer cell lines were obtained from the American Tissue Culture 
Collection (ATCC, Manassas, VA, USA). The main breast cell line used was 
MDA-MB-231 breast cancer cell line. It is a highly metastatic epithelial breast 
cancer cell line, which was derived from the pleural effusion of a 51 years old 
Caucasian woman with breast adenocarcinoma (Cailleau et al., 1974). Another 
cell line, the T47D breast cancer cell line, which was also used in this study, 
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originated from the pleural effusion of a 54 years old female diagnosed with 
infiltrating ductal carcinoma of the breast (Keydar et al., 1979). The MCF7 
and ZR-75-1 breast cancer cell lines, were isolated from adenocarcinoma and 
ductal carcinoma, respectively (Soule et al., 1973; Engel et al., 1978). Among 
these cell lines, MDA-MB-231 breast cancer cell line does not express ER and 
PR (Kao et al., 2009). On the other hand, T47D and MCF7 breast cancer cells 
are positive for both ER and PR, while ZR-75-1 is only positive for ER (Kao 
et al., 2009).  
The culture medium used for MDA-MB-231, T47D and ZR-75-1 
breast cancer cell lines was Roswell Park Memorial Institute (RPMI) 1640 
medium (GE Healthcare Life Sciences, Buckinghamshire, UK), supplemented 
with 10% FBS (GE Healthcare Life Sciences). The Dulbecco’s modified 
Eagle’s medium (DMEM) comprising 10% FBS, was used to culture the 
MCF7 cells. All the cell lines were incubated at 37°C with atmospheric 
content of 5% CO2. Cells were grown to approximately 80% confluence 
before splitting. Cells were detached from the surface of the flask using 1X 
Trypsin-EDTA, which was prepared by diluting 10X 0.5% Trypsin-EDTA 
(Invitrogen
TM
, Life Technologies, Carlsbad, CA, USA) with 1X PBS. The 
activity of Trypsin-EDTA was halted by the addition of three times the 
volume of fresh complete culture medium to the flask. Cells were resuspended 
and dispensed into a new flask, at a ratio of 1:4. For the purpose of seeding, 
the suspension of cells was spun for 5 minutes at 1000 rpm. After discarding 
the supernatant, the cells were resuspended in fresh complete medium. Cell 
density for seeding was determined by counting cells using a haemocytometer 
or cell counter. 
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2.3.2 Cryopreservation of breast cancer cell lines 
Cell lines with 90% confluency were used for cryopreservation. Cells 
were trypsinized, resuspended and centrifuged according to the method in 
Section 2.3. Cells were then resuspended in their respective medium with 20% 
FBS and 10% DMSO, and 1 ml was aliquoted into each cryotube. The 
cryotubes were then stored at -80°C overnight in a Cryo 1 ºC Freezing 
Container (Nalge Nunc International, Rochester, NY, USA). The cryotubes 
were then transferred to a liquid nitrogen tank for long term storage. 
2.4 Quantitative real-time polymerase chain reaction 
2.4.1 Extraction of total RNA from breast cancer cell lines 
Total RNA was extracted from breast cancer cell lines grown to 
approximately 80% confluence, in 6-well microtitre plates using the RNeasy 
Minikit (Qiagen, Hilden, Germany). Firstly, monolayer cells were washed 
with 1X PBS, to completely discard the culture medium. Cell lysis was done 
using 350 µl of RLT buffer, supplemented with 1% β-mercaptoethanol. The 
lysate was scraped and collected in a 1.5 ml microcentrifuge tube, and 
homogenized by passing the lysate through a blunt 21-gauge needle, fitted 
with a RNase-free syringe. The same amount of 70% ethanol was pipetted into 
the homogenized lysate and gently mixed. The ensuing solution was 
transferred into an RNeasy spin column, and centrifuged at full speed for a 
minute. After which, the flow-through was disposed of, and 700 µl of Buffer 
RW1 was added to the spin column. Centrifugation was done as before, and 
flow-through removed. Traces of ethanol were removed by washing and 
spinning with 500 µl of Buffer RPE twice – 1 min for the first time and 2 min 
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for the second time – at full speed. Flow-through was discarded both times. 
Complete removal of possible Buffer RPE carryover and residual flow-
through was done, by full speed centrifugation in a new 2 ml collection tube 
for 1 min. Finally, total RNA was eluted in a new 1.5 ml collection tube, with 
30 µl of RNase-free water, by centrifugation at maximum speed for 1 min. For 
RNA extraction from cells seeded in 24-well microtitre plates, RNeasy micro 
kit was used. The procedures in this kit were similar to RNeasy Minikit.  
For the RNeasy micro kit, 80% ethanol was used to wash the 
membrane of the spin column after the first wash with Buffer RPE. In 
addition, the spin column membrane was dried by centrifugation at full speed 
for 5 min, with the lid opened. The elution of RNA was done with 14 µl of 
RNase-free water, instead of 30 µl of RNase-free water. The quality and 
concentration of the RNA were determined by A260nm/A280nm, determined by 
nanodrop ND-100 spectrophotometer (Thermo Fisher Scientific, Waltham, 
MA, USA). High purity RNA should yield an A260/A280 value of 1.8 to 2.1. 
2.4.2 Complementary DNA (cDNA) synthesis 
The extracted RNA was converted to cDNA, by using the SuperScript 
III First-Strand Synthesis System (Invitrogen
TM
). A total of 1 µg or 2 µg of 
RNA was added to 1 µl of 50 ng/µl of random hexamers, and 1 µl of 10mM 
dNTP mix. RNase-free water was added to the mixture to a volume of 10 µl. 
The solution was then incubated for 5 minutes at 65°C and then, at 4°C for a 
minute. A cDNA Synthesis Mix was prepared by adding 2 μl of 10X RT 
buffer, 4μl of 25mM MgCl2, 2μl of 0.1M DTT, 1μl of RNaseOUT
TM
 (40U/μl) 
and 1μl of SuperScriptTM III RT (200U/μl). Both solutions were incubated at 
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25°C for 10 min, followed by 50°C for 50 min. The reaction was terminated 
by incubating the mixture at 85°C for 5 min. Subsequently, the cDNA product 
was stored at -20°C. 
2.4.3 Quantitative real-time polymerase chain reaction (Real-time PCR) 
Primers were designed by Primer3 software 
(http://bioinfo.ut.ee/primer3-0.4.0/), and primer specificities were determined 
by Basic Local Alignment Search Tool (BLAST®; 
http://blast.ncbi.nlm.nih.gov/Blast.cgi). The primer sequences (1
st
 Based, 
Singapore) used are depicted in Table 2.1.  
Table 2.1. Primer sequences used in real-time PCR 
Primers Forward sequence (3’-5’) Reverse sequence (5’-3’) 
AP4B1 CAAGGGACCTTTGCTAGCTG CTGCTGCACATTCTCATCGT 
ASMTL GAGTGTCAAGCACGACTCCA CAGGCCCTTGGATAGCATAA 
BCL2 GGTGGGGTCATGTGTGTGG CGGTTCAGGTACTCAGTCATCC 
C1QBP AGAAGCGAAATTAGTGCGGAA CCACGAAATTGGGAGTTGATGTC 
CDC14B GCGCCAGATTAGTAGGCAAC TTGTTTGGCTGAGAACACGG 
FGD1 GGAGTTGACTGTGCAGCAAA AGAGAAGATGCCGTGGACAA 
FOXD3 AAGCCCAAGAACAGCCTAGT GTTGAGTGAGAGGTTGTGGC 
GAPDH GAAGGTGAAGGTCGGAGTCAACG TGCCATGGGTGGAATCATATTGG 
HCAR3 CAGGGCAGCATCATATTCCT GCTGAAGCTGATGCACACAT 
HPR GCGTGTGGGTTACGTGTCT GTTATGCAATCGTATTGGTCAGC 
IL15RA ACGACTGAGAAGAGGTGCAA TGTATTCCAGGCAGCTCACA 
IL23A ACTCAGCAGATTCCAAGCCT CCATGGAGATCTGAGTGCCA 
MAP3K8 CCCTGGAGAGAAACCCCAAT CGTTGCCTCTTGAGCATCTC 
MCM4 ACCTGGTCGCACTGTACTAC TAGCTGTCGAGGGTATGCAG 
MMP23B AGGCTTCTACCCGATCAACC ACGCCTTTCTTCCAGCTGTA 
TPTE CGACGACACAAGACCTCAGA ATACGTGCCTCTGGGTTCAC 
YB-1 AAGTGATGGAGGGTGCTGAC TTCTTCATTGCCGTCCTCTC 
2.4.4 LightCycler 2.0 System 
The LightCycler 2.0 System (Roche Applied Science, Inc., Penzberg, 
Germany) was used for real-time PCR. The PCR reaction mixtures contained 
3 µl of RNase-free water, 0.5 µl each of 10 µM forward and reverse primers, 5 
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µl of 2X QuantiTect SYBR Green PCR master mix (Qiagen) and 1 µl of 
cDNA, that made up a total volume of 10 µl. The PCR conditions were set up 
as followed:  
Step 1: Initial denaturation of cDNA and polymerase activation at 95°C for 15 
min. 
Step 2: Amplification process which includes a cycle of denaturation at 94°C 
for 15 s, annealing at 60°C for 25 s and extension at 72°C for 15 s. This cycle 
was repeated for 45 cycles.  
Step 3: Melting curve analysis conditions were fixed as followed: denaturation 
at 95°C for 0 s with a temperature transition rate of 20°C/s, which is followed 
by incubation of 15 s at 65°C and 95°C with transition rate of 0.1°C/s. 
Step 4: The final step was to cool the Lightcycler rotor and carousel chamber 
at 40°C for 30 s. 
 The product of the PCR reaction from the LightCycler 2.0 system was 
subsequently used to run the agarose gel electrophoresis, to determine its 
primers’ specificity.  
2.4.5 Analysis of PCR product using agarose gel electrophoresis 
The verification of the specificity of primers was done using 2% 
agarose gel electrophoresis. The agarose gel was prepared by heating a 
mixture of 1 g of agarose in 50 ml of 1X TAE buffer. The mixture was left to 
cool for about 5 min, and 0.5 µg/ml of Ethidium bromide (EtBr) was swirled 
into the mixture. The mixture was then poured into a gel cast and left to 
solidify. The amplified PCR product from each sample obtained from the 
LightCycler 2.0 system was mixed with 6X DNA loading dye (Promega 
37 
 
Coorporation, Madison, WI, USA) at a ratio of 5:1. The resulting samples 
were loaded into the wells of the casted agarose gel. A 100 bp DNA ladder 
standard (Promega Corporation) was also loaded to measure the size of the 
PCR products. The electrophoresis program was performed at 100 V for 1 h. 
The ChemiDoc
TM
 MP imaging system was used to visualize and capture the 
gel image. 
2.4.6 HT7900 FAST Realtime PCR system 
Real-time PCR was also performed using the HT7900 FAST Realtime 
PCR system (Applied Biosystems
®
). Each PCR reaction consisted of 3 µl of 
RNase-free water, 0.5 µl each of forward and reverse primers with 
concentration of 10 µM, and 5 µl of Fast SYBR® Green Master Mix (Applied 
Biosystems
®
), together with 1 µl of diluted cDNA template (5X dilution). The 
mixture for each sample was loaded into each well of a MicroAmp® Fast 
Optical 96-well Reaction Plate (Applied Biosystems
®
). The FAST Realtime 
PCR thermal cycling run was programmed with an initial activation at 95°C 
for 20 s, prior to 40 cycles of the amplification process which consists of 
melting at 95°C for 1 s, and annealing of primer as well as, extension at 60°C 
for 20 s.  
2.4.7 Analysis of data obtained from real-time PCR 
Cycle threshold (Ct) is the number of cycles needed for the fluorescent 
intensity of the SYBR Green to exceed a fixed threshold. The relative gene 
expression of target genes obtained from real-time PCR was assessed based on 
the ∆∆Ct value and 2-∆∆Ct value. The expression level of a target gene was 
normalized to a housekeeping gene (GAPDH) by subtracting the Ct value of 
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the housekeeping gene, from the Ct value of the target gene, subsequently 
producing the ∆Ct value. To obtain ∆∆Ct, ∆Ct of a control group was 
deducted from ∆Ct of a treatment group. In short, ∆∆Ct = [(Cttarget – 
Cthousekeeping) of treatment group] – [(Cttarget – Cthousekeeping) of control group]. 
Finally, the formula 2
-∆∆Ct
 was used to calculate the relative fold change of the 
target gene from the treatment group, compared to the control group. 
2.5 Relative quantification of protein expression through western blot 
2.5.1 Extraction of total protein from cell lines 
Total protein extraction was carried out on cells grown in 6-well or 24-
well cell culture plate. The cells were fasted for 24 h prior to nourishment with 
complete medium for 24 h or 48 h, before extraction of protein. Firstly, cells 
were washed with chilled 1X PBS twice. A mixture of Thermo Fisher 
Scientific RIPA Lysis and Extraction Buffer (Pierce Biotechnology, Rockford, 
IL, USA), Halt
TM
 Protease and Phosphatase Inhibitor Cocktail (Pierce 
Biotechnology), and 0.5M EDTA at a ratio 100:1:1 was prepared as the lysis 
buffer, which was incubated with the cells on ice for 15 min. The cell lysate 
was then scraped and collected into a 1.5 ml microcentrifuge tube. Then, the 
lysate was centrifuged for 10 min, at 14000 g at 4°C. Cell pellet containing 
cell debris was discarded, while the resulting supernatant was transferred to a 
new tube and kept at -80°C.  
2.5.2 Quantification and denaturation of protein samples 
Protein samples were relatively quantified based on the Bradford 
method. The colorimetric change of the dye from the Bio-Rad Protein Assay 
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Dye Reagent Concentrate (Bio-Rad Laboratories, Hercules, CA, USA) 
correlates with various concentrations of protein, and evaluation to a standard 
curve delivers a relative measurement of the protein concentration. The 
concentrated dye reagent was diluted with deionized water, using 1 part of dye 
reagent and 4 parts of deionized water. A series of bovine serum albumin 
(BSA) concentration, ranging from 0.05 mg/ml to 0.5 mg/ml, was used as 
protein standards. Protein samples were subjected to 10X dilution with 
deionized water. Ten microliters of each protein standards and protein samples 
was pipetted into separate wells in triplicates. Then, 200 µl of the diluted dye 
reagent was dispensed into each well. After thorough mixing, absorbance was 
measured at 595 nm, with the GENios plate reader (Tecan Group Ltd, 
Mannedorf, Switzerland). A standard curve was derived from the protein 
standards’ absorbance values. From the standard curve, the concentrations of 
each protein sample were deduced.  
The protein concentrations obtained were used to calculate the volume 
of protein, and deionized water needed to prepare 1.25 µg/µl, 2.5 µg/µl or 
3.125 µg/µl of protein samples. Depending on each samples’ volume, 5X 
protein loading dye was added to each protein samples to produce protein 
samples with a final concentration of 1 µg/µl, 2 µg/µl or 2.5 µg/µl, 
respectively. The resulting solution was mixed and denatured at 95°C for 5 
min. The denatured protein samples were immediately used for subsequent 
experiments or stored at -20°C for future use. 
40 
 
2.5.3 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE) 
Differential percentage of resolving gel, and a stacking gel (5%) was 
used for SDS-PAGE, depending on the size of target proteins, using the 
formula depicted in Table 2.2. 
Table 2.2. Reagents for resolving gel and stacking gel 
Reagent Resolving gel (ml) 5% Stacking 
gel (ml) 8% 10% 15% 
Milipore water 4.6 4.0 2.3 3.4 
30% acrylamide 2.7 3.3 5.0 0.83 
1.5 M Tris 
(pH8.8) 
2.5 2.5 2.5 - 
1.0 M Tris 
(pH6.8) 
- - - 0.63 




0.1 0.1 0.1 0.05 
TEMED 0.006 0.004 0.004 0.005 
Total 10 10 10 5 
 Clean glass plates and spacer plates were assembled, according to the 
manufacturer’s instructions (Bio-Rad Laboratories). Ammonium persulfate 
(APS) and N,N,N’,N’-tetramethylethylenediamine (TEMED) were mixed in at 
the last step in the resolving gel solution. As soon as TEMED was added, the 
mixture was swirled and immediately poured into the gap between the spacer 
plate and glass plate, with sufficient space left for the stacking gel. Acrylamide 
solution was overlaid with isopropanol, to acquire an even gel surface. The 
polymerization of the resolving gel was allowed to be completed for at least 
30 minutes. The overlaid isopropanol was removed, and the top of the gel was 
washed several times with deionized water. Likewise, APS and TEMED were 
added last to the stacking gel and immediately poured onto the resolving gel. 
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Without delay, a clean comb was inserted, ensuring that air bubbles were not 
introduced. Similarly, stacking gel was allowed to polymerize for 
approximately 30 min. 
 The polymerized SDS-PAGE gel was then mounted to the 
electrophoresis apparatus. 1X Tris/Glycine/SDS buffer (Bio-Rad 
Laboratories), which was prepared by diluting 10X Tris/Glycine/SDS buffer 
(Bio-Rad Laboratories; 25 mM Tris, 192 mM glycine, 0.1% SDS, pH8.3) with 
deionized water, were added to the electrophoresis tank. The comb was then 
cautiously removed from the gel. Equal amount of denatured protein samples, 
which were prepared as detailed in the previous section, were loaded into each 
well. To assess the molecular weight of the protein samples, Precision Plus 
Protein
TM
 Dual Color Standard Marker (Bio-Rad Laboratories) was also 
loaded. The SDS-PAGE was carried out at 70V for 1 hour and followed by 
100V, until the dye front reaches the end of the resolving gel.  
2.5.4 Transfer of protein to polyvinyl difluoride membrane 
The protein separated by SDS-PAGE was transferred to a polyvinyl 
difluoride (PVDF) membrane (Bio-Rad Laboratories). Prior to the transfer, the 
PVDF membrane was soaked in 100% methanol for approximately 20 s. The 
membrane was then rinsed with deionized water. The membrane, together 
with filter pads, were immersed in 1X transfer buffer, which contained 25 mM 
Tris, 192 mM glycine and 20% (v/v) methanol. A piece of filter pad was 
placed on the TransBlot SD Semi-Dry Transfer Cell (Bio-Rad Laboratories), 
and the equilibrated PVDF membrane was laid on that filter pad. The SDS-
PAGE gel was then placed on top of the membrane, and lastly, another filter 
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pad was used to cover the gel, creating a ‘gel sandwich’. Trapped air bubbles 
were removed by rolling the ‘gel sandwich’ with a glass rod. The lid was 
closed, and protein was transferred at 15 V for 1 h.  
2.5.5 Blocking and probing of the membrane 
The membrane containing the transferred protein was blocked for 
unspecific sites, before probing with antibodies. The blocking reagent used 
was 5% non-fat milk (Bio-Rad Laboratories), prepared in 1X TBST (Tris-
buffered saline with 0.1% (v/v) Tween 20). On the other hand, 5% BSA in 1X 
TBST was used instead of milk, when phosphorylated proteins were targeted. 
The membrane was blocked with either milk or BSA, for 1 h at room 
temperature. After which, it was washed with 1X TBST thrice, where each 
wash lasted for 5 min. The membrane was then incubated with primary 
antibody overnight at 4°C, with slow shaking. Following that, the membrane 
was washed three times as before, to remove excess antibodies. The 
appropriate secondary antibody was added to the membrane and incubated for 
1.5 h, with slow shaking at room temperature. This was followed by washing 
of the membrane with 1X TBST twice, for 10 minutes each. The final wash 
was done with 1X TBS for 10 min. The housekeeping protein, β-actin was 
measured to ensure equal loading. The primary antibodies used are shown in 






Table 2.3. Primary antibodies’ sources and dilution used for western blot 
Antibody Source Host species Dilution 
Bcl-2 Cell Signaling, Danvers, 
MA, USA 
Rabbit 1:1000 
C1QBP RIKEN, Wako, Japan Rabbit 1:1000 
Cdc25a Cell Signaling, Danvers, 
MA, USA 
Rabbit 1:1000 
Cdk4  Cell Signaling, Danvers, 
MA, USA 
Mouse 1:1000 
Cdk6 Cell Signaling, Danvers, 
MA, USA 
Mouse 1:1000 
Cyclin D1 Cell Signaling, Danvers, 
MA, USA 
Rabbit 1:2000 
Mcl-1 Cell Signaling, Danvers, 
MA, USA 
Rabbit 1:1000 




(Ser 338)  





Cell Signaling, Danvers, 
MA, USA 
Rabbit 1:2000 





Cell Signaling, Danvers, 
MA, USA 
Rabbit 1:1000 










Cell Signaling, Danvers, 
MA, USA 
Rabbit 1:1000 
Total Stat3 Cell Signaling, Danvers, 
MA, USA 
Rabbit 1:1000 
YB-1 RIKEN, Wako, Japan Rabbit 1:1000 
β-actin Sigma-Aldrich, St Louis, 
MO, USA 
Mouse  1:6000 
2.5.6 Detection and densitometric analysis of protein bands 
Enhanced chemiluminescence (ECL) via Supersignal West Pico 
Chemiluminescent substrate (Pierce Biotechnology) was used to detect the 
protein bands. The ECL substrates provided were mixed well at a 1:1 ratio, 
and pipetted onto the membrane. The membrane was incubated with the 
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solution for 5 min at room temperature. The membrane was then exposed to 
clear blue x-ray films, which were developed in an automatic film processor. 
The densitometer (Model GS-710; Bio-Rad Laboratories) was utilized 
to scan and obtain the images of the protein bands formed on the x-ray film, 
and subsequently, using Quantity-One Image Analysis software version 4.62 
(Bio-Rad Laboratories) or ImageJ, the intensity of the protein bands were 
quantified. The relative protein expression of the protein samples were 
obtained by calculating the ratio of the optical density (O.D.) of the target 
proteins, to the O.D. of the respective β-actin.  
2.6 Immunofluorescence 
Breast cancer cell lines were grown on coverslips, in 6 well plates or 
Lab-Tek® 4-Chambered Coverglass (Nalge Nunc International), until 70% to 
80% confluent. Paraformaldehyde (4%) was used for cells fixation for 15 min. 
This was followed by washing with 1X wash buffer (0.05% Tween-20 in 1X 
PBS). Subsequently, 0.1% Triton X-100 in 1X PBS was used to permeabilize 
the cells for 5 min. Unspecific sites were blocked with 1% BSA, at room 
temperature for 30 min. Primary antibody was then added to the cells and 
incubated at 4°C overnight (Table 2.4). After three series of washing with 1X 
wash buffer, cells were incubated with secondary antibody conjugated with 
Cy-3 or FITC (Sigma-Aldrich) for 1 h at room temperature, followed by 
thorough washing. The coverslip or coverglass was removed and mounted 
with Vectashield® fluorescence mounting medium with 4,6-diamidino-2-
phenylindole (DAPI, Vector Laboratories), to counterstain the nucleus and 
mount the slides at the same time. The slides were visualized using the 
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Olympus Fluoview FV1000 Laser Scanning Confocal Microscopy. Negative 
controls were included where primary antibody was omitted.  
Table 2.4: Primary antibodies’ sources used for immunofluorescence staining 
and dilution used   
Antibody Source Host species Dilution 
C1QBP RIKEN, Wako, Japan Rabbit 1:200 
YB-1 RIKEN, Wako, Japan Rabbit 1:200 
Actin cytoskeleton 
and focal adhesion 
staining kit 
Millipore, Billerica, MA, 
USA 
Mouse 1:100 




2.6.1 Mitochondrial staining  
Mitochondrial staining was done using MitoTracker® Red CMXRos 
(Invitrogen
TM
). Culture medium from cells, which were grown on coverslips 
or Lab-Tek® 4-Chambered Coverglass, was replaced and incubated with pre-
warmed culture medium (37°C) containing 250 nM MitoTracker® probe, for 
30 min at 37°C. Pre-warmed 1X PBS was used for washing to remove residual 
medium, before fixation with 4% paraformaldehyde for 15 min. The 
subsequent steps were as detailed in Section 2.6. 
2.7 Down-regulation of C1QBP and STAT3 in breast cancer cell lines 
2.7.1 Silencing of C1QBP in MDA-MB-231 and T47D breast cancer cell 
line via siRNA targeting C1QBP 
Twenty four hours prior to transfection, 2.5 X 10
5
 cells of MDA-MB-
231 cells or T47D cells were seeded in each well of a 6-well microtitre plate.  
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The ON-TARGETplus SMARTpool siRNA targeting C1QBP, which 
consisted of 4 siRNA sequences (Table 2.5) and the non-targeting siRNA 
pool, were commercially available from GE Dharmacon (Lafayette, CO, 
USA). The transfection reagent used, DharmaFECT2, was also purchased 
from GE Dharmacon. From here on, siRNA targeting C1QBP and non-
targeting siRNA, will be referred to as siC1QBP and NT respectively. 
Table 2.5. Sequences of siRNA used in the study 
siRNA Source ID Target sequence 
C1QBP J-011225-13 GCGAAAUUAGUGCGGAAAG 
 J-011225-14 CGCAAGGGCAGAAGGUUGA 
 J-011225-15 UUUCGUGGUUGAAGUUAUA 
 J-011225-16 GAAGUUAGCUUUCAGUCCA 
The stock siRNA stock solution was 20 µM. The appropriate amount 
of transfection reagent and diluted siRNA were then combined and mixed to 
give a final concentration of 20 nM of siRNA for administration to the cells in 
each well, which were then incubated at 37°C in 5% CO2.  
The transfection procedure applied to cells cultured in 24-well plate 
was similar to the above with the final concentration of siRNA at 20 nM. For 
24-well plates, 0.625 X 10
5
 cells were seeded in each well, with a total volume 
of 1 ml/well.  
The transfection medium was replaced with 2 ml or 1 ml of complete 
culture medium (RPMI1640 containing 10% FBS), for each well of a 6-well 
or 24-well plate, respectively, 24 h post-transfection. Silencing efficiency at 
the gene and protein levels were examined at 48 h and 72 h, after transfection 
respectively. Additionally, cells were fasted for 24 h with serum-free medium 
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and replenished with complete culture medium for 24 h, before harvesting or 
using the cells for further experiments. 
2.7.2 Silencing of STAT3 in MDA-MB-231 breast cancer cell line 
The methods used to silence STAT3 in MDA-MB-231 breast cancer 
cell line were identical to the conditions mentioned above. The only exception 
was the volume of siRNA diluted. The siRNA targeting STAT3 (Santa Cruz 
Biotechnology, Dallas, TX, USA) was supplied as a stock of 10 µM. Thus, the 
transfection procedure for STAT3 required twice the amount of siRNA needed 
previously to obtain a final siRNA concentration of 20 nM. The amount of 
culture medium was adjusted accordingly.  
2.7.3 Double knockdown of YB-1 and C1QBP in MDA-MB-231 cells 
Conditions such as, cell seeding density, culture medium, siRNA, 
transfection reagent and incubation time remained the same as the transfection 
process for individual siRNA. The volume of siRNA was modified for optimal 
silencing of the two genes. Four different treatment groups were constructed 
and supplied with different concentration of siRNAs as followed: 
Group 1: 10 nM of siYB-1 + 10 nM of NT 
Group 2: 10 nM of siC1QBP + 10 nM of NT 
Group 3: 10 nM of siYB-1 + 10 nM of siC1QBP 
Group 4: 20 nM of NT 
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2.7.4 Knockdown of C1QBP in MDA-MB-231 cells overexpressing YB-1 
MDA-MB-231 cells stably overexpressing YB-1 were established 
previously (Yu, 2010). The conditions, concentration and cell density of the 
transfection is the same as Section 2.7.1. 
2.8 Establishment of MDA-MB-231 cells overexpressing C1QBP 
Full length human C1QBP cDNA with a C-terminal c-myc tag was 
inserted into pCI-neo (Promega Corporation), to produce a C1QBP expression 
vector, pCI-neo-C1QBP, a gift from Dr. Ken Matsumoto from RIKEN, Japan. 
pCI-neo-C1QBP and pCI-neo empty plasmids were transfected into MDA-
MB-231 cells using 4 µl of Lipofectamine2000 at a concentration of 1µg, 
respectively. Neomycin-resistant colonies were selected in the presence of 
Geniticin® (Gibco®, Life Technologies, Grand Island, NY, USA) at a 
concentration of 400µg/ml. The overexpression of C1QBP was determined 
using real-time PCR and western blot, at the gene and protein levels, 
respectively. The resulting cells were labelled 231.Vec for MDA-MB-231 
cells transfected with pCI-neo empty plasmids, and 231.C1QBP for MDA-
MB-231 cells transfected with pCI-neo-C1QBP.  
2.9 Assessment of cell proliferation and cell growth 
Breast cancer cell lines were initially fasted for 24 h with serum-free 
medium, and re-nourished with complete medium supplemented with 10% 
FBS, before subjecting to cell proliferation assays. Briefly, at 48 h post-
transfection, transiently transfected cells were starved for 24 h with serum-free 
medium. After starvation, the cells were supplied with fresh complete medium 
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for 24 h before collection or experimentation. On the other hand, C1QBP-
overexpressing cells were starved for 24 h with serum-free medium, and 
replenished with fresh complete medium with 10% FBS for 48 h, before 
harvesting. In total, cells were maintained in culture for 96 h. 
2.9.1 CellTiter 96® AQueous Non-Radioactive Cell Proliferation (MTS) 
assay 
The MTS assay (Promega Corporation) was employed for assessment 
of cell proliferation. The assay is a tetrazolium-based assay, which consists of 
MTS, a tetrazolium compound and phenazine methosulfate (PMS), an electron 
coupling reagent. The reduction of MTS into a soluble formazan dye in the 
presence of metabolic activity by living cells reflects the number of viable 
cells. The working solution was prepared by mixing MTS/PMS solution with 
complete culture medium at a ratio of 1:5. As proliferation assay was 
performed in 24-well culture plates, 1 ml of this solution was added to each 
well of the culture plates and incubated for 1 to 4 hours at 37°C, 5% CO2. The 
absorbance was read at 490 nm using a plate reader (GENios, Tecan Group 
Ltd). 
2.9.2 Growth curve analysis using alamarBlue® assay 
The alamarBlue® assay (Invitrogen
TM
) was used to attain cell growth 
curves. The system, a minimally toxic oxidation-reduction indicator, was able 
to detect fluorometric and colorimetric changes during cellular metabolism in 
living cells. As such, the same set of cells can be used repeatedly for this 
assay, to obtain its growth curve. The working reagent consisted of a mixture 
of alamarBlue® reagent and complete culture medium at a 1:10 ratio. The 
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working reagent was thoroughly mixed, and 1 ml of the reagent was added to 
each well of a 24-well culture plate. The culture was incubated at 37°C in 5% 
CO2 for 1 to 4 hours, and the fluorescent intensity was measured at excitation 
and emission wavelengths of 530 nm and 590 nm, respectively. To reuse the 
set of cells, the alamarBlue® mixture was replaced with culture medium and 
cells were incubated at 37°C with 5% CO2. The procedures above were 
repeated every 24 h for up to 168 h.  
2.9.3 Cell cycle analysis 
Propidium iodide (PI), an intercalating agent which binds to DNA 
enabled the profiling of the DNA content in cell cycle analysis (Pozarowski 
and Darzynkiewicz, 2004). Cell cycle analysis entailed the collection of all 
cells within the culture medium. Therefore, culture media from each set of 
cells was collected, and 1X PBS used to wash the cells was not dispensed but 
collected as well. Adhered cells were collected using the trypsin-EDTA 
method. The cells were centrifuged at 1700 rpm at 4°C for 5 min and washed 
thrice with 1X PBS. The supernatant was discarded each time. After the last 
wash, cells were resuspended in 500 µl of 1X PBS. For fixation, the cell 
suspension was added, drop by drop into 4.5 ml of ice cold 70% ethanol, while 
vortexing the solution. The cells were fixed at 4°C, overnight, and collected by 
centrifuging at 1700 rpm for 5 min. Traces of ethanol was removed by 
washing the cells twice with 1X PBS. Meanwhile, 200 µl of 1mg/ml PI, 2 mg 
of RNase A (Sigma-Aldrich) and 0.1% Triton-X 100 in PBS, were prepared to 
a final volume of 10 ml. The PI dye solution was used to resuspend the cells. 
After 30 min of incubation in the dark, the stained cells were run through the 
CyAn
TM
 ADP Analyzer (Beckman Coulter, Inc., Indianapolis, IN, USA) for 
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cell cycle analysis. The data obtained was analysed by the Summit version 4.3 
software (Beckman Coulter).  
2.10 Cell migration assay 
2.10.1 Wound healing assay 
Wound healing or wound scratch assay was carried out for cells 
transfected with siC1QBP. A straight gap was created with a yellow pipette 
tip, in the middle of each well of a 6-well culture plate, 48 h after transfection. 
The well was washed twice with 1X PBS to remove floating cells, and 
complete culture medium was added after the last wash. The images of the 
‘wound’ were taken at 0 h and 6 h. The gap of the ‘wound’ was measured and 
the difference in measurement between 0 h and 6 h was calculated. 
2.10.2 Transwell migration assay 
The transwell migration assay was carried out by using transwell 
inserts, with a polycarbonate membrane diameter of 6.5 mm and 8.0 µm pores 
(Corning Inc., Corning, NY, USA). Hydration of the inserts were carried out 
by submerging them into 600 µl of serum-free RPMI1640 medium in a 24 
well plate, and loading 200 µl of the same medium into the upper chamber of 
the inserts, followed by incubation at 37°C with 5% CO2 overnight. Prior to 
seeding, MDA-MB-231 cells were resuspended in serum-free RPMI1640 
medium. After removal of the hydration medium, the lower chamber of the 
inserts were filled with 600 µl of RPMI1640 medium containing 15% FBS, 
while the upper chamber of the inserts were seeded with 3 X 10
4
 cells in 200 
µl of serum-free medium. The transwell system was then incubated at 37°C in 
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5% CO2 for 20 h. Following that, the inserts were washed twice with 1X PBS, 
and fixed with 100% methanol for 15 min. Residual methanol was removed by 
air-drying the inserts. Crystal violet (0.5% (w/v) in 20% methanol) was used 
for staining of migrated cells, on the membrane of the inserts. Residual crystal 
violet solution was removed by rinsing the inserts in 2 changes of clean water. 
Non-migratory cells were swabbed off with a moist cotton bud. The transwell 
inserts were left to dry, and viewed under a Nikon SMZ 1500 stereo 
microscope at 10X magnification. Number of cells in the middle and 4 
peripheral fields of the membrane was counted.  
2.11 Cell invasion assay 
BD BioCoat™ Matrigel™ Invasion Chamber with 8 μm pore size PET 
membrane (BD Biosciences, Franklin Lakes, NJ, USA) was used for cell 
invasion assay. Firstly, the inserts were thawed to room temperature and 
rehydrated, by adding 600 µl and 400 µl of serum-free RPMI1640 medium 
into the lower and upper chambers of the inserts, respectively. The inserts 
were incubated at 37°C in 5% CO2 overnight. After careful removal of the 
medium, 3 X 10
4
 MDA-MB-231 cells in 200 µl of serum-free medium, were 
dispensed in the upper chamber of the inserts and 600 µl of RPMI1640 
containing 15% FBS, was dispensed to the lower chamber of the inserts. 
Incubation of the inserts was done at 37°C in 5% CO2 for 20 h. Subsequent 
washing, fixing, staining and viewing steps were done in the same way as for 
the cell migration assay.  
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2.12 Determination of chemoresistance of chemotherapeutic drugs 
2.12.1 Chemotherapeutic drugs  
Doxorubicin hydrochloride, Epirubicin hydrochloride and 5-
Fluorouracil were obtained from Sigma-Aldrich. Stock solution of each of 
these drugs were prepared at a concentration of 10 mM, by dissolving 10 mg 
of Doxorubicin hydrochloride in 1.724 ml of DMSO; 5 mg of Epirubicin 
hydrochloride in 0.862 ml of DMSO and 2.6 mg of 5-Fluorouracil in 2 ml of 
DMSO. These drugs were kept at 4°C for further experiments. Working drug 
solutions for treatment of cells were prepared from the stock, by diluting with 
complete culture medium.  
2.12.2 Assessment of half maximal inhibitory concentration (IC50) of 
chemotherapeutic drugs after silencing or overexpression of 
C1QBP in MDA-MB-231 breast cancer cell line 
MDA-MB-231 cells were seeded at 0.625 X 10
5
 cells/well in 24-well 
plates. The cells were then transfected with siC1QBP or NT siRNA, following 
the procedures in Section 2.7.1. Drugs with a range of concentrations were 
added at 48 h post transfection. The concentrations used were as followed: 
Doxorubicin hydrochloride and Epirubicin hydrochloride: 0 µM, 0.1 µM, 0.3 
µM, 0.5 µM, 1 µM and 2 µM; 5-Fluorouracil: 0 µM, 0.5 µM, 1.0 µM, 2.5 µM, 
4 µM and 5 µM. The cells were incubated with the drugs for 48 h at 37°C with 
5% CO2. The cell viability was evaluated using MTS assay following the 
protocol in Section 2.9.1. The percentage of survival for each set of cells was 
plotted against the log concentration of drug, and the IC50 was compared. 
Two-way ANOVA was done for statistical analysis. The same methods 
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applied to C1QBP-overexpressing cells. However, the cells were fasted for 24 
h and replenished with complete medium for 48 h, before addition of the 
drugs. 
2.12.3 Determination of expression of C1QBP in doxorubicin 
hydrochloride-resistant MCF7 cells and parental MCF7 cells 
Doxorubicin hydrochloride-resistant MCF7 cell line (MCF7R) was a 
gift from Professor Eric Lam from Imperial College London. The MCF7R 
cells were cultured in DMEM medium containing 10% FBS and 0.01 mg/ml 
of Doxorubicin hydrochloride. These cells together with parental MCF7 cells, 
were subjected to treatment with 0.6 µM of Doxorubicin hydrochloride for 0 
h, 12 h, 24 h and 48 h, and the protein lysate from both, cells in the medium 
and adhered cells were collected. Western blot was conducted to determine the 
expression of C1QBP in these two cell lines. The concentration of 
Doxorubicin hydrochloride used that is 0.6 µM, is the IC25 obtained from 
‘kill-curve’ plotted from treatment of parental MCF7 cells with Doxorubicin 
hydrochloride for 48 h. The lower concentration used is to prevent massive 
cell death.  
2.13 Gene expression profiling by GeneChip ST 2.0 microarray 
Total RNA was collected from MDA-MB-231 cells transfected with 
siC1QBP and NT siRNA on the 2
nd
 day after transfection. Silencing efficiency 
of siC1QBP was verified through real time PCR, before delivery to Origen 
Labs (Singapore) for further processing. The Shimadzu spectrophotometer 
(BioSPEC-Mini, Shimadzu Corporation, Kyoto, Japan) and Agilent 
Bioanalyzer, were used to measure the concentration and RNA integrity 
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number (RIN) of the RNA samples, respectively. The processing of the 
samples was in accordance to the Affymetrix and NuGEN recommended 
protocols, while the Ribo-SPIA RNA Amplification/Encore Biotin 
Fragmentation and Labeling was done using Origen Laboratory’s Standard 
Operating Procedure. In short, 100 ng of total RNA was reverse transcribed to 
create a cDNA/mRNA hybrid molecule, which was used as a template to 
produce double stranded cDNA, with a DNA/RNA heteroduple on one end. 
Single stranded anti-sense DNA was produced by amplifying the unique 
double stranded cDNA through SPIA (Single Primer Isothermal 
Amplification). Biotin-labelled sense target cDNA was produced by post-
SPIA modification. Hybridization of these cDNA to the Affymetrix Human 
Gene 2.0 ST array was done with constant rotation at 60 rpm at 45°C for 18 h. 
The FS450_0007 fluidics protocol was employed for the washing and staining 
steps. The array was then scanned using an Affymetrix 3000 7G scanner. 
Hybridization efficiency was elucidated through the scanned images and 
quality control (QC) was carried out in Expression Console (EC) 1.1 software.  
2.13.1 Data analysis for microarray  
The genome-wide gene expressions between MDA-MB-231 cells 
treated with siC1QBP and NT siRNA was compared. Analysis of CEL files 
were carried out by GeneSpring 11.5 software (Silicon Genetics, Redwood 
City, CA, USA) and Partek Genomics Suite (Partek Inc., St. Louis, MI, USA). 
Potential gene candidates were screened by a cut-off point of ±1.5 fold change 
with P<0.05. The Partek Genomics Suite and Database for Annotation, 
Visualization and Integrated Discovery (DAVID) 6.7 were further used to 
determine the potential pathways and genetic annotations involved.  
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2.14 Protein expression of signalling molecules in C1QBP-overexpressing 
cells 
The PathScan® Intracellular Signaling Array Kit (Chemiluminescent 
Readout) (Cell Signaling) is an antibody array, which utilized the enzyme-
linked immunosorbent assay (ELISA) principle. The kit enabled the detection 
of 18 well-characterized signalling molecules in its active form 
(phosphorylated or cleaved). The antibodies provided in the array are depicted 
in Table 2.6. 
Table 2.6. Antibodies included in the PathScan® Intracellular Signaling Array 
Kit 
Target Phosphorylation Site Modification 
ERK1/2 Thr202/Tyr204 Phosphorylation 
Stat1 Tyr701 Phosphorylation 
Stat3 Tyr705 Phosphorylation 
Akt Thr308 Phosphorylation 
Akt Ser473 Phosphorylation 
AMPKα Thr172 Phosphorylation 
S6 Ribosomal Protein Ser235/236 Phosphorylation 
mTOR Ser2448 Phosphorylation 
HSP27 Ser78 Phosphorylation 
Bad Ser112 Phosphorylation 
P70 S6 Kinase Thr389 Phosphorylation 
PRAS40 Thr246 Phosphorylation 
p53 Ser15 Phosphorylation 
p38 Thr180/Tyr182 Phosphorylation 
SAPK/JNK Thr183/Tyr185 Phosphorylation 
PARP Asp214 Cleavage 
Caspase-3 Asp175 Cleavage 
GSK-3β Ser9 Phosphorylation 
 MDA-MB-231 cells stably overexpressing C1QBP and MDA-MB-231 
cells containing empty vector were seeded at 2.5 X 10
5
 cells, in 2 ml of 
complete medium supplemented with 10% FBS and 0.4 mg/ml of geneticin, in 
each well of a 6-well culture plate, and allowed to adhere for 24 h in a 37°C 
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incubator supplied with 5% CO2. Cells were then fasted for 24 h with serum-
free medium and subsequently, replenished with complete medium for 48 h 
before collection.  
 Protein collection was done using 1X Cell Lysis Buffer #7018, which 
was included in the kit. The lysis buffer was thawed and mixed with Halt
TM
 
Protease and Phosphatase Inhibitor Cocktail (Pierce Biotechnology) and 0.5M 
EDTA at a ratio 100:1:1. Medium from the cell culture was removed, and cells 
were washed with ice-cold 1X PBS once. PBS was discarded and 100 µl of 
ice-cold lysis buffer was added to each well. The cells were lysed for 2 min on 
ice. The resulting lysate was scraped, collected and centrifuged at maximum 
speed at 4°C for 3 min, to remove cell debris. Supernatant was collected and 
stored at -80°C as single-use aliquots. The protein concentration of the lysate 
was quantified just before performing the assay, and diluted with Array 
Diluent Buffer to a final concentration of 1.0 mg/ml.  
 Glass slides and blocking buffer were equilibrated to room temperature 
before use. 1X Array Wash Buffer was prepared by diluting 1 ml of 20X 
Array Wash Buffer in 19 ml of deionized water. The multi-well gasket was 
fixed to the glass slide, and assembled as designated in the manufacturer’s 
protocol. Each well was then filled with 100 µl of Array Blocking Buffer, 
covered with sealing tape and incubated for 15 min at room temperature on an 
orbital shaker. The blocking buffer was then discarded. 75 µl of the protein 
lysate was then added to each well, covered with sealing tape and incubated 
overnight at 4°C on an orbital shaker. The lysate was removed and wells were 
washed with 1X Array Wash Buffer for 5 min on a shaker at room 
temperature. The washing step was repeated 3 times and each time, the 
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contents were discarded. Next, 75 µl of 1X Detection Antibody Cocktail was 
added to each well, covered with a sealing tape and incubated at room 
temperature for an hour on an orbital shaker. The wells were then washed for 
4 times, as described previously. After the last wash, 75 µl of HRP-linked 
Streptavidin was added to each well, covered with sealing tape and incubated 
for 30 min at room temperature on a shaker. Again, wells were washed as 
before. The multi-well gasket was then removed and separated from the glass 
slide. The glass slide was washed with 10 ml of 1X Array Wash Buffer. 
LumiGLO®/Peroxide reagent was used to produce the chemiluminescent 
signal. Immediately before use, 9 ml of deionized water, 0.5 ml of 20X 
LumiGLO® and 0.5 ml of 20X Peroxide, were combined to produce 1X 
LumiGLO®/Peroxide chemiluminescent reagent. The wash buffer was 
removed and slide was covered with 1X LumiGLO®/Peroxide 
chemiluminescent reagent. The slide image was captured directly by the 
ChemiDoc
TM
 MP system (Bio-Rad Laboratories). The intensity of each dots 
were measured by ImageLab Version 5.0 (Bio-Rad Laboratories). 
2.15 Stable isotope labelling by amino acids in cell culture (SILAC)-
immunoprecipitation quantitative proteomics analysis 
2.15.1 SILAC 
MDA-MB-231 cells containing empty vector and MDA-MB-231 cells 
overexpressing the myc-tagged C1QBP plasmid, were differentially labelled 
to incorporate isotopic forms of lysine and arginine present in DMEM media. 
Media containing normal (or ‘light’ (L)) isotypes of L-lysine (12C614N2) (143 




N4) (83 µg/ml, Sigma-Aldrich), 
59 
 
was used to culture 231.Vec cells, while 231.C1QBP cells were cultured in 





N4) (Cambridge Isotope Laboratory, Tewksbury, MA, USA). Cells 
were grown in their respective SILAC media for at least 5 to 6 doublings, to 
ensure complete incorporation of labelled amino acids. Subsequently, these 
cells were harvested for immunoaffinity purification of protein complexes.  
2.15.2 Immunoaffinity Purification of Protein Complexes 
Cell pellets were lysed in ice-cold modified RIPA buffer (50mM Tris 
pH7.5, 150mM NaCl, 1% NP40) containing Complete, Mini, EDTA-free 
Protease Inhibitor Cocktail Tablet and PhosSTOP Phosphatase Inhibitor 
Cocktail Tablet (Roche Diagnostic, Basel, Switzerland), and centrifuged at 
20000 g for 20 min at 4°C. For the immunoaffinity experiments, 10mg of 
extracts from each differentially labelled cell line were affinity purified 
separately by overnight incubation at 4ºC, with equal amount of normal mouse 
IgG (Santa Cruz Biotechnology) or anti-c-myc antibody (Santa Cruz 
Biotechnology) for 231.Vec and 231.C1QBP cells, respectively. The 
following day, each of the antibody-bound samples were added to protein A/G 
Plus agarose beads (Santa Cruz Biotechnology) and incubated at 4°C for 2 to 3 
h. The beads were combined carefully after one wash step in RIPA buffer, and 
were washed for an additional three times with RIPA buffer thereafter. To 
elute the bound proteins from the anti-myc agarose beads, a 1.5X bead-volume 
of 2X lithium dodecyl sulfate sample buffer with reducing agent was added, 
and the matrix was boiled for 5 min. Separation of proteins were conducted on 
NuPAGE 4-12% Bis-Tris gels (Invitrogen
TM
), that were then stained with 
Colloidal Blue (Invitrogen
TM
), followed by overnight destaining, before being 
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processed for mass spectrometry. Mass Spectrometry and Data Analysis 
Eluted protein complexes were separated and digested as detailed previously 
(Shevchenko et al., 2006). Samples were analysed on an Orbitrap or Orbitrap 
XL (Thermo Fisher Scientific), coupled to a Proxeon Easy-nLC. The MS 
spectra and protein identity, as well as quantification, was obtained as 
described previously (Gunaratne et al., 2011). Briefly, the Mascot version 2.2 
software (Matrix Science, London, UK) was used to identify and quantify 
proteins, against a database prepared from the human International Protein 
Index (IPI) (version 3.68), with addition of common contaminants such as, 
human keratins, porcine trypsin and proteases. MaxQuant version 1.0.13.13 
with default settings was used for SILAC peptide and protein quantification, 
with a maximum false discovery rates (FDR) of 0.01 (Cox and Mann, 2008). 
2.15.3 Validation of YB-1 as an interacting partner of C1QBP by co-
immunoprecipitation 
Modified RIPA buffer (50mM Tris pH7.5, 150mM NaCl, 1% NP40) 
supplemented with Halt
TM
 Protease and Phosphatase Inhibitor Cocktail (Pierce 
Biotechnology), was used to obtain protein lysate from MDA-MB-231 cells 
overexpressing C1QBP. Cell pellet obtained from cells, was lysed with 3X the 
cell pellet volume of modified RIPA buffer and incubated for 20 min on ice. 
The lysate was then centrifuged at 15000 g for 20 min at 4°C and supernatant 
was kept. At least 1 mg of protein was used for co-immunoprecipitation. The 
protein lysate was incubated with either 2 µg of YB-1 antibody, 1 µg of c-myc 
antibody (Santa Cruz Biotechnology) or 1 µg of appropriate IgG (Santa Cruz 
Biotechnology) and topped-up to 1 ml with modified RIPA buffer at 4°C, 
overnight. The rabbit polyclonal YB-1 antibody was a gift from Dr. Ken 
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Matsumoto from RIKEN, Japan. Forty microliters of protein A/G sepharose 
beads (Sigma-Aldrich) were washed with 500 µl of modified RIPA buffer 
twice, by spinning at 2000 rpm for 2 min at 4°C. After each wash, supernatant 
was discarded. Pre-incubated lysate with antibodies was then mixed with the 
protein A/G beads and incubated for 3 h at 4°C.  The complex formed was 
then washed with 1 ml modified RIPA buffer to remove unspecific binding, by 
centrifugation at 2000 rpm for 2 min at 4°C. After each wash, supernatant was 
removed with gel loading tips and this was repeated for 4 times. Peptide 
elution using K13 peptide (Genescript, Piscataway, NJ, USA) for YB-1 and 
myc peptide (Sigma-Aldrich) for anti-myc, was then carried out. 
Approximately 30 µl of peptide (2.5 mg/ml) was incubated with the beads. 
The tube was placed in a tube shaker for 20 min at 4°C. Then, the mixture was 
centrifuged at 2000 rpm for 2 min at 4°C. The supernatant was transferred to 
another tube and loading dye was added to the supernatant, as well as the 
leftover beads. The samples were boiled at 95°C for 5 min and run on SDS-
PAGE.  
2.15.4 Immunostaining of C1QBP and YB-1 in MDA-MB-231 cells 
overexpressing C1QBP 
To represent C1QBP, mouse monoclonal anti-myc was used, as C1QBP-
overexpressing cells were tagged with myc. The immunofluorescence 
procedure was detailed in Section 2.6. The dilution factor of mouse 
monoclonal anti-myc used was 1:100, while for rabbit polyclonal YB-1 
antibody, the dilution factor used was 1:200. Secondary antibodies were 
diluted at 1:200, for both anti-mouse and anti-rabbit. Anti-mouse and anti-
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rabbit secondary antibodies were used for cells incubated with anti-myc and 
anti-YB-1, respectively.  
2.16 Statistical analyses used for in vitro experiments 
Statistical analyses were carried out by GraphPad Prism 5 (GraphPad 
Prism, San Diego, CA, USA). Two-tailed student t-test was done for 
comparison of means between two groups. When more than two groups were 
involved, one-way ANOVA was used instead. Data are presented as mean ± 
SEM and a P<0.05 was considered as statistically significant. Two-way 
ANOVA was used when two variables were introduced. For two-way 
ANOVA, P-value of less than 0.05 for interaction between variables was 
considered statistically significant. Experiments were carried out with at least 

















3.1 Gene expression profile of C1QBP in breast cancer tissue samples 
The mRNA expression profile of C1QBP was carried out in Human 
Breast Cancer Panel I TissueScanTM Tissue qPCR Array, which consisted of 
48 cDNA samples from normal and cancerous breast tissue specimens 
(Adenocarcinoma of the breast, ductal: 39 samples; Adenocarcinoma of the 
breast, lobular: 2, Normal breast tissue: 7). The clinicopathological data are 
provided in Table 3.1. The term ‘Not applicable’ refers to clinicopathological 
data which is not relevant for the normal tissue samples, while the term 




Table 3.1. Clinicopathological parameters of samples from Human Breast 
Cancer Panel I TissueScan
TM

















































































The gene expression of C1QBP was evaluated in breast cancer stages 
which had been divided into two groups, – AJCC stage normal to stage IIa and 
AJCC stage IIb to IIIc – the latter being the more advanced stages of breast 
cancer. In the advanced stages of breast cancer, the expression of C1QBP was 
significantly increased (P=0.0109, Figure 3.1A). Apart from that, C1QBP 
expression was also remarkably higher in tissues of breast cancer patients with 
lymph node spread (P=0.0169, Figure 3.1B) and in T3 tumor size compared to 




Figure 3.1. Relative gene expression of C1QBP in breast cancer tissue 
samples. The expression of C1QBP gene was increased in (A) higher stages of 
breast cancer, (B) positive lymph node spread and (C) tumor size of stage 3 
compared to tumor sizes of stage 1 and 2. The panel contained 48 pre-
normalized breast cancer tissue mRNA samples. The relative expression of 
C1QBP was obtained by comparing each sample’s Ct value to mean Ct value 
of normal breast tissues. The values are represented as mean ± SEM. P<0.05 
was considered statistically significant. 
 The amplification curve which plots ∆Rn to PCR cycle number, 
reflected the quantitative expression of C1QBP in the array (Figure 3.2A). 
∆Rn represents the log of normalized reporter signal without the baseline 
signal. The single peak of the melting curve indicated that the primer used to 




Figure 3.2. (A) Amplification plot and (B) melting curve indicated the Ct 
value and specificity of the C1QBP primer, respectively.  
3.2 Immunohistochemical analysis of C1QBP in breast cancer tissue 
microarray samples 
3.2.1 Clinicopathological parameters of breast cancer patients 
diagnosed with invasive ductal carcinomas 
Following the assessment of the gene expression of C1QBP in clinical 
samples, protein expression of C1QBP was evaluated in breast cancer TMAs. 
Only tissue sections from patients diagnosed with invasive ductal carcinoma 
were included in the study. A total of 132 out of 199 breast cancer tissue 
sections were used for the study. The excluded sections accounted for different 
subtypes of breast cancer, and also, loss of sections during processing of 
TMAs and immunohistochemical staining. The statistical distribution of 
clinicopathological parameters containing continuous variables are shown in 
Table 3.2 and clinicopathological parameters of the tissues from the breast 




Table 3.2. Statistical distribution of parameters with continuous variable (age 
and tumor size) 
Parameters Statistical distribution 
Minimum Maximum Mean 
Age (years) 23 88 56 
Tumor size (mm) 10 140 41 
All tissue sections of the study were obtained from female patients. 
Patients’ age ranged from 23 to 88 years old, with a mean age of 56 years old 
(Table 3.2). A majority of the patients were Chinese (77.3%), followed by 
Malay (9.8%) and Indian (1.5%). Other ethnic races accounted for 10.6% of 
the total study population. Histological grade of the tissue sections were 
available for 126 patients and 6.1% of the tissues were classified under Grade 
1, while 89.4% were Grade 2 and 3. The extent of DCIS was known for 118 
cases of which, 72.0% were categorized as negative or minimal, and 17.4% as 
extensive. Information for DCIS grade was available for 85 cases. Among the 
cases, 3% were graded low while 61.4% were graded as intermediate or high. 
Information on tumor size was available for 130 cases. Tumor size was 
stratified according to its mean of 41 mm (Table 3.2). Out of the available 
cases, 63.6% of the tumors were 41 mm or less, and 34.8% of the tumors were 
larger than 41 mm. ER status, PR status and HER2 receptor status were 
recorded for 129 patients. 37.1% of the tissues were ER-positive while 60.6% 
were negative. Patients with PR-negative and PR-positive tumors made up 
47.0% and 50.8% of the available cases, respectively. Out of the 129 




Table 3.3. Clinicopathological parameters of the study population (n=132) 








































Nuclear Pleomorphism Score 
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3.2.2 Association between immunohistochemical expression of C1QBP 
and clinicopathological parameters 
3.2.2.1 Expression of C1QBP in breast cancer tissues 
The expression of C1QBP in breast cancer tissues was determined by 
immunohistochemical staining, and its expression was associated with 
clinicopathological parameters via Chi-square analysis. The various intensities 
of C1QBP staining are shown in Figure 3.3A-C. The expression of C1QBP 
was scored based on the staining intensity with 1+ for weak staining, 2+ for 
moderate staining and 3+ for strong staining, respectively. A negative control 
was included with omission of primary antibody (Figure 3.3D). The 
immunostaining of C1QBP in breast cancer epithelial cells was predominantly 
cytoplasmic and mainly observed to be granular in nature. Although there 
seemed to be accentuation of the staining at the cell membrane, no distinct 
membrane staining was observed.  
 
Figure 3.3. Representative images of immunohistochemical staining of 
C1QBP in breast cancer tissue microarrays. The intensity of the staining was 
assigned as (A) 1+ for weak staining, (B) 2+ for moderate staining and (C) 3+ 
for strong staining. Scale bar: 100 µm. (D) Absence of staining in the negative 





3.2.2.2 Statistical analysis of association between immunohistochemical 
expression of C1QBP and clinicopathological parameters 
Out of 132 cases, only one case did not show immunopositive staining. 
The immunostaining of C1QBP was quantified by the weighted average index 
(WAI) score.  The minimum WAI score was recorded as 0 while the 
maximum WAI score reached 2.5. Mean WAI score was 1.5 (Table 3.4).  
Table 3.4. Statistical distribution of WAI score for C1QBP 
immunohistochemical expression 
Parameters Statistical distribution 
Minimum Maximum Mean 
Weighted average index (WAI)  0.0 2.5 1.5 
With a cut-off point at 1.5, the WAI scores were grouped into two sets. 
Number of cases with WAI of less than or equal 1.5 accounted for 58.3% 
(n=77) of the cases, while number of cases with WAI of more than 1.5 
accounted for 41.7% (n=55) of the total cases (Table 3.5).  
Table 3.5. Statistical distribution of C1QBP immunostaining in breast cancer 
tissue microarray (n=132) 


















Chi-square analysis was used to determine the association of C1QBP 
expression and clinicopathological parameters. The associations between the 
expression of C1QBP and histological grade, nuclear pleomorphism, tubule 
formation, mitotic index, DCIS extent and grade, ER status, PR status and 
HER2 status were not statistically significant. Breast cancer tissue expression 
of C1QBP was significantly up-regulated in patients who are more than 56 
years old (P=0.001), patients having tumor of more than 41 mm in size 
(P=0.002) and positive lymph node spread (P=0.027). The data is summarized 




Table 3.6. Univariate analysis for C1QBP immunostaining with 





















2 and 3 
  






















































































































Unavailable cases for each parameter are shown in Table 3.3 
Statistical significance: *P<0.05, **P<0.01 
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Multivariate analysis using backwards logistic binary regression was 
then carried out to determine the independence of C1QBP as a predictor of 
tumor size and lymph node spread. After adjustment of confounding factors, 
which include age, ER status, PR status and HER2 status, C1QBP was 
determined to be independently associated to tumor size in PR-positive breast 
cancer patients (P<0.001, Table 3.7). A WAI value of more than 1.5 increased 
the odds ratio of possessing a tumor size that is larger than 41 mm, by 10.8 
times. Also from the analysis, C1QBP was not an independent predictor for 
lymph node spread.  
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Statistical significance: *P<0.05, **P<0.01, ***P<0.001 
3.2.3 Association of C1QBP expression and Proliferating Cell Nuclear 
Antigen (PCNA) 
3.2.3.1 Expression of PCNA in breast cancer tissue samples 
As tumor size is a gauge for tumor proliferation, the association of 
C1QBP expression and PCNA, which is a well-known marker of proliferation 
was determined. A total number of 66 cases were used for comparison of 
PCNA. All tissue sections were positive for PCNA staining with percentage of 
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staining in tissue sections ranging from 5% to 100%. PCNA staining was 
mostly seen in the nucleus (Figure 3.4).   
 
Figure 3.4. Representative micrographs of PCNA immunostaining in breast 
cancer tissue microarrays. Tissue sections with (A) high and (B) low 
expressions of PCNA. Scale bar: 100 µm.  
3.2.3.2 Correlation between immunohistochemical expression of C1QBP 
and PCNA 
The expression of C1QBP has a significant correlation to the 
expression of PCNA as determined by Pearson’s correlation (P=0.0229, 
Pearson’s R=0.2863).  
 
Figure 3.5. Correlation between C1QBP and PCNA immunopositive staining; 





3.3 Expression of C1QBP in breast cancer cell lines 
3.3.1 Characteristics of various breast cancer cell lines 
To uncover the functional characteristics of C1QBP in breast cancer, in 
vitro experimentation was performed. The breast cancer cell lines that were 
used included, ZR-75-1, T47D, MCF7 and MDA-MB-231. The ZR-75-1 cells 
are positive for ER and negative for PR. T47D and MCF7 cell lines are 
positive for both ER and PR, while MDA-MB-231 cells are negative for both 
hormone receptors (Kao et al., 2009). The potential of the cell lines to invade 
varied widely with ZR-75-1 cells, and MCF7 cells being non-invasive, T47D 
cells are less invasive while MDA-MB-231 cells are highly invasive (Tai et 
al., 2003). This is summarized in Table 3.8. 
Table 3.8: Breast cancer cell lines with its respective estrogen receptor, 
progesterone receptor and invasiveness status.  
Breast cancer cell line ER status PR status Invasiveness  
(Tai et al., 2003) 
ZR-75-1 + - Non-invasive 
T47D + + Less invasive 
MCF7 + + Non-invasive 
MDA-MB-231 - - Highly invasive 








ZR-75-1 cells, T47D cells and MCF7 cells displayed an epithelial-like 
morphology, while MDA-MB-231 cells possessed spindle-like shaped cells 
(Figure 3.6). 
 
Figure 3.6. Breast cancer cell lines used in this study. (A) ZR-75-1 (B) T47D 










3.3.2 Gene profile of C1QBP in breast cancer cell lines 
The C1QBP gene was constitutively expressed in all the breast cancer 
cell lines examined. ZR-75-1 had the lowest gene expression of C1QBP. The 
expression of C1QBP was relatively higher in T47D, MDA-MB-231 and 
MCF7 breast cancer cell lines (Figure 3.7).  
 
Figure 3.7. Real-time PCR of C1QBP in breast cancer cell lines. (A) ∆Ct 
values of C1QBP in breast cancer cell lines obtained by normalization to 
GAPDH, a housekeeping gene. (B) Relative expression of C1QBP in breast 
cancer cell lines compared to ZR-75-1. Values are presented as mean ± SEM. 
**P<0.01, ***P<0.001. Experiments were done in triplicates and repeated 
three independent times. 
Primer specificity of the primers for C1QBP and GAPDH were 
determined by gel electrophoreses. A single band was seen from the gel 
indicating the specificity of the primers (Figure 3.8). 
 
Figure 3.8. Representative gel electrophoresis image for real-time PCR 
products of (A) C1QBP and (B) GAPDH, with sizes of 161 bp and 160 bp, 




3.3.3 Protein expression of C1QBP in breast cancer cell lines 
The protein expression of C1QBP was next examined in the breast 
cancer cell lines. Consistently, ZR-75-1 cells had the lowest expression of 
C1QBP. However, the expression of C1QBP was highest in MCF7 cells, 
followed by MDA-MB-231 cells and T47D cells. There was no significance 
difference between the expression of C1QBP in T47D, MCF7 and MDA-MB-
231 cell lines (Figure 3.9).  
 
Figure 3.9. Protein expression of C1QBP in breast cancer cell lines. (A) 
Western blot representation of C1QBP and β-actin protein expression in breast 
cancer cell lines. (B) O.D. ratio of C1QBP to β-actin in breast cancer cell 
lines. O.D. ratio are presented as mean ± SEM. Statistical significance was 
achieved at *P<0.05 and **P<0.01. Experiments were done in triplicates and 









Intracellular localization of C1QBP was observed by 
immunofluorescence staining in both the MDA-MB-231 and T47D breast 
cancer cell lines (Figure 3.10). From the images, C1QBP was observed to be 
present in both the cytoplasm and nucleus. Cytoplasmic expression of C1QBP 
appeared spotty in nature.   
 
Figure 3.10. Immunofluorescence images of C1QBP in (A) MDA-MB-231 
indicating nuclear and cytoplasmic staining and (B) MDA-MB-231 cells 
indicating only a proportion of cells have nuclear staining. (C) 
Immunofluorescence images of T47D breast cancer cell lines showing that 
C1QBP expression was localized in the cytoplasm and nucleus of the cells. 




The localization of C1QBP was further validated by double staining of 
C1QBP and MitoTracker® Red CMXRos in MDA-MB-231 cells and T47D 
cells, to determine the co-localization of C1QBP and mitochondria. Indeed, 
the expression of C1QBP in both cell lines was mainly observed to co-localize 
with the red mitochondrial staining when the images were merged as depicted 
in Figure 3.11. 
 
Figure 3.11. Co-localization of C1QBP with mitochondria in (A) MDA-MB-
231 and (B) T47D. C1QBP was stained green with FITC-conjugated antibody 
while mitochondria were stained red with MitoTracker® Red CMXRos. The 
co-localization of C1QBP and mitochondria was displayed as yellow in the 






3.4 Transient down-regulation of C1QBP in breast cancer cell lines 
3.4.1 Knockdown of C1QBP in MDA-MB-231 breast cancer cell line 
MDA-MB-231 breast cancer cells were used as the main cell line in 
the study, as the gene and protein expression of C1QBP were relatively high. 
In addition, MDA-MB-231 is a metastatic cell line with high invasive 
capabilities, which are not present in the other cell lines. 
The transfection efficiency of DharmaFECT2 transfection reagent in 
MDA-MB-231 was assessed using a cy3-conjugated non-targeting siRNA, 
warranting that the siRNA complex entered the cells. More than 90% of the 
cells were transfected with the siRNA using the DharmaFECT2 transfection 
reagent (Figure 3.12).  
 
Figure 3.12. DharmaFECT2 transfection efficiency in MDA-MB-231 
observed by using cy3-conjugated non-targeting siRNA. (A) Cy3-conjugated 
non-targeting siRNA transfected into MDA-MB-231 cells using 
DharmaFECT2 transfection reagent. (B) Cy3 staining superimposed onto 
corresponding MDA-MB-231 cells bright field image indicating a transfection 




Knockdown of C1QBP in MDA-MB-231 cells at the gene and protein 
levels, were established by real-time PCR and western blot respectively. The 
expression of C1QBP at the gene level was depleted by 94% (Figure 3.13), 
while the protein expression of C1QBP was depleted by 76%, after 
transfection with siRNA targeting C1QBP (Figure 3.14).  
 
Figure 3.13. Relative C1QBP gene expression in MDA-MB-231 cells 48 h 
after transfection with siC1QBP. The C1QBP gene level was reduced by 
approximately 94% in MDA-MB-231 cells. Values are presented as mean ± 
SEM, ***P<0.001. Experiments were done in triplicates and repeated twice. 
 
Figure 3.14. Silencing efficiency of siC1QBP at the protein level in MDA-
MB-231 breast cancer cell lines 72 h after transfection. (A) Western blot 
showed an obvious reduction of C1QBP protein in MDA-MB-231 cells 
transfected with siC1QBP. (B) The protein level was decreased by 76% 
compared to cells transfected with non-targeting siRNA. Relative protein 
expression are presented as mean ± SEM.  ***P<0.001. Experiments were 




3.4.2 Knockdown of C1QBP in T47D breast cancer cell lines 
T47D breast cancer cell line was also used, to verify the effect of 
C1QBP on proliferation in PR-positive breast cancer cells. Silencing 
efficiency of siC1QBP in T47D cells was attained at 85% and 81% at the gene 
and protein level, respectively (Figure 3.15 and Figure 3.16). 
 
Figure 3.15. Down-regulation of C1QBP gene in T47D breast cancer cell line, 
96 h after transfection. Silencing efficiency was achieved at approximately 
85%. Fold change are presented as mean ± SEM. ***P<0.001. Experiments 
were done in triplicates and repeated twice. 
 
Figure 3.16. Knockdown of C1QBP protein in T47D breast cancer cell line 96 
h post-transfection. (A) Western blot of the knockdown efficiency of siC1QBP 
in T47D cells. (B) Graph showing about 81% reduction of C1QBP protein 
expression in T47D cells. Relative protein expression are presented as mean ± 




3.5 Association of C1QBP knockdown with cell proliferation 
3.5.1 Knockdown of C1QBP affected cell proliferation in MDA-MB-231 
cell line 
In MDA-MB-231 cells, cell proliferation was measured using MTS 
assay after knockdown of C1QBP. The cells were fasted for 24 h before 
measurement of MTS at 72 h and 96 h. At both these time points, cell 
proliferation was significantly decreased in MDA-MB-231 cells transfected 
with siC1QBP (P=0.0115, P=0.0029, Figure 3.17). 
 
Figure 3.17. Down-regulation of C1QBP decreased cell proliferation in MDA-
MB-231 cells at (A) 72 h and (B) 96 h post-transfection, as measured by MTS 
assay. Cells were fasted on the 3
rd
 day after transfection and replenished with 
complete medium after 24 h. Absorbance value of MTS assay was read at 490 
nm. Each column represents the percentage of growth ± SEM. *P<0.05, 









In addition, cell growth curve was also plotted for MDA-MB-231 cells, 
after knockdown of C1QBP for a period of 96 h (Figure 3.18). The 
measurements were taken every 24 h using the alamarBlue assay. Using two-
way ANOVA, the cell growth was found to be significantly lower in 
231.siC1QBP cells which reflected the results from the MTS assay 
(P=0.0005).  
 
Figure 3.18. Knockdown of C1QBP significantly decreased the cell growth of 
MDA-MB-231 cells. Cell growth curve was plotted by measurements from 
alamarBlue assay taken at 0 h, 24 h, 48 h, 72 h and 96 h. Percentage of 
measurements ± SEM are shown. Statistical significance was determined by 
two-way ANOVA (***P<0.001). Experiments were done in quadruplicates 
and repeated twice. 
Cell proliferation could be governed by the cell cycle process. The cell 
cycle process is controlled by regulatory molecules, such as the cyclins and 
cyclin-dependent kinases (CDKs), which determine the progression of cells to 
subsequent cell cycle phases. Hence, several main regulatory proteins of the 
cell cycle process were examined after knockdown of C1QBP (Figure 3.19). 
There was a significant decrease of Cyclin D1 after knockdown of C1QBP 
compared to control cells (P=0.007). In addition, there was a decrease in 
CDK4 expression (P=0.0882). The expressions of CDC25a and CDK6 were 




Figure 3.19: Cell cycle-related proteins’ expression after knockdown of 
C1QBP. The expression of CDK4 and Cyclin D1 was downregulated after 
knockdown of C1QBP in MDA-MB-231 cells. The protein levels of CDC25A 
and CDK6 were not affected. Although the difference was not statistically 
significant, the difference in protein expression of CDK4 between the two 
groups was marginally significant (P=0.0882). Statistical significance was 
achieved at **P<0.01. Values are presented as mean ± SEM. Experiments 






3.5.2 Knockdown of C1QBP in T47D breast cancer cell line affected 
proliferation 
Based on the TMA results shown earlier, C1QBP seemed to affect 
tumor growth in PR-positive breast cancer patients. Therefore, knockdown of 
C1QBP in T47D breast cancer cell lines was carried out to determine the 
effect of C1QBP on proliferation in a PR-positive cell line. At 72 h after 
transfection, there was no significant difference in cell growth as measured by 
MTS assay (P=0.8854, Figure 3.20A). However, cell growth measured by the 
same method was significantly reduced in T47D cells 96 h after transfection 
with siC1QBP (P=0.0015, Figure 3.20B). The alteration of cell growth by 
C1QBP was further verified by the alamarBlue assay (Figure 3.20C). A 
decrease in cell growth of T47D cells was observed, when measured by 
alamarBlue assay over 168 h. The difference was statistically significant 
(P=0.0008). 
 
Figure 3.20. Cell growth and proliferation were affected after knockdown of 
C1QBP in T47D breast cancer cell line. Cell proliferation measured by MTS 
assay was not affected at (A) 72 h, but significantly decreased at (B) 96 h after 
transfection of siC1QBP in T47D breast cancer cell line. Bar chart was 
presented as mean(%) ± SEM. **P<0.01. (C) AlamarBlue assay indicated a 
decrease in cell growth over 168h, after knockdown of C1QBP. The difference 
was statistically significant with P=0.0008, determined by two-way ANOVA. 





3.6 Effect of knockdown of C1QBP on cell migration and invasion in 
MDA-MB-231 cells 
Cell migration was measured using the wound scratch method, and 
limited to 6 h to prevent interference from cell proliferation. In addition, 
transwell migration assay was carried out. Knockdown of C1QBP 
significantly decreased cell migration in MDA-MB-231 cells as measured by 
wound scratch assay (Figure 3.21, P=0.0006). 
 
Figure 3.21. Decreased expression of C1QBP inhibited cell migration in 
MDA-MB-231 cells via wound healing assay. A gap was created using a 
yellow tip at 72 h after transfection. (A) Images were taken at 0 h and 6 h 
thereafter. Five fields were taken for each sample and five measurements were 
made for each field. Scale bar: 200 µm. The width of the gap was measured at 
0 h and 6 h, using ImageJ software. (B) The distance of cell migration was 
determined by the difference of the gap measurements at 0 h and 6 h. Each bar 
in the bar chart are presented as mean ± SEM. ***P<0.001. Experiments were 




In addition, transwell migration assay was carried out after down-
regulatin of C1QBP. Knockdown of C1QBP significantly decreased cell 
migration in MDA-MB-231 cells as measured by transwell migration assay 
(Figure 3.22, P=0.0435). 
 
Figure 3.22: Knockdown of C1QBP in MDA-MB-231 cells decreased cell 
migration as observed in transwell migration assay. (A) Representative images 
of the transwell inserts and the respective membranes at 15X magnification 
and 100X magnification, respectively. (B) Cell migration was significantly 
decreased after knockdown of C1QBP in MDA-MB-231 cells. Experiment 






Cell invasion was also assessed after knockdown of C1QBP. Although 
a general decrease was observed, it was statistically not significant (P=0.3623, 
Figure 3.23). 
 
Figure 3.23. Invasion assay using transwell inserts after knockdown of C1QBP 
in MDA-MB-231 breast cancer cells. (A) Representative images of the 
transwell inserts and the respective membranes at 15X magnification and 
100X magnification, respectively. (B) Although cell invasion was slightly 
diminished after knockdown of C1QBP, the difference was not statistically 







3.7 Effect of C1QBP attenuation on chemosensitivity of MDA-MB-231 
cells 
Chemosensitivity of MDA-MB-231 cells towards Doxorubicin 
hydrochloride, Epirubicin hydrochloride and 5-Fluorouracil were examined 
after transient knockdown of C1QBP. After 48 h of treatment with the drugs, 
cells with reduced expression of C1QBP displayed lower percentage of cell 
viability (Figure 3.24). The IC50 values for each treatment generally exhibited 
a lower IC50 value after knockdown of C1QBP. Statistically, only treatment 
of cells with Doxorubicin hydrochloride demonstrated a marginal difference 
when C1QBP was diminished (P=0.0579). 
 
Figure 3.24. Chemosensitivity of MDA-MB-231 breast cancer cell line to 
various drugs - (A) Doxorubicin hydrochloride (B) Epirubicin hydrochloride 
and (C) 5-Fluorouracil – was increased after knockdown of C1QBP. Cell 
viability measurements are presented as mean ± SEM. (D) IC50s of 
chemotherapeutic drugs were determined for MDA-MB-231 breast cancer cell 
line transfected with non-targeting and siRNA targeting C1QBP, respectively. 
Statistical analysis was done using two-way ANOVA. Experiments were done 





3.8 Stable overexpression of C1QBP in MDA-MB-231 breast cancer cell 
line 
The full-length human C1QBP cDNA with a C-terminal c-myc tag, was 
inserted into pCI-neo (Promega Corporation) to produce a C1QBP expression 
vector, pCI-neo-C1QBP. Stable overexpression of C1QBP was established in 
MDA-MB-231 breast cancer cell line by transfection of pCI-neo-C1QBP 
plasmid into MDA-MB-231 cells. MDA-MB-231 cells were also transfected 
with empty pCI-neo plasmid, which acted as the control cells. The C1QBP 
insert was sequenced to ensure its specificity (Figure 3.25).  
 




The resulting colonies after selection with G418 were elected and 
cultured. The selected colony has a stable overexpression of C1QBP gene, 8 
folds higher than cells transfected with empty plasmids (Figure 3.26).  
 
Figure 3.26. Stable overexpression of C1QBP gene in MDA-MB-231 breast 
cancer cell line. The C1QBP-overexpressing cells expressed approximately 8 
folds higher expression of the C1QBP gene, compared to cells stably 
transfected with empty vector. Experiments were done in triplicates and 
repeated twice. 
Measurements of the protein levels in C1QBP-overexpressing cells 
indicated that protein expression of C1QBP was approximately 3.3 times 
higher compared to control cells (Figure 3.27). 
 
Figure 3.27. Protein overexpression of C1QBP in MDA-MB-231 breast cancer 
cells stably transfected with pCI-neo-C1QBP. (A) Representation of western 
blot images showing an increase expression of C1QBP in MDA-MB-231 cell 
line stably transfected with C1QBP-containing plasmid, compared to cells 
transfected with plasmid without inserts. β-actin served as the loading control. 
(B) C1QBP was significantly overexpressed in selected MDA-MB-231 breast 
cancer cell line transfected with C1QBP-containing plasmid compared to cells 
transfected with empty vector. O.D. ratios are presented as mean ± SEM. 




The overexpression of C1QBP was also validated by 
immunofluorescence staining (Figure 3.28). Increased FITC staining was 
observed in C1QBP-overexpressing cells. The increased expression of C1QBP 
also co-localized with Mitotracker, indicating that the overexpression of 
C1QBP mostly occurred in cell mitochondria. 
 
Figure 3.28. Immunofluorescence images of MDA-MB-231 cells 
overexpressing C1QBP. C1QBP-overexpressing cells showed more intense 
FITC staining (green), indicating a higher presence of C1QBP protein 
compared to cells transfected with empty vector. When the images were 
merged with the Mitotracker dye, overexpression of C1QBP protein was 






3.9 Association of C1QBP overexpression and cell proliferation 
After establishing C1QBP-overexpressing cells, cell proliferation was 
measured using MTS or alamarBlue assays. The stable overexpression of 
C1QBP in MDA-MB-231 cells increased cell growth, as measured by MTS at 
72 h after seeding (Figure 3.29A). Growth curve of the C1QBP-
overexpressing cells, plotted using readings from alamarBlue taken over 96 h, 
also showed a remarkable escalation compared to control cells (Figure 3.29B).  
 
Figure 3.29. Stable overexpression of C1QBP increased cell growth in MDA-
MB-231 breast cancer cell line. (A) Measurements done by MTS assay 
showed that the overexpression of C1QBP significantly increased cell viability 
in MDA-MB-231 cells. Bar chart are presented as mean(%) ± SEM. 
***P<0.001. (B) The growth curve of MDA-MB-231 stably overexpressing 
C1QBP displayed accelerated growth rate compared to control cells. The 
graph was generated by alamarBlue fluorescence measurements taken, up till 
96 h. Each point in the growth curve was presented as mean(%) ± SEM. 
Statistical analysis was done by two-way ANOVA. ***P<0.001. Experiments 
were done in quadruplicates and repeated twice. 
Cell cycle analysis was then carried out by flow cytometry at 72 h after 
seeding (Figure 3.30A). The cell cycle profile revealed that a lower percentage 
of C1QBP-overexpressing cells was in sub-G1 phase (231.Vec: 2.46% vs 
231.C1QBP: 1.33%, P=0.0234) and the G1 phase (231.Vec: 70.02% vs 
231.C1QBP: 64.83%, P=0.0155), compared to the control cells (Figure 
3.30B). Concomitantly, there was an increase percentage of C1QBP-
overexpressing cells in the S phase (231.Vec: 7.31% vs 231.C1QBP: 10.37%, 
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P=0.0185) and G2/M phase (231.Vec: 20.45% vs 231.C1QBP: 23.99%, 
P=0.0195). Overall, the cell cycle profiling has implied that C1QBP promotes 
cell cycle progression.  
 
Figure 3.30. Overexpression of C1QBP promoted progression of cell cycle 
from the G1 phase to the G2/M phase. (A) Representation of the cell cycle 
profiles obtained by flow cytometry from 231.Vec and 231.C1QBP cells, 
respectively. (B) Percentage of cells within each phase of the cell cycle 
detected by flow cytometry by PI staining. Percentages are presented as mean 
± SEM. *P<0.05. Experiments were done in triplicates and repeated twice. 
 Since cell cycle progression was dysregulated after overexpression of 
C1QBP in MDA-MB-231 cells, cell cycle regulatory proteins for the G1 to S 
progression were measured. In C1QBP-overexpressing cells, there was a 
significant increase of CDK6 (P=0.0115) and Cyclin D1 (P=0.0035), proteins 
involved in the G1 to S phase checkpoint (Figure 3.31). Contrary to the 
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findings after knockdown of C1QBP, the expression of CDK4, another protein 
involved in the G1 to S phase checkpoint was not affected. CDC25a, was also 
not affected in C1QBP-overexpressing cells.  
 
Figure 3.31. Expression of cell cycle proteins in C1QBP-overexpressing cells. 
Left panel: Representations of western blots for the respective proteins and its 
molecular weight. The first lane, V, represents protein from 231.Vec cells and 
the second lane, OE, represents protein from 231.C1QBP cells. Right panel: 
Relative quantification of protein expression by densitometry analysis. The 
expression of CDK6 and Cyclin D1 were significantly upregulated in C1QBP-
overexpressing cells. The protein level of CDK4 and CDC25A remained 
unchanged. Relative protein expression are presented as mean ± SEM. 





3.10 Effect of C1QBP overexpression on cell migration and cell invasion 
3.10.1 Effect of C1QBP overexpression on cell migration 
The effect of C1QBP overexpression in MDA-MB-231 breast cancer 
cell line on cell migration was evaluated using the transwell migration system. 
The stable overexpression of C1QBP increased the cells’ migration capability 
through the polycarbonate membrane (Figure 3.32A). Quantitatively, the 
number of C1QBP-overexpressing cells migrating through the membrane, was 
higher compared to the control cells (Figure 3.32B, P=0.0262). 
 
Figure 3.32. MDA-MB-231 breast cancer cells overexpressing C1QBP 
demonstrated a higher ability to migrate through the membrane of the 
transwell inserts. (A) Representative images of C1QBP-overexpressing MDA-
MB-231 cells and control cells migrating through the transwell membrane 
after incubation at 37°C in 5% CO2 for 20 h. Images were taken at 15X and 
100X magnification. (B) Bar chart showed that a higher number of cells 
migrated through the transwell membrane from the C1QBP-overexpressing 
cells group, compared to the control group. The average number of migratory 
cells/field for each insert was obtained from 5 fields per insert. Data shown are 
presented as mean number of migrated cells ± SEM. *P<0.05. Experiments 




3.10.2 Changes in cytoskeletal structure of C1QBP-overexpressing cells 
As cell migration was affected after overexpression of C1QBP in 
MDA-MB-231 cells, the cytoskeletal structure and the expression of vinculin, 
a focal adhesion protein was ascertained in C1QBP-overexpressing cells. This 
was done by treatment of cells with phalloidin to stain F-actin and 
immunostaining with vinculin. As shown in Figure 3.33, C1QBP-
overexpressing cells displayed prominent actin stress fibres and punctate 
vinculin staining as compared to control cells, indicating changes in 
cytoskeletal structure and diminished focal adhesion.  
 
Figure 3.33: Immunostaining of F-actin and vinculin in C1QBP-
overexpressing cells. C1QBP-overexpressing cells displayed prominent actin 
stress fibres and punctate vinculin staining as compared to control cells. Scale 






3.10.3 Effect of C1QBP overexpression on cell invasion 
Cell invasion was also carried out using the transwell invasion system. 
The overexpression of C1QBP in MDA-MB-231 cells increased the 
invasiveness of the cells compared to control cells (Figure 3.34A). The 
number of C1QBP-overexpressing cells that were able to invade through the 
membrane was significantly higher compared to the control cells (Figure 
3.34B, P=0.0151).  
 
Figure 3.34. Cell invasion was increased in C1QBP-overexpressing cells. (A) 
Representative images of the transwell inserts and the corresponding field 
showed an apparent increase of invasion from the C1QBP-overexpressing 
cells compared to control cells. Images were taken at 15X and 100X 
magnification. (B) A count of invading cells confirmed that C1QBP-
overexpressing cells possessed an augmented ability to invade compared to 
control cells. Data are presented as mean ± SEM. *P<0.05. Experiments were 




3.11 Cytotoxic effect of doxorubicin in C1QBP-overexpressing cells 
Since treatment with Doxorubicin hydrochloride produced a 
marginally significant difference in MDA-MB-231 cells after knockdown of 
C1QBP, the effect of Doxorubicin hydrochloride on C1QBP-overexpressing 
cells was evaluated. MDA-MB-231 cells overexpressing C1QBP were 
observed to be more resistant to Doxorubicin hydrochloride treatment 
compared to the control cells (Figure 3.35). Evaluation of the IC50 of 
Doxorubicin hydrochloride treatment showed that C1QBP-overexpressing 
cells possessed a higher IC50 (1.096 µM) compared to the control cells 
(0.9126 µM). The difference between the two curves was also statistically 
significant as determined by two-way ANOVA (P=0.0117). 
 
Figure 3.35. (A) Increased chemoresistance to Doxorubicin hydrochloride was 
observed in MDA-MB-231 cells overexpressing C1QBP. Values are presented 
as mean ± SEM. (B) IC50 of Doxorubicin hydrochloride on MDA-MB-231 
cells with and without overexpression of C1QBP. *P<0.05. Experiments were 




3.12 Expression of C1QBP in parental MCF7 cells and Doxorubicin 
hydrochloride-resistant MCF7 cell line 
Next, the expression of C1QBP in Doxorubicin hydrochloride-resistant 
MCF7 cells was compared to parental MCF7 cells. The dose of Doxorubicin 
hydrochloride used for treatment of the MCF7 cell lines, was obtained from a 
‘kill-curve’ of cells treated with Doxorubicin hydrochloride, at a range of 
concentration for 48 h. The IC25 concentration of Doxorubicin hydrochloride 
i.e., 0.6 µM was used to treat the parental MCF7 and MCF7R cell line to 
reduce cell death rate. The cells were treated for 0 to 48 h, and the protein 
expression of C1QBP was obtained. The constitutive expression of C1QBP in 
MCF7 cells was lower than in MCF7R cells. The treatment of these cells with 
Doxorubicin hydrochloride for 12 h, 24 h and 48 h gradually increased the 
expression of C1QBP in MCF7 cells. However, the expression of C1QBP in 
MCF7R cells remained unchanged.  
 
Figure 3.36. Expressions of C1QBP in parental MCF7 and Doxorubicin 
hydrochloride-resistant MCF7 cell line, after treatment with Doxorubicin 
hydrochloride in a time-dependent fashion. The expression of C1QBP in 
parental MCF7 cells was increased in a time-dependent manner after treatment 
with Doxorubicin hydrochloride, while the C1QBP expression was not altered 
in Doxorubicin hydrochloride-resistant MCF7 cell line. Experiments were 




3.13 Genome-wide analysis of MDA-MB-231 cells with diminished 
C1QBP expression 
Genome-wide analysis using gene microarray, is a widely used 
technology enabling the simultaneous study of the expression of many genes. 
Previously, the study has shown that the knockdown of C1QBP affected the 
function and characteristics of MDA-MB-231 cells. Gene expression profiling 
of MDA-MB-231 cells with knockdown of C1QBP, was carried out to gain an 
understanding of the underlying molecular pathway that could possibly be 
involved in its functional changes.  
3.13.1 Quality control of total RNA extracted from MDA-MB-231 cells 
with diminished expression of C1QBP 
Good quality total RNA is required to obtain reliable data from the 
microarray. Extracted RNA was first assessed by obtaining the A260/A280 ratio 
using Nanodrop ND-1000. Only RNA samples with A260/A280 ratio of more 
than 1.9 were considered. The silencing efficiency was then confirmed by 
real-time PCR to be approximately 90% before further processing (Figure 
3.37).  
 
Figure 3.37. Silencing efficiency of siC1QBP in MDA-MB-231 breast cancer 
cell lines that were used for the gene microarray analysis. The gene expression 
of C1QBP was diminished by 90%. Relative gene expression are presented as 




The quality of RNA was again verified using spectrophotometric 
methods. All samples showed A260/A280 ratios of between 2.00-2.07, with 
concentrations ranging from 389.65 ng/µl to 484.86 ng/µl (Table 3.9). The 
RNA Integrity Number (RIN) reflects RNA integrity. The RIN score ranges 
from 1 to 10, where the score 10 indicates a completely intact RNA. All 
samples have RIN of 9.8 to 10, demonstrating that RNA integrity was 
satisfactory (Table 3.9).  
Table 3.9. Quality control of RNA samples determined by spectrophotometric 
reading 
Sample OD260/OD280 Concentration 
(ng/µl) 
RIN 
231.siC1QBP A 2.026 448.24 9.9 
231.siC1QBP B 2.004 458.98 10 
231.siC1QBP C 2.074 450.68 9.9 
231.NT A 2.051 389.65 9.8 
231.NT B 2.047 469.73 10 
231.NT C 2.077 484.86 9.8 
 The RIN was obtained from the Agilent Bioanalyzer which produced a 
gel-like image and electrophoregram from its analyses. The gel-like image 
showed two distinct bands indicating mostly intact RNA (Figure 3.38A). The 
electrophoregram of the 6 samples, showed two distinct ribosomal peaks 
representing the 18S fragment and 28S fragment (Figure 3.38B). The first 




 peaks represented the 18S 
fragment and 28S fragment, respectively. The RIN values obtained was 




Figure 3.38. The Agilent Bioanalyzer analysis produced (A) a gel-like image 
and (B) electrophoregram of the 6 samples. 
Ribo-SPIA assay was carried out using 100 ng total RNA according to 
Origen Labs SOP. The processing of the samples yielded good purity with a 
high concentration, and the results are shown in Table 3.10. 
Table 3.10. Spectrophotometric reading of purified sense target cDNA 
Sample OD260/OD280 Concentration 
(µg/µl) 
Yield (µg) 
231.siC1QBP A 1.844 539.73 8.10 
231.siC1QBP B 1.753 528.89 7.93 
231.siC1QBP C 1.840 467.92 7.02 
231.NT A 1.837 531.15 7.97 
231.NT B 1.822 471.53 7.07 
231.NT C 1.775 385.72 5.79 
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3.13.2 Array quality control (QC) metrics 
The arrays were scanned and images were analysed by AGCC 
(GeneChip Command Console Software). CEL files generated from AGCC 
were imported into the Expression Console 1.3 software and subsequently 
underwent RMA normalization to generate the quality control (QC) metrics, 
which were used to determine data quality.  
Generally, the probe level data was used as the quality assessment 
metrics. The data consisted of perfect match (PM) mean and background 
(bgrd) mean. PM mean is the mean of the raw intensity for all the PM probes, 
while bgrd mean is the mean of the raw intensity for the probes used to 
calculate background prior to any intensity transformations. These could be 
used to assess whether the chip produced proper signal intensity. All the 6 
arrays produced lower bgrd_mean, compared to PM_mean, pointing to good 
separation between background and true signal (Figure 3.39A).  
Apart from that, the Pos vs Neg area under the curve (AUC), which 
was used to compare signal values of positive controls to the negative 
controls, were used as another QC metric. A group of recognized exon based 
probe sets from recognized housekeeping genes, was used as the positive 
control. The negative control consisted of known intron based probe sets from 
known housekeeping genes, which usually have very low signal values. The 
ROC curve was plotted by evaluating the separation of the positive and 
negative controls, with the postulation that the negative and positive controls 
represents false and true positive, respectively. Perfect separation generates an 
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AUC of 1 while an AUC of 0.5 denotes no separation. The 6 samples used in 
the study generated acceptable values of above 0.77 (Figure 3.39B). 
Proper hybridization was usually assessed by the signal intensity from 
bacterial spike control. Pre-labeled bacterial spike controls prepared in 
staggered concentration, were hybridized to probe sets. All the samples 
showed correct concentration of bacterial spike controls, indicating good 
hybridization (Figure 3.39C).  
 
Figure 3.39. Array QC metrics. (A) PM_mean and Bgrd_mean. The 6 samples 
produced a lower bgrd_mean than PM_mean indicating good quality data. (B) 
Pos vs Neg AUC. All 6 samples have Pos vs Neg AUC values above 0.77. (C) 
Bacterial spike control for all 6 samples showed similar intensity for the 4 
spike controls in staggered concentration, which indicated good hybridization. 
1: 231.siC1QBP A, 2: 231.siC1QBP B, 3: 231.siC1QBP C, 4: 231.NT A, 5: 
231.NT B, 6: 231.NT C. 
The QC test for total RNA processing and array chip indicated that the 
assay performance was robust and the data produced should be of high quality.  
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3.13.3 Data analysis of Human GeneChip ST2.0 microarray 
Using FS450_0002 fluidics, the hybridized sense target cDNA was 
stained and subsequently, scanned by Affymetrix 3000 7G scanner to produce 
the raw data of all probesets in the form of CEL files. The hierarchical 
clustering showed that the replicates of 231.siC1QBP had different 
expressions from the replicates of 231.NT (Figure 3.40A). The two groups 
showed that differential gene expressions existed after C1QBP was silenced.  
A volcano plot was constructed from the data to visualize the changes 
of gene expression after knockdown of C1QBP (Figure 3.40B). Although a 
majority of the genes were not affected, a number of genes were differentially 
expressed by more than 1.5 folds with high statistical significance. A total of 
77 genes were significantly up-regulated and 109 genes were down-regulated 
after knockdown of C1QBP. The list of these genes is shown in 




Figure 3.40. (A) Hierarchical clustering and (B) volcano plot of the Human 
GeneChip ST 2.0 microarray data. In the volcano plot, spots on the outside of 
the thick vertical lines and above the thick horizontal line have an absolute 
fold change of 1.5 with P<0.05. 
3.13.4 Validation of differential gene expressions based on microarray 
data analysis 
Five up-regulated and 10 down-regulated genes were examined using 
real-time PCR for validation purposes. The majority of the genes showed 
consistent patterns when compared to the microarray data (Figure 3.41). 
 
Figure 3.41. Validation of up-regulated and down-regulated genes obtained 
from the Gene ST 2.0 microarray data. The relative gene expression was 
obtained from real-time PCR and values are presented as mean of triplicates ± 
SEM. This was compared to the fold change value obtained from the gene 




3.13.5 Functional classification of microarray data 
To have a general understanding of the data, the differentially 
expressed genes were clustered based on enrichment of gene ontologies for 
biological functions, using the Partek Genomics Suite 6.6 software (Figure 
3.42). Notably, the differentially expressed genes were primarily enriched for 
growth functions which were consistent with the clinical and in vitro data.  
 
Figure 3.42. Enrichment scores for biological functions of genes affected by 
knockdown of C1QBP in MDA-MB-231 breast cancer cells. 
In addition, the DAVID (Database for Annotation, Visualization and 
Integrated Discovery) software was also used to categorise the differentially 
expressed genes based on gene ontology for biological processes, as shown in 
Table 3.11. These genes were categorized into various functions, such as, 





Table 3.11. Functional categorization of genes that were affected after 
knockdown of C1QBP in MDA-MB-231 breast cancer cells 




TCEANC Transcription elongation factor A 
(SII) N-terminal and central d 
170082 
TCEB3C Transcription elongation factor B 
polypeptide 3C (elongin A3) 
728929 
TCEA2 Transcription elongation factor A 
(SII), 2  
6919 
Metal-ion binding FGD1 FYVE, RhoGEF and PH domain 
containing 1 
2245 
ZBTB9  Zinc finger and BTB domain 
containing 9 
221504 
QTRT1 Queuine tRNA-ribosyltransferase 
1  
81890 
ZFP112 Zinc finger protein 112 homolog  7771 
TRIM65 Tripartite motif containing 65  201292 
OSR1 Odd-skipped related 1 130497 
RASGRP1 RAS guanyl releasing protein 1 
(calcium and DAG-regulated) 
10125 
ZNF735 Zinc finger protein 735  168417 
TCEA2 Transcription elongation factor A 
(SII), 2  
6919 
DNAJA4 DnaJ (Hsp40) homolog, 
subfamily A, member 4  
55466 
ZNF575 Zinc finger protein 575 284346 
CRIP1 Cysteine-rich protein 1 
(intestinal)  
1396 
BRF1 RNA polymerase III transcription 
initiation factor 90 
2972 
MTA2 Metastasis associated 1 family, 
member 2 
9219 
SIRT4 Sirtuin 4 23409 
KLF15 Kruppel-like factor 15 28999 
ZNF37A Zinc finger protein 37A 7587 
ZSWIM5 Zinc finger, SWIM-type 
containing 5 
57643 
TRIM56 Tripartite motif containing 56 81844 
RNF44 Ring finger protein 44 22838 
EBF4 Early B-cell factor 4 57593 
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Function Gene ID Gene name Gene 
Entrez ID 
ZFYVE27 Zinc finger, FYVE domain 
containing 27 
118813 
MMP23B Matrix metallopeptidase 23B 8510 
TOP3A Topoisomerase (DNA) III alpha  7156 
ZNHIT1 Zinc finger, HIT-type containing 
1  
10467 
UPF1 UPF1 regulator of nonsense 
transcripts homolog  
5976 
MAP3K8 Mitogen-activated protein kinase 
kinase kinase 8 
1326 
POLL Polymerase (DNA directed), 
lambda 
27343 
KCND1 Potassium voltage-gated channel, 
Shal-related subfamily, member 
1 
3750 
NME3 NME/NM23 nucleoside 
diphosphate kinase 3 
4832 
KCNK10 Potassium channel, subfamily K, 
member 10  
54207 
SMOC2 SPARC related modular calcium 
binding 2 
64094 
ITIH1 Inter-alpha-trypsin inhibitor 
heavy chain 1 
3697 
TREX2 Three prime repair exonuclease 2 11219 
SNTN Sentan, cilia apical structure 
protein  
132203 
Neurogenesis PSPN Persephin 5623 
OSR1 Odd-skipped related 1 130497 
BCL2 B-cell CLL/lymphoma 2  596 
GREM1 Gremlin 1, DAN family BMP 
antagonist  
26585 
LCE2A Late cornified envelope 2A 353139 
Regulation of 
transcription 
POLL Polymerase (DNA directed), 
lambda 
27343 
SOX10 SRY (sex determining region Y)-
box 10  
6663 
ZBTB9  Zinc finger and BTB domain 
containing 9 
221504 





Function Gene ID Gene name Gene 
Entrez ID 
KLF15 Kruppel-like factor 15 28999 
ZFP112 Zinc finger protein 112 homolog  7771 
MCM4 Minichromosome maintenance 
complex component 4 
4173 
ZNF37A Zinc finger protein 37A 7587 
HIST2H4B Histone cluster 2, H4b 8370 
HIF1A Hypoxia inducible factor 1, alpha 
subunit (basic helix-loop 
3091 
EBF4 Early B-cell factor 4 57593 
GTF2IRD1 GTF2I repeat domain containing 
1  
9569 
HES2 Hairy and enhancer of split 2  54626 
TOP3A Topoisomerase (DNA) III alpha  7156 
HIST1H3B Histone cluster 1, H3b 126961 
ZNF735 Zinc finger protein 735  168417 
TCEA2 Transcription elongation factor A 
(SII), 2  
6919 
ZNF575 Zinc finger protein 575 284346 
NAT14 N-acetyltransferase 14 (GCN5-
related, putative) 
57106 
FOXD3 Forkhead box D3  27022 
TCEANC Transcription elongation factor A 
(SII) N-terminal and central d 
170082 
POLR2J Polymerase (RNA) II (DNA 
directed) polypeptide J, 13.3kDa 
5439 
BRF1 RNA polymerase III transcription 
initiation factor 90 
2972 
UPF1 UPF1 regulator of nonsense 
transcripts homolog  
5976 
TCEB3C Transcription elongation factor B 
polypeptide 3C (elongin A3) 
728929 
BCL2 B-cell CLL/lymphoma 2  596 
PSMD9 Proteasome (prosome, 
macropain) 26S subunit, non-
ATPase, 9 
5715 
VOPP1 Vesicular, overexpressed in 
cancer, prosurvival protein 1 
81552 
CDC14B Cell division cycle 14B  8555 





Function Gene ID Gene name Gene 
Entrez ID 
WDR55 WD repeat domain 55 54853 
OSR1 Odd-skipped related 1 130497 
IL15RA Interleukin 15 receptor, alpha 3601 
TREX2 Three prime repair exonuclease 2 11219 
NLE1 Notchless homolog 1 
(Drosophila)  
54475 
Immune response MICA MHC class I polypeptide-related 
sequence A  
4276 
IL23A Interleukin 23, alpha subunit p19  51561 
ITIH1 Inter-alpha-trypsin inhibitor 
heavy chain 1 
3697 
BCL2 B-cell CLL/lymphoma 2  596 
KIR3DL1 Killer cell immunoglobulin-like 
receptor, three domains, long c 
3811 
POLL Polymerase (DNA directed), 
lambda 
27343 
IGLV1-44 Immunoglobulin lambda variable 
1-44 
3538 
C1QBP Complement component 1, q 
subcomponent binding protein 
708 
HLA-L Major histocompatibility 
complex, class I, L (pseudogene) 
3139 
CLEC4C C-type lectin domain family 4, 
member C  
170482 
TPSAB1 Tryptase alpha/beta 1  7177 
GAL Galanin/GMAP prepropeptide 51083 
HIF1A Hypoxia inducible factor 1, alpha 
subunit (basic helix-loop 
3091 
HPR Haptoglobin-related protein 3250 
Hormone activity RLN1 Relaxin 1 6013 
GAL Galanin/GMAP prepropeptide 51083 
POMC Proopiomelanocortin 5443 
MMP23B Matrix metallopeptidase 23B 8510 
Phosphorylation 
activity 
CDC14B Cell division cycle 14B  8555 
BCL2 B-cell CLL/lymphoma 2  596 
CCDC155 Coiled-coil domain containing 
155 
147872 
TPTE Transmembrane phosphatase 




Function Gene ID Gene name Gene 
Entrez ID 
MAP3K8 Mitogen-activated protein kinase 
kinase kinase 8 
1326 
PI4KAP2 Phosphatidylinositol 4-kinase, 
catalytic, alpha pseudogene 2 
375133 
ADRBK2 Adrenergic, beta, receptor kinase 
2 
157 
TSSK3 Testis-specific serine kinase 3 81629 
Regulation of cell 
motion 
HIF1A Hypoxia inducible factor 1, alpha 
subunit (basic helix-loop 
3091 
BCL2 B-cell CLL/lymphoma 2  596 





TPSAB1 Tryptase alpha/beta 1  7177 
TPSD1 Tryptase delta 1  23430 
HPR Haptoglobin-related protein 3250 
MMP23B Matrix metallopeptidase 23B 8510 
USP50 Ubiquitin specific peptidase 50  373509 
ASB18 Ankyrin repeat and SOCS box 
containing 18  
401036 
PSMD9 Proteasome (prosome, 
macropain) 26S subunit, non-
ATPase, 9 
5715 
CDC14B Cell division cycle 14B  8555 
TREX2 Three prime repair exonuclease 2 11219 
PNPLA6 Patatin-like phospholipase 
domain containing 6 
10908 
TPTE Transmembrane phosphatase 
with tensin homology 
7179 
Homeostasis HIF1A Hypoxia inducible factor 1, alpha 
subunit (basic helix-loop 
3091 
BCL2 B-cell CLL/lymphoma 2  596 
NARFL Nuclear prelamin A recognition 
factor-like 
64428 
SLC2A4 Solute carrier family 2 
(facilitated glucose transporter), 
member 
6517 
HPR Haptoglobin-related protein 3250 
TFF1 Trefoil factor 1 7031 





Function Gene ID Gene name Gene 
Entrez ID 
MICA MHC class I polypeptide-related 
sequence A  
4276 
HIF1A Hypoxia inducible factor 1, alpha 
subunit (basic helix-loop 
3091 
UPF1 UPF1 regulator of nonsense 
transcripts homolog  
5976 
BCL2 B-cell CLL/lymphoma 2  596 
TREX2 Three prime repair exonuclease 2 11219 
TOP3A Topoisomerase (DNA) III alpha  7156 
MCM4 Minichromosome maintenance 




BCL2 B-cell CLL/lymphoma 2  596 
TFF1 Trefoil factor 1 7031 
GAL Galanin/GMAP prepropeptide 51083 
Sensory 
perception 
OR2T4 Olfactory receptor, family 2, 
subfamily T, member 4 
127074 
OR14I1 Olfactory receptor, family 14, 
subfamily I, member 1 
401994 
ADRBK2 Adrenergic, beta, receptor kinase 
2 
157 
OR51F2 Olfactory receptor, family 51, 
subfamily F, member 2 
119694 
OR5A1 Olfactory receptor, family 5, 
subfamily A, member 1  
219982 
TAS2R19 Taste receptor, type 2, member 
19  
259294 
TAS2R31 Taste receptor, type 2, member 
31 
259290 
P2RY8 Purinergic receptor P2Y, G-
protein coupled, 8 
286530 
GPR20 G protein-coupled receptor 20 2843 
POMC Proopiomelanocortin 5443 
LRP10 Low density lipoprotein receptor-
related protein 10  
26020 
CLEC9A C-type lectin domain family 9, 
member A 
283420 
IL15RA Interleukin 15 receptor, alpha 3601 
KIR3DL1 Killer cell immunoglobulin-like 
receptor, three domains, long c 
3811 
GAL Galanin/GMAP prepropeptide 51083 
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MTA2 Metastasis associated 1 family, 
member 2 
9219 
HIST1H3B Histone cluster 1, H3b 126961 
HIST2H4B Histone cluster 2, H4b 8370 
Voltage-gated ion 
channel activity 
KCND1 Potassium voltage-gated channel, 
Shal-related subfamily, member 
1 
3750 
CLCNKA Chloride channel, voltage-
sensitive Ka 
1187 
KCNK10 Potassium channel, subfamily K, 
member 10  
54207 
TPTE Transmembrane phosphatase 
with tensin homology 
7179 
SLC16A2 Solute carrier family 16, member 
2 (thyroid hormone transporter 
6567 
SLC2A4 Solute carrier family 2 
(facilitated glucose transporter), 
member 
6517 
TOMM6 Translocase of outer 
mitochondrial membrane 6 
homolog (yeast) 
100188893 
NECAP2 NECAP endocytosis associated 2 55707 
AP4B1 Adaptor-related protein complex 
4, beta 1 subunit 
10717 
Cell death FGD1 FYVE, RhoGEF and PH domain 
containing 1 
2245 
MICA MHC class I polypeptide-related 
sequence A  
4276 
NME3 NME/NM23 nucleoside 
diphosphate kinase 3 
4832 
ZFYVE27 Zinc finger, FYVE domain 
containing 27 
118813 
BCL2 B-cell CLL/lymphoma 2  596 
GREM1 Gremlin 1, DAN family BMP 
antagonist  
26585 
PNPLA6 Patatin-like phospholipase 
domain containing 6 
10908 
GAL Galanin/GMAP prepropeptide 51083 
RASGRP1 RAS guanyl releasing protein 1 




Function Gene ID Gene name Gene 
Entrez ID 
MAP3K8 Mitogen-activated protein kinase 
kinase kinase 8 
1326 
Cytoskeleton GABARAPL1 GABA(A) receptor-associated 
protein like 1 
23766 
TREX2 Three prime repair exonuclease 2 11219 
TUBA4B Tubulin, alpha 4b (pseudogene) 80086 
FAM110A Family with sequence similarity 





MAP3K8 Mitogen-activated protein kinase 
kinase kinase 8 
1326 
ADRBK2 Adrenergic, beta, receptor kinase 
2 
157 
TSSK3 Testis-specific serine kinase 3 81629 
CBWD1 COBW domain containing 1 55871 
UPF1 UPF1 regulator of nonsense 
transcripts homolog  
5976 
MCM4 Minichromosome maintenance 
complex component 4 
4173 
BCL2 B-cell CLL/lymphoma 2  596 
PI4KAP2 Phosphatidylinositol 4-kinase, 
catalytic, alpha pseudogene 2 
375133 
GCDH Glutaryl-CoA dehydrogenase 2639 
NME3 NME/NM23 nucleoside 
diphosphate kinase 3 
4832 
TOP3A Topoisomerase (DNA) III alpha  7156 
PCCB Propionyl CoA carboxylase, beta 
polypeptide 
5096 
SIRT4 Sirtuin 4 23409 
RAB44 RAB44, member RAS oncogene 
family 
401258 
TUBA4B Tubulin, alpha 4b (pseudogene) 80086 
PABPC1L Poly(A) binding protein, 
cytoplasmic 1-like  
80336 
Cell cycle UPF1 UPF1 regulator of nonsense 
transcripts homolog  
5976 
BCL2 B-cell CLL/lymphoma 2  596 
MAP3K8 Mitogen-activated protein kinase 
kinase kinase 8 
1326 
TREX2 Three prime repair exonuclease 2 11219 
TOP3A Topoisomerase (DNA) III alpha  7156 
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Function Gene ID Gene name Gene 
Entrez ID 
PSMD9 Proteasome (prosome, 





MMP23B Matrix metallopeptidase 23B 8510 
TPSAB1 Tryptase alpha/beta 1  7177 
TPSD1 Tryptase delta 1  23430 
USP50 Ubiquitin specific peptidase 50  373509 
HPR Haptoglobin-related protein 3250 
ASB18 Ankyrin repeat and SOCS box 
containing 18  
401036 
PSMD9 Proteasome (prosome, 
macropain) 26S subunit, non-
ATPase, 9 
5715 
UPF1 UPF1 regulator of nonsense 
transcripts homolog  
5976 
Protein transport TOMM6 Translocase of outer 
mitochondrial membrane 6 
homolog (yeast) 
100188893 
NECAP2 NECAP endocytosis associated 2 55707 
AP4B1 Adaptor-related protein complex 
4, beta 1 subunit 
10717 
RAB44 RAB44, member RAS oncogene 
family 
401258 
Besides that, pathway analysis using Partek Genomics Suite 6.6 
software identified a few genes involved in the MAPK and JAK-STAT 
pathway (Table 3.12). The full list of the pathway analysis is available in 
Supplementary Table 2.  
Table 3.12. Pathway analysis done on gene microarray using Partek Genomics 
Suite 6.6 
Pathway Name Enrichment Score Genes 
Jak-STAT signaling pathway 1.37955 IL15RA, IL23A 




3.14 PathScan® Intracellular Signaling Array 
Aside from the gene expression profile, the PathScan® Intracellular 
Signaling Array was used to elucidate the possible signalling pathways that 
were utilized by C1QBP. The array enabled the simultaneous investigation of 
18 established and important signalling molecules, which are shown in Figure 
3.43.  
 
Figure 3.43. Layout of the PathScan® Intracellular Signaling Array. Each 
array contained 42 spots. Each antibody was tested in duplicates. Three spots 
of positive and negative control each, were included in the array. 
Protein lysate from C1QBP-overexpressing cells and control cells were 
prepared in triplicates and incubated with the array. The chemiluminescent 
signals produced from the arrays incubated with lysate from C1QBP-
overexpressing cells, showed alterations for several signalling molecules, 
compared to the lysate from control cells (Figure 3.44A). Detailed 
measurements using densitometry analysis, showed that expression of 
phosphorylated ERK1/2 (Thr202/Tyr204) (P=0.0121) and GSK-3β (Ser9) 
122 
 
(P=0.0236) was significantly increased in C1QBP-overexpressing cells. 
Additionally, phosphorylation of STAT3 (Tyr705) (P=0.0576), AKT (Ser473) 
(P=0.0635) and S6 ribosomal protein (Ser235/236) (P=0.0596) was 
augmented with borderline significance (Figure 3.44B).  
 
Figure 3.44. Assessment of changes in activity of signalling molecules in 
C1QBP-overexpressing cells via the PathScan® Intracellular Signaling Array 
Kit. (A) Representative images of array for 231.Vec and 231.C1QBP cells 
after processing. (B) Protein expression of various signalling molecules in 
MDA-MB-231 cells overexpressing C1QBP or empty vector. Relative protein 
expression was measured by obtaining the ratio of O.D.target proteins to O.D.positive 
control. Values are presented as mean of triplicates ± SEM. Statistical 
significance was achieved at *P<0.05. 
# 
represented borderline significance, 
where P-values of p-STAT3(Tyr705), p-Akt(Ser473) and p-S6 Ribosomal 




3.15 Association of C1QBP with the ERK1/2 pathway 
From the analysis of the PathScan® Intracellular Signaling Array, a 
marked increase was observed for p-ERK1/2 after overexpression of C1QBP. 
Together with pathway analysis from the gene microarray, differential 
expression of RASGRP1 and MAP3K8 after knockdown of C1QBP in MDA-
MB-231 cells, indicated that C1QBP could potentially be involved in the 
MAPK/ERK pathway. Therefore, the expression of activated proteins along 
the MAPK/ERK pathway was evaluated. In C1QBP-overexpressing cells, the 
expression of p-ERK1/2 was significantly increased, validating the results 
obtained from the Pathscan array (P=0.0240, Figure 3.45). In addition, there 
was also a significant up-regulation of activated MEK1/2 in C1QBP-
overexpressing cells (P=0.0441, Figure 3.45). The expression of p-MSK1 and 




Figure 3.45. Protein expressions of p-ERK1/2 and p-ERK1/2-related proteins 
in MDA-MB-231 cells stably overexpressing C1QBP. The left panel shows 
the western blot representation of the respective proteins. V stands for 
231.Vec and OE stands for 231.C1QBP. The right panel shows the 
densitometry analyses of the bands obtained. A statistically significant 
increase was observed for p-ERK1/2 and p-MEK1/2 expressions. The bar 
charts were presented as mean of O.D. ratio ± SEM. *P<0.05, **P<0.01. 






3.16 Association of C1QBP with the STAT3 pathway 
Further analysis of the gene expression profile after knockdown of 
C1QBP, combined with data from Pathscan array revealed that C1QBP could 
also be associated to the STAT3 pathway. The gene microarray pathway 
analysis data detected a differential expression of IL23A and IL15RA 
expression – proteins involved in STAT3 pathway – after knockdown of 
C1QBP. Additionally, the Pathscan array showed that the overexpression of 
C1QBP caused an increase in p-STAT3 (Tyr705) expression. Hence, the 
expression of downstream targets of p-STAT3 was evaluated. Overexpression 
of C1QBP caused a significant increase of p-STAT3 (Tyr705) shown by 
western blot (P=0.0411, Figure 3.46), verifying the results obtained from the 
Pathscan array. The protein expression of BCL2 and MCL1 were also 
increased, following overexpression of C1QBP (P=0.0436 and P=0.0550, 
respectively, Figure 3.46). Further investigation also showed down-regulation 




Figure 3.46. Expressions of p-STAT3(Y705) and its downstream targets after 
overexpression of C1QBP. The western blot representations were shown on 
the left side of the diagram together with its respective quantification on the 
right side. The overexpression of C1QBP in MDA-MB-231 led to an increase 
in p-STAT3(Y705), followed by up-regulation of BCL2 and MCL1, as well as 
down-regulation of p53. Values are presented as mean of O.D. ratio ± SEM. 






3.16.1 Down-regulation of STAT3 in C1QBP-overexpressing cells 
As p-STAT3 (Tyr705) has been implicated in carcinogenesis, and the 
data supported an association between C1QBP and p-STAT3 (Tyr705), the 
effects of STAT3 attenuation in C1QBP-overexpressing cells were explored. 
Knockdown of STAT3 using siRNA targeting STAT3 reduced the expression 
of p-STAT3 in C1QBP-overexpressing cells by approximately 82% (Figure 
3.47B).  
 
Figure 3.47. (A) Western blot representation of p-STAT3 (Y705) knockdown 
after siSTAT3 transfection in 231.Vec and 231.C1QBP cells. (B) Expression 
of p-STAT3(Y705) in C1QBP-overexpressing cells was decreased by 82% 
while in 231.Vec cells, p-STAT3(Y705) was decreased by 55%. Experiments 




3.16.1.1 Effect of STAT3 attenuation in C1QBP-overexpressing cells on 
cell proliferation 
The down-regulation of STAT3 in C1QBP-overexpressing cells was 
accompanied by diminished cell growth, measured by alamarBlue assay over 
144 h (Figure 3.48). As perceived from Figure 3.48, the overexpression of 
C1QBP increased cell growth, compared to vector-expressing cells 
(P=0.0040). The knockdown of STAT3 in 231.Vec cells caused a significant 
decrease in cell growth (P=0.0257). In C1QBP-overexpressing cells, the 
attenuation of STAT3 significantly decreased cell growth to similar levels as 
231.Vec cells with STAT3 knockdown (P=0.0006).  
 
Figure 3.48. Cell growth curve of C1QBP-overexpressing cells after 
knockdown of STAT3. The overexpression of C1QBP increased the cell 
growth rate of MDA-MB-231 cells. Knockdown of STAT3 caused a drastic 
decrease of cell growth in 231.C1QBP and 231.Vec cells. There was no 
statistical difference between cell growth rate of 231.C1QBP.siSTAT3 and 
231.Vec.siSTAT3 cells. ***, P<0.001, **, P<0.01, *, P<0.05. Experiments 






3.16.1.2 Silencing of STAT3 in C1QBP-overexpressing cells altered cell 
migration and cell invasion 
Cell migration was significantly increased after C1QBP 
overexpression (P<0.05). In addition, the knockdown of STAT3 in 231.Vec 
cells decreased cell migration (P<0.001). After knockdown of STAT3 in 
C1QBP-overexpressing cells, the ability of cells to migrate was significantly 
lowered (P<0.001) to approximately the same level as 231.Vec.siSTAT3 cells 
(Figure 3.49).  
 
Figure 3.49. Cell migration was reduced after knockdown of STAT3 in both 
231.Vec and 231.C1QBP cells. The overexpression of C1QBP increased cell 
migration, and the subsequent reduction of STAT3 was accompanied by a 
dramatic decrease in the ability of cells to migrate. Cell count are presented as 





A similar phenomenon was observed for cell invasion after knockdown 
of STAT3 in C1QBP-overexpressing cells. Overexpression of C1QBP caused 
an increase of cell invasion (P<0.05). However, although a decrease of cell 
invasion was observed when STAT3 was knockdown in 231.Vec cells, the 
difference was not statistically significant. Subsequently, knockdown of 
STAT3 in C1QBP-overexpressing cells diminished the cell invasiveness of the 
cells (P<0.01, Figure 3.50). 
 
Figure 3.50. Cell invasion was decreased after knockdown of STAT3. 
C1QBP-overexpressing cells were more invasive compared to empty vector-
expressing cells. However, the knockdown of STAT3 decreased both the 
invasive capabilities of 231.Vec and 231.C1QBP cells. Cell count of invasive 
cells are presented as mean of cells/field ± SEM. *P<0.05, **P<0.01. 




3.17 SILAC-immunoprecipitation Quantitative Proteomics of C1QBP 
interacting partners 
Next, SILAC-immunoprecipitation quantitative proteomics was carried 
out to determine the C1QBP interactome. Table 3.13 listed the interacting 
partners of C1QBP. Additional information such as Protein IDs and Peptide 
counts can be found in Supplementary Table 3. 
Table 3.13. Interacting partners of C1QBP with a ratio H/L of above 2  







Complement component 1 Q 
subcomponent-binding protein, 
mitochondrial 
C1QBP 51.4 67.376 
Bifunctional lysine-specific demethylase 
and histidyl-hydroxylase NO66 
NO66 44 59.393 
Centromere protein V CENPV 37.1 51.369 
Ribosomal RNA processing protein 1 
homolog A 
RRP1 14.8 45.853 
N-acylneuraminate cytidylyltransferase CMAS 42.6 45.504 
THO complex subunit 4 ALYREF 34.2 40.451 
ATP-dependent RNA helicase DDX54 DDX54 31.3 38.316 
Melanoma-associated antigen D2 MAGED2 31.8 33.31 
Coiled-coil-helix-coiled-coil-helix 
domain-containing protein 2, 
mitochondrial;Putative coiled-coil-helix-
coiled-coil-helix domain-containing 








YBX1 51.2 20.563 
Protein LSM14 homolog B LSM14B 34.3 20.43 




40S ribosomal protein S7 RPS7 40.7 19.184 
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40S ribosomal protein S17-like;40S 




60S ribosomal protein L28 RPL28 59.4 15.03 
Fragile X mental retardation syndrome-
related protein 2 
FXR2 23.8 13.896 
Fragile X mental retardation syndrome-
related protein 1 
FXR1 31.6 13.774 
Mannosyl-oligosaccharide glucosidase MOGS 11.2 11.476 
Protein PRRC2A PRRC2A 8.2 10.753 
60S ribosomal protein L27a RPL27A 38 10.532 
40S ribosomal protein S26;Putative 40S 





Plasminogen activator inhibitor 1 RNA-
binding protein 
SERBP1 29.5 10.434 
60S ribosomal protein L11 RPL11 22.6 9.725 
Protein PRRC2C PRRC2C 5.5 8.9975 
60S ribosomal protein L32 RPL32 30.1 7.6816 
60S ribosomal protein L23a RPL23A 14.7 6.4511 
40S ribosomal protein S6 RPS6 25.7 5.649 
Pre-rRNA-processing protein TSR1 
homolog 
TSR1 10.8 5.5874 
40S ribosomal protein S14 RPS14 37.7 4.9595 
40S ribosomal protein S18 RPS18 62.5 4.7925 
ATP-dependent RNA helicase 





Lamin-B receptor LBR 12.8 4.2938 
40S ribosomal protein S2 RPS2 32.1 3.7432 
rRNA 2-O-methyltransferase fibrillarin FBL 34.9 3.4512 
60S ribosomal protein L23 RPL23 44.3 3.0869 
Heterogeneous nuclear ribonucleoprotein 
U 




STRING analysis showed the interaction of the listed proteins (Figure 
3.51).  
 
Figure 3.51. STRING analysis displayed the association of C1QBP and its 
interacting partners. 
DAVID analysis indicated that the C1QBP interactome was generally 
involved in ribonucleoprotein complex, RNA processing, DNA binding, ATP 
binding, DEAD box binding, cell death and transcription regulation (Table 
3.14). Common functions identified between DAVID analyses done on gene 
microarray with depletion of C1QBP, and C1QBP interactome, include 
transcription regulation and cell death.   
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Table 3.14. DAVID analysis of C1QBP interactome 
Functions Genes Protein name Gene 
ID 
Ribonucleoprotein RPS26P11 Putative 40S ribosomal protein 
S26-like 1 
441502 
 RPL27A 60S ribosomal protein L27a 6157 
 RPL23A 60S ribosomal protein L23a 6147 
 RPS2 40S ribosomal protein S2 6187 
 RPS6 40S ribosomal protein S6 6194 
 RPL28 60S ribosomal protein L28 6158 
 FBL rRNA 2-O-methyltransferase 
fibrillarin 
2091 
 HNRNPU Heterogeneous nuclear 
ribonucleoprotein U 
3192 
 RPS7 40S ribosomal protein S7 6201 
 LSM14B Protein LSM14 homolog B 149986 
 RPS26 40S ribosomal protein S26 6231 
 RPS18 40S ribosomal protein S18 6222 
 RPL23 60S ribosomal protein L23 9349 
 RPL32 60S ribosomal protein L32 6161 
 RPS17 40S ribosomal protein S17-like;40S 
ribosomal protein S17 
6218 
 RPS14 40S ribosomal protein S14 6208 
 RPL11 60S ribosomal protein L11 6135 
 RRP1 Ribosomal RNA processing protein 
1 homolog A 
8568 
 FXR2 Fragile X mental retardation 
syndrome-related protein 2 
9513 
 YBX1 Nuclease-sensitive element-binding 
protein 1 
4904 
 FXR1 Fragile X mental retardation 
syndrome-related protein 1 
8087 
 TSR1 Pre-rRNA-processing protein TSR1 
homolog 
55720 
 CENPV Centromere protein V 201161 









E3 ubiquitin-protein ligase ZFP91 386607 
 ZFP91 E3 ubiquitin-protein ligase ZFP91 80829 
RNA processing RRP1 Ribosomal RNA processing protein 
1 homolog A 
8568 
 TSR1 Pre-rRNA-processing protein TSR1 
homolog 
55720 
 RPS17 40S ribosomal protein S17-like;40S 
ribosomal protein S17 
6218 
 RPS14 40S ribosomal protein S14 6208 
 RPL11 60S ribosomal protein L11 6135 
 RPS6 40S ribosomal protein S6 6194 
 FBL rRNA 2-O-methyltransferase 
fibrillarin 
2091 
 RPS7 40S ribosomal protein S7 6201 
 DDX54 ATP-dependent RNA helicase 
DDX54 
79039 
 HNRNPU Heterogeneous nuclear 
ribonucleoprotein U 
3192 
 YBX1 Nuclease-sensitive element-binding 
protein 1 
4904 
 RPL23 60S ribosomal protein L23 9349 
 FXR1 Fragile X mental retardation 
syndrome-related protein 1 
8087 
 DDX3X ATP-dependent RNA helicase 
DDX3X 
1654 




mRNA stability SERBP1 Plasminogen activator inhibitor 1 
RNA-binding protein 
26135 
 HNRNPU Heterogeneous nuclear 
ribonucleoprotein U 
3192 
 YBX1 Nuclease-sensitive element-binding 
protein 1 
4904 
 RPS26 40S ribosomal protein S26 6231 
 RPS14 40S ribosomal protein S14 6208 
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Functions Genes Protein name Gene 
ID 
DEAD box, DNA 
and ATP binding  
DDX3X ATP-dependent RNA helicase 
DDX3X 
1654 
 DDX3Y ATP-dependent RNA helicase 
DDX3Y 
8653 





E3 ubiquitin-protein ligase ZFP91 386607 
 RRP1 Ribosomal RNA processing protein 
1 homolog A 
8568 
 TSR1 Pre-rRNA-processing protein TSR1 
homolog 
55720 
 CMAS N-acylneuraminate 
cytidylyltransferase 
55907 
 FBL rRNA 2-O-methyltransferase 
fibrillarin 
2091 
 YBX1 Nuclease-sensitive element-binding 
protein 1 
4904 
 HNRNPU Heterogeneous nuclear 
ribonucleoprotein U 
3192 
 ZFP91 E3 ubiquitin-protein ligase ZFP91 80829 
 SERBP1 Plasminogen activator inhibitor 1 
RNA-binding protein 
26135 
 CENPV Centromere protein V 201161 
 LBR Lamin-B receptor 3930 
 RPS18 40S ribosomal protein S18 6222 
 FXR2 Fragile X mental retardation 
syndrome-related protein 2 
9513 
 FXR1 Fragile X mental retardation 
syndrome-related protein 1 
8087 
 MOGS Mannosyl-oligosaccharide 
glucosidase 
7841 




TSR1 Pre-rRNA-processing protein TSR1 
homolog 
55720 
 RPS14 40S ribosomal protein S14 6208 
 CENPV Centromere protein V 201161 
137 
 




E3 ubiquitin-protein ligase ZFP91 386607 





E3 ubiquitin-protein ligase ZFP91 386607 
 ZFP91 E3 ubiquitin-protein ligase ZFP91 80829 
 RPL11 60S ribosomal protein L11 6135 





E3 ubiquitin-protein ligase ZFP91 386607 
 ZFP91 E3 ubiquitin-protein ligase ZFP91 80829 
 DDX54 ATP-dependent RNA helicase 
DDX54 
79039 
 YBX1 Nuclease-sensitive element-binding 
protein 1 
4904 
 RPS14 40S ribosomal protein S14 6208 
3.18 Interaction of C1QBP to YB-1 
Since STRING analysis showed a strong connection between C1QBP 
and YB-1, and YB-1 has been shown to interact with C1QBP (Matsumoto et 
al., 2005), YB-1 was selected for further investigations. The effects of the 
interaction of C1QBP and YB-1, on cell proliferation, migration and invasion 
were carried out.  
3.18.1 Physical interaction of C1QBP and YB-1 
Co-immunoprecipitation was done to determine the physical 
interaction of C1QBP and YB-1 in MDA-MB-231 cells (Figure 3.52). Using 
antibody against YB-1, it was discovered that C1QBP was also pulled down 
with the YB-1 protein. In addition, anti-myc was also able to pull down the 
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myc-tagged C1QBP together with the YB-1 protein. This indicated a physical 
interaction existed between C1QBP and YB-1. 
 
Figure 3.52. Co-immunoprecipitation blot of interaction between C1QBP and 
YB-1 in MDA-MB-231 cell line overexpressing C1QBP. The C1QBP protein 
was pulled down by anti-YB-1 and YB-1 was detected when anti-myc was 
used for immunoprecipitation. WB: Antibodies used for western blot; IP: 
Antibodies used for immunoprecipitation. Experiments were repeated at two 
independent times.  
In addition, immunofluorescence staining of C1QBP and YB-1 were 
carried out to determine whether co-localization existed between these two 
proteins. Since C1QBP and YB-1 antibodies were both derived from rabbit, 
mouse anti-myc was used to represent C1QBP staining in MDA-MB-231 cells 
overexpressing myc-tagged C1QBP. Firstly, myc staining was performed to 
determine whether it could represent C1QBP staining. As seen in Figure 3.53, 
myc staining perfectly co-localized with C1QBP staining. Thus, anti-myc can 





Figure 3.53. Co-localization of myc tag and C1QBP. (A) Myc and (B) C1QBP 
staining was co-localized perfectly as indicated by the yellow staining, 
showing that myc staining can be used to represent C1QBP staining in 
C1QBP-overexpressing cells. Scale bar: 20 µm. 
Then, the co-localization of C1QBP represented by myc staining, and 
YB-1 was determined in MDA-MB-231 cells overexpressing C1QBP. Judging 
from the images, co-localization between C1QBP and YB-1 was observed in 
the mitochondria (Figure 3.54). 
 
Figure 3.54. Co-localization of YB-1 and C1QBP in C1QBP-overexpressing 
cells. (A) Mouse anti-myc was used to represent C1QBP and (B) rabbit anti-
YB-1 was used to stain YB-1. (C) Merged image showed co-localization of 
these two proteins in yellow. (D) Single stain control for C1QBP, where YB-1 
antibody was omitted. (E) Single stain control for YB-1, where C1QBP 
antibody was omitted. (F) Negative control where both antibodies were 




3.18.2 Correlation of expression between C1QBP and YB-1 
Correlation of expression between C1QBP and YB-1 was first 
identified in breast cancer tissue samples. Gene expressions of C1QBP and 
YB-1 were obtained from TissueScan array (Panel 1). A statistically 
significant correlation was observed and Pearson’s R was recorded as 0.5688 
(P<0.0001, Figure 3.55). 
 
Figure 3.55. Correlation of mRNA levels of C1QBP and YB-1 in breast cancer 
tissue samples. 48 breast cancer tissue samples obtained from TissueScan 










Similarly, the expression of YB-1 based on WAI score was correlated 
to C1QBP in breast cancer tissue samples. The Pearson’s R value obtained is 
0.1982 and P-value= 0.0626 (Figure 3.56).  
 
Figure 3.56. Representative image of YB-1 staining in breast cancer TMAs. 
Scoring was done according to the scoring method of C1QBP in the TMAs 
where (A) 1+ denotes weak staining, (B) 2+ denotes moderate staining and (C) 
3+ denotes strong staining. Scale bar: 100 µm. (D) Correlation of C1QBP and 











Subsequently, the gene and protein expressions of C1QBP and YB-1 in 
various breast cancer cell lines were obtained to determine its correlation. 
Similar to the gene expression of C1QBP, the lowest gene level of YB-1 was 
present in ZR-75-1 cells. T47D contained the highest gene expression of YB-1 
while MDA-MB-231 and MCF7 contained moderate levels of the YB-1 gene 
(Figure 3.57A). Pearson’s correlation test was conducted to determine the 
correlation between the expressions of these two genes in the breast cancer 
cell lines. Correlation between the gene expression of C1QBP and YB-1 was 
observed with Pearson’s R=0.6245 (P=0.0299, Figure 3.57B). 
 
Figure 3.57. Gene expression of YB-1 and correlation to C1QBP expression in 
breast cancer cell lines. (A) Relative gene expression of YB-1 in breast cancer 
cell lines. ∆Ct values of each cell lines were obtained by normalization to the 
corresponding Ct values of GAPDH. Subsequently, the relative expressions of 
YB-1 gene expression in the breast cancer cell lines were determined by 
comparison to ZR-75-1. Bar chart represents mean ± SEM. **P<0.01 and 
***P<0.001. (B) Correlation between the gene expression of YB-1 and 
C1QBP in breast cancer cell lines with Pearson’s correlation R= 0.6245 and 
*P value= 0.0299. Experiments were done in triplicates and repeated twice. 
 The protein expressions of C1QBP and YB-1 were also evaluated to 
determine its correlation. In accordance to its gene level, the YB-1 protein was 
least expressed in ZR-75-1 cells while highly expressed in T47D cells (Figure 
3.58A).  ith a Pearson’s correlation of 0.2643, the correlation between 
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C1QBP and YB-1 protein expression in breast cancer cell lines was not 
significant (Figure 3.58B) 
 
Figure 3.58. Protein expression of YB-1 in breast cancer cell lines and its 
correlation with the protein expression of C1QBP. (A) Western blot 
representations for protein expression of C1QBP in ZR-75-1, T47D, MDA-
MB-231 and MCF7. (B) Expression of YB-1 in breast cancer cell lines. Each 
bar represents mean of O.D. ratio ± SEM. (C) Correlation of C1QBP and YB-
1 protein expression with Pearson’s R=0.2643. Experiments were done in 




3.18.3 Double knockdown of C1QBP and YB-1 in MDA-MB-231 cells 
Reduced expression of YB-1 has been shown to diminish cell 
proliferation, migration and invasion (Yu, 2010). Hence, double knockdown 
of C1QBP and YB-1 was done in MDA-MB-231 cells, to determine whether 
the knockdown of these two proteins concurrently could produce a synergistic 
effect on cell proliferation, migration or invasion. The efficiency of the double 
knockdown on the YB-1 and C1QBP genes are shown in Figure 3.59A and on 
the proteins in Figure 3.59B.  
 
Figure 3.59. Double knockdown of C1QBP and YB-1 in MDA-MB-231 cells. 
(A) More than 80% of the C1QBP and YB-1 genes were knockdown after 
transfection with both siC1QBP and siYB-1 in MDA-MB-231 cells at the 
gene level, with ***P<0.001. (B) Western blot representations after double 
knockdown of C1QBP and YB-1 in MDA-MB-231 cells. (C) At the protein 
level, C1QBP and YB-1 expressions were decreased with statistical 
significance. **P<0.01. Values are presented as mean ± SEM. Experiments 




3.18.3.1 Effect of C1QBP and YB-1 knockdown on cell proliferation in 
MDA-MB-231 cells 
Attenuation of C1QBP and YB-1, respectively decreased cell 
proliferation over 120h. The knockdown of both C1QBP and YB-1 in the cells 
also caused a significant decrease in cell proliferation; however, a synergistic 
effect was not observed (Figure 3.60). 
 
Figure 3.60. Cell growth curve was plotted using alamarBlue assay over 120h. 
The knockdown of C1QBP and YB-1 separately was able to significantly 
reduce the cell proliferation rate. Double knockdown of C1QBP and YB-1 did 
not synergistically reduce cell proliferation rate. Proliferation rate after 
attenuation of C1QBP and YB-1 was similar to knockdown of YB-1 alone. 
**P<0.01, ***P<0.001. Values are presented as mean ± SEM. Experiments 




3.18.3.2  Effect of double knockdown of C1QBP and YB-1 on cell 
migration and invasion in MDA-MB-231 cell 
MDA-MB-231 cells treated with siC1QBP and siYB-1 respectively, 
showed a significant decrease in cell migration (P<0.05). The migratory 
ability of MDA-MB-231 cells was also significantly diminished after double 
knockdown of C1QBP and YB-1, although synergistic decrease was not 
observed (Figure 3.61). 
 
Figure 3.61. Simultaneous knockdown of C1QBP and YB-1 in MDA-MB-231 
cells decreased cell migration but the effect was not synergistic. Knockdown 
of C1QBP and YB-1 respectively, decreased cell migration to the same level 
as cells with double knockdown of C1QBP and YB-1. *P<0.05. Values are 





Likewise, the simultaneous reduction of C1QBP and YB-1 in MDA-
MB-231 cells did not show a synergistic decrease of cell invasion, although 
reduction of YB-1 alone showed diminished cell invasion.  
 
Figure 3.62. The cell invasiveness of MDA-MB-231 cells with double 
knockdown of C1QBP and YB-1 was similar to cell invasiveness of MDA-
MB-231 cells with knockdown of YB-1 itself. No statistical significance was 
observed for the decrease in cell invasiveness after knockdown of C1QBP. 
*P<0.05, **P<0.01. Values are presented as mean ± SEM. Experiments were 
done in triplicates and repeated twice. 
3.18.4 Functional significance of C1QBP in YB-1 overexpressing cells 
Overexpression of YB-1 has been reported to increase cancer 
progression. Among others, the overexpression of YB-1 has been reported to 
increase cell migration and invasion in breast cancer (Yu, 2010). It is therefore 
interesting to determine whether reduction of C1QBP expression in the 




3.18.4.1 Silencing efficiency of siC1QBP in YB-1 overexpressing cells 
Firstly, previously established MDA-MB-231 cells stably 
overexpressing YB-1 were verified to contain higher levels of YB-1 
expression (Yu, 2010). The YB-1 gene expression of the cells was up-
regulated by 3.7 times in the YB-1-overexpressing cells compared to the 
control cells (P=0.003, Figure 3.63A). Analysis of the YB-1 protein levels by 
western blot also showed higher expression of YB-1 in MDA-MB-231 cells 
overexpressing YB-1, compared to MDA-MB-231 cells containing the empty 
vector (Figure 3.63B). Quantitatively, the protein expression was elevated by 
53.5% in the YB-1-overexpressing cells (P=0.0402, Figure 3.63C). 
 
Figure 3.63. (A) The YB-1 gene expression was overexpressed by 
approximately 3.7 times in MDA-MB-231 breast cancer cells. Relative YB-1 
gene expression are presented as mean ± SEM and ***P<0.001. (B) Increased 
YB-1 protein expression in 231.YB1 cells as seen in western blot. (C) The 
protein expression of YB-1 was approximately 53.5% higher in YB-1 
overexpressing cells compared to control cells. Values are presented as mean 






 Following that, knockdown of C1QBP was done in both 231.Vec and 
231.YB-1 cell lines by siC1QBP transfection. The level of C1QBP was 
significantly reduced by 92%, 48 hours after transfection (P<0.0001).   
 
Figure 3.64. Gene expression of C1QBP and YB-1 in MDA-MB-231 cells 
overexpressing YB-1, 48 h after transfection with siC1QBP. Gene levels of 
C1QBP were decreased by 92%. ***P<0.0001. Values are presented as mean 












3.18.4.2 Down-regulation of C1QBP in MDA-MB-231 cells with YB-1 
overexpression altered cell growth 
Cell proliferation was measured by MTS assay at 48 h and 72 h after 
transfection. Cell proliferation was significantly diminished at 48 h and 72 h 
after transfection (P=0.0220, Figure 3.65A; P=0.0069, Figure 3.65B). Further 
clarification was made by examining the cell growth curve of YB-1 
overexpressing cells after knockdown of C1QBP. AlamarBlue assay was used 
to measure and plot the cell growth curve. A decrease trend was observed for 
cells with knockdown of C1QBP, although the difference was not statistically 
significant (Figure 3.65C).   
 
Figure 3.65. Down-regulation of C1QBP decreased proliferation and cell 
growth of YB-1 overexpressing cells. Measurement of cell viability was done 
by MTS assay at (A) 48 h and (B) 72 h, post-transfection. Values are 
presented as mean of absorbance at 490 nm ± SEM. *P<0.05 and **P<0.01. 
(C) Cell growth curves of 231.YB1.NT and 231.YB1.siC1QBP cells were 
plotted over 96 h by repeated measurements of alamarBlue absorbance every 
24 h. The difference between the two curves were not statistically significant. 
Values are presented as mean ± SEM. Experiments were done in 





3.18.4.3 Cell migration and invasion was altered after knockdown of 
C1QBP in YB-1 overexpressing cells 
Overexpression of YB-1 has been associated with increased cell 
migration and cell invasion abilities (Yu, 2010). Using the transwell migration 
system, knockdown of C1QBP decreased cell migration of YB-1-
overexpressing cells (Figure 3.66). However, upon further inspection, it was 
discovered that the level of cell migration did not return to the original level 
i.e. to the migration level of 231.Vec.NT cells. 
 
Figure 3.66. Cell migration was mitigated after knockdown of C1QBP in YB-
1 overexpressing cells. (A) Cells which have migrated through the membrane 
were stained with fixed and stained with crystal violet. (B) The attenuation of 
C1QBP in MDA-MB-231 cells overexpressing YB-1 significantly reduced the 
ability of cells to migrate through the transwell membrane; however the 
reduction was not sufficient to return cell migration level to the level of 
231.Vec.NT cells. Bar chart represents mean of number of migrated cells ± 
SEM. ***P<0.0001, **P<0.01, *P<0.01. Experiments were done in triplicates 




Similarly, cell invasion was decreased after knockdown of C1QBP in 
YB-1 overexpressing cells (Figure 3.67A). However, the knockdown of 
C1QBP by itself was not sufficient to reduce the number of invasive cells to 
that of 231.Vec.NT cells (Figure 3.67B; P<0.05). Therefore, it can be 
postulated that the interaction of C1QBP and YB-1 affected cell migration and 
invasion but other factors or proteins were also involved in these processes.  
 
Figure 3.67. The invasiveness of MDA-MB-231 overexpressing YB-1 was 
diminished after knockdown of C1QBP. (A) Representative images of cells 
with invasive capability in the control and C1QBP-knockdown group. Cells 
were fixed with methanol and stained with crystal violet dye. (B) The number 
of invasive cells in YB-1-overexpressing cells treated with siC1QBP 
decreased but treatment of cells with siC1QBP was not enough to return cell 
invasiveness to its original state. Bar chart represents mean number of invasive 

















4.1 Association of C1QBP with cell proliferation 
One of the fundamental traits of cancer cells is the ability to sustain 
chronic proliferation (Hanahan and Weinberg, 2011). In normal tissues and 
organs, cell growth and number are tightly regulated by a balance of cell loss 
and organized cell proliferation (Rue and Martinez Arias, 2015). However, 
cancer develops due to an accumulation of genetic and epigenetic alterations 
to oncogenes and tumor suppressor genes, which among other characteristics, 
provides a growth advantage to cancer cells (Corn and El-Deiry, 2002).  
In breast cancer tissue samples examined in the present study, the 
mRNA expression of C1QBP was observed to be upregulated in advanced 
stages of breast cancer (Stages IIb and higher) and in tumor size of more than 
5 cm (T3). The results were further corroborated by immunohistochemical 
analyses of C1QBP in breast cancer TMAs, whereby overexpression of 
C1QBP was significantly associated with tumor size. Furthermore, 
multivariate analysis showed that the expression of C1QBP can independently 
predict tumor size in PR-positive breast cancer tissue samples. In addition, the 
expression of C1QBP was significantly correlated to PCNA, a proliferative 
marker which has been associated with mitotic index and tumor size in breast 
cancer (Agarwal et al., 1997). Prior reports have revealed that higher 
expression of C1QBP was observed in malignant tissues, compared to their 
normal counterpart (Chen et al., 2009b; Dembitzer et al., 2012). 
Comparatively, analysis of the expression of C1QBP in breast cancer TMAs 
done by Zhang et al. (2013) showed a significant association to the TNM 
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staging of breast cancer, although a correlation between tumor size and 
C1QBP was not detected. Cell proliferation, being a hallmark of cancer has 
been extensively attributed to tumor growth and progression (Hanahan and 
Weinberg, 2011). Additionally, standard breast cancer treatments, such as 
chemotherapy and radiotherapy, are largely based on the proliferative activity 
of breast cancer. In particular, treatment for luminal receptor-positive subtype 
of breast cancer is generally based on the evaluation of proliferation (Nilsson 
et al., 2013).   
 Hence, further studies on proliferation were conducted on breast cancer 
cell lines. The attenuation of C1QBP in PR-positive T47D breast cancer cell 
line and triple negative MDA-MB-231 breast cancer cell line reduced cell 
proliferation and cell growth rate. Consistent with the findings, previous 
reports have shown that knockdown of C1QBP in breast cancer and prostate 
cancer cell lines decreased cell proliferation (Amamoto et al., 2011; McGee et 
al., 2011). Complementarily, overexpression of C1QBP in MDA-MB-231 
breast cancer cells increased cell proliferation and cell growth rate. Similar 
findings were reported after overexpression of C1QBP in a liver carcinoma 
cell line (Kaul et al., 2012). A deeper analysis into the cell cycle profile of 
MDA-MB-231 cells overexpressing C1QBP, indicated an increase in cell 
survival and G1 to S phase progression. In agreement with the data obtained, 
knockdown of C1QBP in PC3 prostate cancer cells resulted in cell cycle arrest 
at the G1 to S phase (Amamoto et al., 2011). Moreover, the alteration of cell 
cycle progression observed in MDA-MB-231 cells after manipulation of 
C1QBP, was accompanied by changes in the expression of Cyclin D1 and its 
156 
 
relevant cyclin-dependent kinases (CDKs). From the data obtained, up-
regulation of C1QBP increased Cyclin D1 and CDK6. 
Cancer cells with uncontrolled cell cycle progression, as an effect of 
dysregulated growth signals, consequently affect other biological properties 
such as cell survival (Hanahan and Weinberg, 2011). Regulation of cell cycle 
is highly dependent on cyclin-dependent protein kinases (CDKs), which 
require binding to cyclins (Sherr, 1996; Casimiro et al., 2014). The G1 phase 
is a critical point in the cell cycle process, where the decision to proceed with 
cell division, or withdraw from the cycle and enter resting phase was made 
(Sherr, 1994). In cancer cells, the G1 phase transition to S phase continues 
unrestricted, and as cell cycle exit expedites cell maturation and 
differentiation, these processes are subsequently subverted as well (Sherr, 
1996). Upon entering the G1 phase, CDK4 and CDK6 form complexes with 
D-type cyclins (Cyclins D1, D2, D3). The G1-S phase transition is restricted 
by the inhibitory effect of retinoblastoma susceptibility protein (Rb) (Giacinti 
and Giordano, 2006). This restriction is overcome by hyperphosphorylation of 
the Rb protein by sequential phosphorylation of CDK4/6-Cyclin D and CDK2-
Cyclin E, which consequently, releases E2F transcription factors, causing 
activation of genes necessary for S-phase DNA replication (Casimiro et al., 
2014). The CDK/cyclin complexes are negatively regulated by the INK4 
family and the Cip/Kip family, together forming the CDK inhibitors (CKIs). 
The INK4 family consisting of p15, p16, p18 and p19, specifically inhibits 
CDK4 and CDK6. Conversely, the Cip/Kip family (p21, p27 and p57) appears 
to broadly affect cyclin D-, E-, A- and B-dependent kinase complexes 
(Albrecht et al., 1998; Sherr and Roberts, 1999; Corn and El-Deiry, 2002). 
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The Cyclin D-CDK complex sequesters Cip/Kip family members, which 
relieve Cyclin E-CDK2 from the inhibitory effect, facilitating the activation of 
Cyclin E-CDK2 in the later stages of the G1 phase (Sherr and Roberts, 1999).  
Cyclin D1, a part of the D-type cyclin family is a well-established 
regulator of the G1 to S phase progression of the cell cycle (Heichman and 
Roberts, 1994; Sherr, 1996; Pestell, 2013; Casimiro et al., 2014). The 
overexpression of Cyclin D1 has been widely reported in haematological 
malignancies of the lymphoid lineage and cancer of the breast, lung, prostate, 
bladder and endometrium (Pestell, 2013; Casimiro et al., 2014). Augmentation 





 away from the CDK2-Cyclin E complex, resulting in the increase 
hyperphosphorylation of Rb, hence enhancing entry into S-phase and 
subsequently, encouraging cell cycle progression (Casimiro et al., 2014). 
Previous in vitro studies in liver and prostate cancer cell lines showed a 
positive relationship between C1QBP and Cyclin D1 (Amamoto et al., 2011; 
Kaul et al., 2012). Additionally, the expression of p21
Cip1
 was found to be 
inversely correlated with Cyclin D1 expression after knockdown or 
overexpression of C1QBP in prostate and liver cancer cell lines, respectively 
(Amamoto et al., 2011; Kaul et al., 2012).  
Taken together, it can be postulated that C1QBP enhanced G1 to S 
phase progression in MDA-MB-231 breast cancer cell line, by regulating the 
expression of Cyclin D1 and CDK6, which could subsequently increase 
hyperphosphorylation of Rb, thereby promoting breast cancer proliferation. 




Figure 4.1. The expression of C1QBP affected the G1 to S phase progression 
in the cell cycle by altering Cyclin D1 and CDK4/6 expression. Augmentation 
of Cyclin D1 and CDK6 expression by C1QBP leads to hyperphosphorylation 
of Rb protein, which releases E2F transcription factors, necessary for cell 
cycle progression. 
4.2 Association of C1QBP with metastasis 
The immunohistochemical analysis of breast cancer TMAs in the current 
study, indicated that C1QBP overexpression was associated with lymph node 
spread. This was also corroborated by analysis of C1QBP gene expression in 
breast cancer tissues, where the mRNA expression of C1QBP was higher in 
breast cancer cases with positive lymph node spread, and advanced stages of 
breast cancer. In agreement to this, it has been shown that overexpression of 
C1QBP mRNA was associated with lymph node metastasis in breast cancer 
tissue samples (Chen et al., 2009b). Zhang et al. (2013) also shown that 
overexpression of C1QBP in breast cancer tissue samples was associated with 
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distant metastasis to the lung and liver, although an association with lymph 
node spread was not observed (Zhang et al., 2013).  
In the present study, C1QBP has been demonstrated to promote cell 
migration and cell invasion in MDA-MB-231 cells. Changes in cytoskeletal 
structure was observed in C1QBP-overexpressing cells, as evident by 
prominent F-actin stress fibres formation in these cells compared to control 
cells. The re-organization of actin molecules at the leading edge of cells and 
the formation of actin stress fibres are necessary for cell migration (Vallenius, 
2013). In addition, the expression of vinculin – a focal adhesion molecule – 
appeared to be less intense compared to control cells indicating a reduction of 
cell adhesion. It has been shown that loss of vinculin promotes migration and 
invasion. Also, it is indicative of poor prognosis in colorectal cancer (Li et al., 
2014). A recent study has shown that C1QBP interacts with PKCδ upon 
stimulation with epidermal growth factor, causing modulation of cell polarity 
and chemotaxis (Zhang et al., 2013). In addition, ligand-induced lamellipodia 
formation requires the expression of C1QBP, and it is present in lamellipodial 
protrusions together with lamellipodial components, such as, CD44, F-actin, 
p-FAK and GM1 upon growth stimulation (Kim et al., 2011). Another way by 
which C1QBP mediates migration is by interacting with αvβ3 integrin, which 
induces the NFκβ signalling pathway, leading to an increase of MT1-MMP 
expression and subsequently, activates MMP2 (Prakash et al., 2011). In vivo 
studies using mice reinforced the role of C1QBP in metastasis, whereby 
C1QBP-attenuated cells showed a decrease in metastatic potential, when 
introduced into the animal models (Kim et al., 2011; Zhang et al., 2013).   
160 
 
4.3 Mechanistic pathways for C1QBP 
As mentioned earlier, genetic and epigenetic changes that lead to 
uncontrolled cell growth and migration are the impelling causes of cancer 
progression. Often, these alterations can be mapped to various cell signalling 
transduction pathways, such as, pathways that control cell growth and 
proliferation, cell motility and cell death. Consequently, dysregulation of these 
signalling transduction pathways will affect wider signalling networks, that 
promotes cancer progression, by altering tumor microenvironment, 
angiogenesis and inflammation (Sever and Brugge, 2015).  
As such, it is imperative to elucidate whether C1QBP was involved in 
any cancer signalling transduction pathways. To do this, genome wide analysis 
of MDA-MB-231 cells after knockdown of C1QBP was carried out. In 
addition, MDA-MB-231 cells overexpressing C1QBP were subjected to a 
panel of antibodies targeting the main regulators of various signalling 
pathways, including the MAPK pathways, JAK-STAT pathway and Akt 
signalling pathway.  
4.3.1 Involvement of C1QBP in the ERK1/2 pathway 
4.3.1.1 The MAPK pathways – focusing on ERK1/2 pathway 
The MAPK pathways are evolutionary conserved kinase proteins, that 
transduce extracellular signal to intracellular signals and facilitate cell 
biological processes, such as cell growth, proliferation, migration, 
differentiation and apoptosis (Dhillon et al., 2007; Roskoski, 2012). A few 
signalling families constitute the MAPK pathways, namely the ERK family, 
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BMK1 family, p38 kinase family and c-Jun N-terminal kinase family 
(Roskoski, 2012; Burotto et al., 2014). Generically, the MAPK pathways 
consist of at least a three-tier system of which, MAPK kinase kinase 
(MAP3K) phosphorylates MAPK kinase (MAP2K) which subsequently, 
phosphorylates MAPK. The phosphorylation of other substrate proteins by 
activated MAPK, such as transcription factors and other functional proteins, 
follows the phosphorylation of MAPK, resulting in different biological 
processes (Roskoski, 2012). Identified MAPKs include ERK1- ERK8, 
p38α/β/γ/δ and JNK1-JNK3 (Schaeffer and Weber, 1999; Chen et al., 2001; 
Kyriakis and Avruch, 2001; Dhillon et al., 2007; Roskoski, 2012).  
Among these, the ERK pathway is the first and most widely studied, 
and accounts for approximately one third of all human cancers (Seger and 
Krebs, 1995; Dhillon et al., 2007).  This cascade plays a central role in signal 
transduction of many extracellular agents via numerous receptors. In general, 
the activation of these receptors stimulates transformation of RAS to its active 
form, which enables the recruitment of RAF (a-RAF, b-RAF, c-RAF), the first 
kinase of the ERK pathway to the plasma membrane, inducing its activation 
(Plotnikov et al., 2011; Burotto et al., 2014; Samatar and Poulikakos, 2014). 
Once activated, RAF phosphorylates and activates MEK (MEK1/2), which in 
turn, phosphorylates ERK1/2 – the final effectors of the ERK pathway 
(Robinson and Cobb, 1997; Burotto et al., 2014). Activation of ERK 
phosphorylates multiple substrates, which execute various processes, 
including but not limited to; cell cycle progression, cell adhesion, cell 
differentiation, cell survival and cell migration (Roskoski, 2012; Samatar and 
Poulikakos, 2014).  
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4.3.1.2 Overexpression of C1QBP affects the ERK pathway 
In the present study, two genes - RASGRP1 and MAP3K8 - involved in 
the MAPK pathways were identified after performing pathway analysis of 
gene microarray studies, following knockdown of C1QBP in the MDA-MB-
231 breast cancer cell line. RASGRPs are a group of guanine nucleotide 
exchange factors, which regulates conversion of small GTPase Ras from its 
inactive GDP-bound form to its active GTP-bound form (Ksionda et al., 
2013). In this study, the RASGRP1 gene expression decreased by 1.6 folds 
after knockdown of C1QBP in MDA-MB-231 breast cancer cell line. 
RASGRP1 has been reported to activate the Ras-Raf-Mek-Erk signalling 
cascade in blood cells, especially T cells (Dower et al., 2000; Stone, 2011). In 
addition, overexpression of RASGRP1 has been shown to cause resistance to 
treatment of acute myeloid leukemia by MEK1 inhibitor, but most 
importantly, the attenuation of RASGRP1 expression in acute myeloid 
leukemia restored the sensitivity to MEK1 inhibitors (Lauchle et al., 2009; 
Ksionda et al., 2013).  
Unexpectedly, the gene microarray analysis also revealed an up-
regulation of MAP3K8 gene expression, after knockdown of C1QBP in MDA-
MB-231 cells. While MAP3K8 has been implicated in the activation of the 
ERK pathway, the functional role of MAP3K8 in cancer is still unclear, as 
both tumor promoter and tumor suppressor functions have been reported for 
this protein (Vougioukalaki et al., 2011). Contrarily, the overexpression of 
C1QBP in MDA-MB-231 cells caused a significant increase of 
phosphorylated ERK1/2 as detected by Pathscan® Intracellular Signaling 
Array. In addition, further validation of active regulators in the ERK1/2 
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signalling cascade, revealed that overexpression of C1QBP also caused an 
increased in p-MEK1/2. In line with this, Kaul et al. (2012) has shown that the 
expression of p-ERK increased after overexpression of C1QBP in liver 
carcinoma cell line. Together with p-Akt and β-catenin, the group reported an 
increase in survival of HepG2 liver carcinoma cell line after overexpression of 
C1QBP (Kaul et al., 2012).  
The ERK1/2 pathway has long been known as a growth-promoting and 
proliferation pathway (Katz et al., 2007). For example, using dominant-
negative inactive MEK1 mutants or anti-sense RNA targeting ERK1/2, it has 
been shown that by blocking activation of the ERK1/2 pathway, fibroblast cell 
proliferation was inhibited (Pages et al., 1993; Seger et al., 1994). 
Furthermore, the ERK pathway, through several machineries, could induce 
cell cycle progression by influencing each phase of the cell cycle process 
(Chambard et al., 2007; Katz et al., 2007). For instance, the ERK pathway 
supported DNA synthesis during S phase by phosphorylation of carbamoyl 
phosphate synthase II, which has a role in pyrimidine biosynthesis (Graves et 
al., 2000). Blocking MEK or ERK activation not only retarded G2/M 
transition, but also prolonged the duration of mitosis (Chambard et al., 2007).  
However, ERK1/2 pathway has been shown to be a master regulator 
particularly of the G1 to S progression in the cell cycle process (Meloche and 
Pouyssegur, 2007). One way in which it regulates G1 to S progression, is by 
targeting the D-type cyclins (Meloche and Pouyssegur, 2007). It was deduced 
that the activation of ERK1/2 could possibly induce the expression of Cyclin 
D1 (Lavoie et al., 1996). This could be possible due to the presence of AP-1 
site in the promoter region of Cyclin D1, which was activated by AP-1 
164 
 
transcription factors such as Fos and Jun (Albanese et al., 1995). Notably, 
sustained activation of ERK1/2 has been shown to increase expression of 
certain AP-1 proteins, such as Fra-1, c-Jun and JunB, as well as Cyclin D1 
accumulation (Balmanno and Cook, 1999; Cook et al., 1999). Other than the 
Fos and Jun family, ERK could also regulate the transcription of Cyclin D1 
via myc, wherein activation of ERK, phosphorylated and stabilized myc, 
which in turn, induced Cyclin D1 transcription (Seth et al., 1991; Daksis et al., 
1994; Chambard et al., 2007). Furthermore, ERK1/2 may also promote the 
degradation of p27
Kip
, a CDK inhibitor, hence, removing its inhibitory effect 
on Cyclin E-CDK2 complex (Kawada et al., 1997). Moreover, activation of 
MEK1/2 has been shown to regulate the assembly of Cyclin D1 and CDK4, 
thus further assisting in the sequestration of p27
Kip
, thereby enhancing G1 to S 
progression (Cheng et al., 1998; Meloche and Pouyssegur, 2007).  
From the current study, C1QBP has been shown to promote cell 
proliferation by enhancing G1 to S progression in MDA-MB-231 cells. This 
was accompanied by changes in expression of Cyclin D1 as well as CDK4/6. 
Hence, it could be postulated that overexpression of C1QBP increased 
activation of ERK, which could subsequently promote proliferation in the 
cells, by enhancing cell cycle progression via induction of Cyclin D1.  
Apart from a well-established role of the ERK pathway in cell growth, 
the ERK pathway has also been frequently implicated in cell migration and 
invasion (Katz et al., 2007). Several downstream effectors such as Rho family 
GTPases, integrins and associated matrix adhesion proteins, extracellular 
proteases, cell-cell adhesion complexes and transcription factors of proteins 
relating to cell migration are regulated by the ERK signalling cascade (Viala 
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and Pouyssegur, 2004; Sever and Brugge, 2015). The lack of ERK activation 
has been shown to impair growth factor-stimulated migration by insulin, 
epidermal growth factor, fibroblast growth factor and vascular endothelial 
growth factor (Katz et al., 2007). Furthermore, the ERK pathway also induces 
expression of proteolytic enzymes, such as matrix metalloproteinases, and 
epithelial to mesenchymal-related factors, such as twist, vimentin, slug and 
fibronectin, thus promoting extracellular matrix protein degradation, as well as 
cell motility, and consequently, encourages invasion and migration 
(Chakraborti et al., 2003; Katz et al., 2007; Chen et al., 2009a; Kim and Choi, 
2015; Sever and Brugge, 2015). In addition, the ERK1/2 cascade has been 
shown to regulate actin polymerization, as well as focal adhesion sites, by 
phosphorylating proteins, such as paxillin, myosin light chain kinase, calpain 
and focal adhesion kinase (Huang et al., 2004a; Katz et al., 2007; Kim and 
Choi, 2010). Through control of the interplay between these proteins, the 
ERK1/2 cascade promotes lamellipodia protrusion, thereafter inducing cell 
migration (Katz et al., 2007).  
In human lung adenocarcinoma cells, C1QBP has been reported to co-
localize at the lamellipodia raft. In addition to disruption of lamellipodia 
formation and migration ability after knockdown of C1QBP, growth factor-
induced phosphorylation of ERK and AKT was also repressed (Eliseeva et al., 
2011). In the present study, knockdown of C1QBP has been shown to decrease 
cell migration ability in MDA-MB-231 breast cancer cells. Complementarily, 
overexpression of C1QBP showed an obvious increase in cell migration 
alongside cell invasion, which was accompanied by up-regulation of p-
ERK1/2 and p-MEK1/2. Thus, it is possible that the augmentation of cell 
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migration and invasion ability could be due to increased activity of the 
ERK1/2 pathway. The summary of the signalling pathway involved in 
C1QBP-mediated cell proliferation and metastasis is shown in Figure 4.2. 
 
Figure 4.2. Role of ERK1/2 signalling pathway in C1QBP-mediated cell 
proliferation and metastasis. Alteration of RASGRP1 and MAP3K8 by C1QBP 
could affect Ras and p-MEK1/2 expression, respectively. This could activate 
the MAPK cascade. Overexpression of C1QBP increased the expression of p-
MEK1/2 and p-ERK1/2, which are the main regulators of the MAPK cascade. 
The activation of this cascade could eventually cause cell proliferation and 
metastasis.  
4.3.2 Involvement of C1QBP in the STAT3 pathway 
4.3.2.1 The JAK-STAT pathway 
The JAK-STAT pathway has been shown to be frequently 
dysregulated in diverse types of cancer (Sansone and Bromberg, 2012). The 
canonical JAK-STAT pathway begins with signal transduction from cytokines 
to its cognate receptors, inducing conformational changes, which lead to 
reorientation of preformed receptor dimers or dimerization of receptors (Li, 
167 
 
2008; Vainchenker and Constantinescu, 2013). This process activates JAK 
proteins, which are linked to the receptors’ cytoplasmic flank, prompting 
receptor tyrosine phosphorylation, creating a docking site for cytoplasmic 
proteins, such as STAT proteins (Mohr et al., 2012). Tyrosine phosphorylation 
of STAT proteins by JAK will cause homodimerization of the STAT proteins 
(Mohr et al., 2012; Vainchenker and Constantinescu, 2013). In doing so, the 
STAT dimers will translocate to and retain in the nucleus, acting as 
transcription factors (Li, 2008; Vainchenker and Constantinescu, 2013). 
Additional posttranscriptional modifications to the STAT proteins, such as, 
serine phosphorylation, lysine acetylation and ubiquitination, regulate the 
transcriptional functions of STAT, contributing considerably to STAT-induced 
gene response (Lim and Cao, 2006; Mohr et al., 2012).  
The STAT family comprised of 7 members i.e. STAT1-4, 5A, 5B and 
6 (Li, 2008). Of these, STAT3 and STAT5 have been reported to play 
significant roles in tumor progression (Haura et al., 2005; Yu et al., 2014). 
While both STAT3 and STAT5 displayed prominent roles in cell proliferation 
and survival in cancer, STAT3 was also involved in the recruitment of 
immune cells to the tumor microenvironment, enhancing tumor progression, 
and at the same time, it has been shown to equip cells with the ability to evade 
the immune system (Haura et al., 2005; Kortylewski and Yu, 2008; Herrmann 
et al., 2010; Yu et al., 2014). In contrast to normal cells, where STAT3 activity 
is transient, cancer cells exhibit constitutive activation of STAT3 (Sellier et 
al., 2013). For example, STAT3 mutations have been shown to cause 
constitutive phosphorylation of STAT3 at Tyr705, in human inflammatory 
hepatocellular adenoma (Pilati et al., 2011). Likewise, mutations in the STAT3 
168 
 
protein were present in 40% of patients with large granular lymphocytic 
leukemia, together with up-regulation of its downstream targets, such as 
BCL2L1, JAK2 and IFNGR2 (Koskela et al., 2012). Apart from these, 
activation of STAT3 has also been shown to affect processes essential for 
tumorigenesis, such as, cell cycle progression, cell survival, angiogenesis, 
cancer inflammation, invasion and metastasis (Yu and Jove, 2004; Haura et 
al., 2005). 
4.3.2.2 C1QBP affects STAT3 activation and its downstream targets 
Pathway analysis done on data from gene microarray in the current 
study, has identified JAK-STAT signalling pathway, as one of the enriched 
pathways involved after silencing of C1QBP in MDA-MB-231 cells. Two 
genes – IL15RA and IL23A – were downregulated after knockdown of C1QBP 
in MDA-MB-231 cells. The IL15RA is a subunit of the IL15 receptor, which 
is part of the IL2R receptor family (Marra et al., 2014; Buchert et al., 2015).  
The IL15RA has been reported to bind to IL15 with the highest affinity 
compared to other IL15R subunits (Anderson et al., 1995). The binding of 
IL15 or IL2 to receptor systems in activated T cells, including the IL15 
receptors, has been shown to induce activation of STAT3 and STAT5 (Lin et 
al., 1995; Tagaya et al., 1996). At the same time, IL15 signalling has also been 
shown to induce anti-apoptotic Bcl2, as well as the ERK signalling pathway 
(Miyazaki et al., 1995; Tagaya et al., 1996). A recent study indicated that 
IL15RA was overexpressed in triple negative breast cancers, especially in the 
immunomodulatory subtypes (Marra et al., 2014). Further, IL15RA was only 
discovered in basal-like breast cancer cell lines and absent in luminal-like cell 
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lines. Upon silencing of IL15RA in the cell lines, growth defects, as well as 
apoptotic cell death were observed (Marra et al., 2014). 
The other downregulated gene related to the JAK-STAT signalling 
pathway, identified after knockdown of C1QBP in MDA-MB-231 cells is the 
IL23A gene. The IL23A gene encodes the p19 subunit of the IL23 ligand 
(Oppmann et al., 2000; Tindall and Hayes, 2010). IL23 binds to receptor 
complexes, which consist of the IL12 receptor β1 chain and IL23 receptor 
subunit. Since the IL12 receptors and IL23 receptor subunits recruit STAT4 
and STAT3, respectively, signal transmission through IL23 could activate 
both STAT3 and STAT4 (Buchert et al., 2015). In the tumor 
microenvironment, STAT3 signalling appeared to transcriptionally activate 
IL23A, which promotes the tumor-enhancing IL23 program, while suppressing 
transcription of IL12-p35 subunit, which favours the antitumor IL12 program 
(Kortylewski et al., 2009).  Notably, the mRNA expression of IL23A has been 
shown to be up-regulated in various cancers, including breast, colon and 
ovarian cancers, compared to its normal adjacent tissues (Langowski et al., 
2006). Moreover, IL23A knockout mice displayed resistance to tumor 
induction, tumor growth and tumor promotion (Langowski et al., 2006).  
Whereas knockdown of C1QBP appeared to decrease signal 
transducers of the JAK-STAT signalling pathway, overexpression of C1QBP 
caused an increase in phosphorylation of STAT3 at Tyr705, as depicted by 
analysis from the Pathscan® Intracellular Signaling Array. MDA-MB-231 
cells overexpressing C1QBP also displayed higher survival rates, evidenced 
by a decrease in sub-G1 phase. As previously cited, the Tyr705 
phosphorylation of STAT3 is an important step in the canonical function of 
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STAT3 (Sellier et al., 2013). Activation of STAT3 has been shown to prevent 
apoptosis and hence enhance cell survival by regulating the anti-apoptotic 
Bcl2 family gene (Yu and Jove, 2004). One of the first evidence illustrating 
the role of STAT3 in cell survival, showed that constitutive activation of 
STAT3 increased expression of Bcl-XL and was essential in the survival of 
multiple myeloma cells (Catlett-Falcone et al., 1999). In addition, other 
members of the anti-apoptotic Bcl2 family, such as Bcl2 and Mcl1, have also 
been shown to be dependent on STAT3 activation (Zushi et al., 1998; 
Rahaman et al., 2002; Bhattacharya et al., 2005). Another target of STAT3 
activation is the p53 protein. p53 is widely known as both an inhibitor of cell 
proliferation and a promoter of cell apoptosis. STAT3 could suppress p53 
expression and more importantly, the attenuation of STAT3 signalling was 
able to restore the apoptosis function of p53 in cancer cells (Yu and Jove, 
2004). As phosphorylation of STAT3 (Y705) was increased in conjunction 
with overexpression of C1QBP in MDA-MB-231 cells, the expression of 
Bcl2, Mcl1 and p53 – downstream targets of p-STAT3 – were explored in this 
study. The results obtained showed that overexpression of C1QBP in MDA-
MB-231 cells, not only increased phosphorylation of STAT3 at Tyr705, but 
also augmented the expression of Bcl2 and Mcl1 while diminished p53. In 
addition, looking back at the gene microarray analysis, Bcl2 gene expression 
was also decreased after knockdown of C1QBP. Thus, the increase in cell 
survival of MDA-MB-231 cells stably overexpressing C1QBP could be due to 
the increased activity of STAT3, which subsequently promoted the expression 
of pro-survival Bcl2 family. 
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In the current study, C1QBP has been shown to influence 
chemosensitivity of MDA-MB-231 cells to Doxorubicin hydrochloride 
treatment. In addition, the constitutive expression of C1QBP was higher in 
doxorubicin-resistant MCF7 breast cancer cells compared to parental MCF7 
cells, indicating a role of C1QBP in mediating chemoresistance. 
Correspondingly, p-STAT3 and its downstream targets tested have also been 
implicated in chemoresistance. Chemoresistance arising from phosphorylation 
of STAT3, in particular at Tyr705 has been accounted for various types of 
cancers such as brain, breast, colorectal, cervical, bladder and prostate cancer 
(Spitzner et al., 2014). The STAT3-dependent modulation of Bcl2 expression 
in breast cancer cells has been shown to affect sensitivity to chemotherapeutic 
drugs (Real et al., 2002). In addition, chemoresistance due to STAT3-mediated 
Mcl1 expression has also been reported (Liu et al., 2011; Becker et al., 2014). 
Notably, in melanoma with B-RAF
V600
 mutation, B-RAF initiated the 
activation of p-STAT3 (Y705) which led to the accumulation of Mcl1, thought 
to be responsible for chemoresistance in this subtype of cancer (Becker et al., 
2014). This also shows a possible crosstalk between the MAPK and STAT3 
pathway through Tyr705 phosphorylation of STAT3 (Becker et al., 2014).  
Aside from cell survival and chemoresistance, the activation of STAT3 
has also been shown to regulate the expression of cell cycle-related proteins, 
such as c-myc and Cyclin D1 which controls G1-S progression (Kiuchi et al., 
1999; Sinibaldi et al., 2000; Yu and Jove, 2004; Haura et al., 2005).  Thus, in 
the present study, the increase of cell proliferation observed in MDA-MB-231 
cells after overexpression of C1QBP could be due to an increase in activation 
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of p-STAT3 (Y705), which subsequently accumulates Cyclin D1, and as a 
consequence, expedited G1 to S progression. 
Furthermore, STAT3 activity has also been reported to govern cell 
motility and invasion, greatly contributing to cancer metastasis (Kamran et al., 
2013; Teng et al., 2014; Wendt et al., 2014). One way in which STAT3 
regulates cell invasion is through the regulation of matrix metalloproteinases, 
(MMPs) such as MMP1, MMP2, MMP7 and MMP9 (Xie et al., 2004; Li et 
al., 2011; Kamran et al., 2013). After knockdown of C1QBP in MDA-MB-231 
cells, gene microarray analysis revealed down-regulation of MMP23B gene, 
belonging to the MMP family. In the context of embryo implantation, a recent 
study showed that stimulation of IL11 in trophoblastic cells regulated STAT3 
and ERK signalling pathways, which increased expression of Jun, Fos, MUC1, 
PDPN and MMP23B, thereby increasing cell invasiveness (Suman et al., 
2012). Hence, activation of STAT3 could affect cell invasiveness through 
MMP23B, although further investigation needs to be done. STAT3 could also 
regulate cell migration by interacting with the Rho GTPases family (Debidda 
et al., 2005; Teng et al., 2009; Kamran et al., 2013). As an example, STAT3 
binding to βPIX, an activator of RAC1, has been shown to control the 
organization of actin cytoskeleton and directional migration (Teng et al., 
2009). In addition, epithelial to mesenchymal transition, one of the key 
mechanisms of cell migration, is highly intertwined with the STAT3 signalling 
pathway (Wendt et al., 2014). For instance, aberrant up-regulation of IL6 has 
been shown to increase STAT3 activity, as well as Twist. Overexpression of 
Twist further stimulates the production of IL6, which consequently leads to 
autocrine activation of STAT3, creating a positive feedback loop which also 
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feeds cancer EMT programs (Wendt et al., 2014). Hence, the increase 
phosphorylation of STAT3 (Y705) observed in the present study could 
possibly explain the increase in cell migration and invasion of MDA-MB-231 
cells after overexpression of C1QBP. C1QBP-mediated JAK-STAT signalling 
and the effects on functional processes is illustrated in Figure 4.3. 
 
Figure 4.3. Role of C1QBP in the JAK/STAT pathway. C1QBP has been 
shown to alter IL15RA, a subunit of the IL15 interleukin receptor and IL23A, a 
subunit of the IL23 ligand. Interleukin and its receptors are important 
activators of the JAK-STAT pathway. Upon activation, p-JAK will activate p-
STAT3. In the present study, C1QBP was shown to increase p-STAT3(Y705) 
expression and its downstream targets, which are involved in cell proliferation, 
survival and chemoresistance. In addition, C1QBP also altered the expression 
of MMP23B, which belongs to the MMP family. This could possibly 
contribute to cell invasion and subsequently, metastasis.  
4.3.3 Potential involvement of C1QBP in the Akt-signalling pathway 
From the Pathscan® Intracellular Signalling array analysis, the activity 
of three other molecules i.e. p-Akt (Ser473), p-S6 ribosomal protein 
(ser235/236) and p-GSK3β (Ser9) were up-regulated. These three proteins 
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have been implicated in the PI3K-Akt signalling pathway. The PI3K-Akt 
signalling pathway is a widely known regulator of cell proliferation, cell 
survival and resistance to anticancer therapy (Polivka and Janku, 2014; Sever 
and Brugge, 2015). Akt activation is triggered by stimulation of the growth 
factor receptor-associated PI3K, which forms 3’-polyphosphoinositides PIP3 
and PIP2 at the plasma membrane (Bellacosa et al., 2005). These two 
molecules bind to the PH domain and recruits Akt to the membrane. The 
relocalization of Akt from cytoplasm to the membrane, primes it for activation 
by phosphorylation at Thr308 and Ser473 (Bellacosa et al., 2005; Toker and 
Marmiroli, 2014). Phosphorylation of Akt is a well proven factor of tumor 
progression, having roles in cell proliferation, growth, survival and metastasis 
(Cheung and Testa, 2013).  
GSK3, a molecular target of activated Akt, is a serine/threonine kinase, 
which has been initially shown to be involved in metabolism. Further studies 
have shown that GSK3 is an important regulatory enzyme, having roles in 
various disorders, such as cancer, immune system disorders, neurological 
disorders and metabolic disorders (McCubrey et al., 2014). GSK3 is highly 
expressed in various tissues, and it has been shown to negatively regulate 
many proto-oncogenes and cell cycle regulators, hence being reputed as a 
tumor suppressor (Takahashi-Yanaga, 2013). The GSK3 protein comprises of 
the GSK3α and GSK3β isoforms. The functions of GSK3 are usually inhibited 
by phosphorylation at Ser21 in GSK3α and Ser9 in GSK3β (Takahashi-
Yanaga, 2013). GSK3β has been shown to target Mcl1 and Cyclin D1 (Maurer 
et al., 2006; Sever and Brugge, 2015). The phosphorylation of these proteins 
by GSK3β marked them for degradation (Bellacosa et al., 2005). Therefore, 
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the phosphorylation of GSK3β by Akt will lead to stabilization of the Cyclin 
D1 and Mcl1 proteins (Bellacosa et al., 2005; Manning and Cantley, 2007). 
Consistent with the data obtained, increased in Akt activity (Ser473) was 
accompanied by increased phosphorylation of GSK3β (Ser9). In addition, p-
GSK3β could potentially suppress the degradation of Mcl1 and Cyclin D1, 
leading to accumulation of these two proteins, which enhanced cell survival, 
proliferation and chemoresistance (Brown and Toker, 2015).  
In conjunction with an increase of GSK3β phosphorylation, data from 
the Pathscan® array also showed that p-Akt (Ser473) up-regulation was 
coupled with p-S6 ribosomal protein (Ser235/236). In the Akt machinery, 
activation of mTOR by p-Akt will stimulate phosphorylation of p70 S6 kinase 
(p70S6K) and eukaryotic initiation factor 4E binding protein 1, 2, and 3 (4E-
BPs). Activated p70S6K will phosphorylate S6 ribosomal protein which leads 
to increase translation and protein synthesis, mediating cell growth and 
proliferation (Dufner and Thomas, 1999). Additionally, S6 ribosomal protein 
has been shown to increase p-Akt (Ser473) and mTORC2 in a positive 
feedback loop (Yano et al., 2014). The activation of 4E-BPs phosphorylates 
the eIF4-binding protein, which releases the eIF4 cap binding factor and 
promotes cap-dependent translation of mRNA such as Cyclin D1, c-Myc and 
VEGF (Bellacosa et al., 2005). The potential role of C1QBP in the Akt 




Figure 4.4. Potential role of C1QBP in the AKT signalling pathway. 
Overexpression of C1QBP increased p-AKT (Ser473). The phosphorylation of 
AKT promotes the phosphorylation of GSK3β, which relieves its inhibitory 
effects on Cyclin D1 and Mcl1. In addition, activation of AKT also leads to 
phosphorylation of S6 ribosomal protein, which enhances cell proliferation. 
Altogether, C1QBP could affect cell proliferation, survival and 
chemoresistance by regulating the AKT signalling pathway.  
4.3.4 Interaction of C1QBP with YB-1 
A key step in understanding a protein’s function is to identify its 
interacting partners. To determine the C1QBP interactome, SILAC-
immunoprecipitation quantitative proteomics was done. This method offers 
various advantages over other quantitative proteomics, such as chemical 
labelling of proteins or peptides. Firstly, metabolic labelling of the cells in 
SILAC culture takes place before any sample processing, thus minimizing 
variability due to subsequent biochemical or mass spectrometry procedures 
(Sap and Demmers, 2012). Complete incorporation of metabolic labelling 
encompassing proteins and peptides lead to extremely accurate and sensitive 
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data (Trinkle-Mulcahy, 2012). In comparison, labelling by chemical methods 
was done at later stages of sample treatment, which potentially introduces 
variability and hence, reducing its accuracy (Sap and Demmers, 2012). 
Additionally, apart from direct interactions, SILAC immunoprecipitation 
enabled the detection of low affinity or indirect interacting partners (Emmott 
and Goodfellow, 2014).  
The data obtained showed that the C1QBP interactome was involved in 
RNA-binding and DNA-binding activities, such as, RNA processing, DEAD-
box helicase activity and transcription factor regulation, demonstrated by 
DAVID analysis. In addition, transcription regulation was also identified as 
one of the enriched functional annotations in DAVID analysis of gene 
microarray performed, after knockdown of C1QBP. Thus, a specific protein, 
YB-1 was chosen for further studies. YB-1 is a multi-functional cold shock 
domain protein (Eliseeva et al., 2011). It is present in the cytoplasm, nucleus 
and can be secreted from cells. Likewise, YB-1 is involved in almost all DNA 
and mRNA-dependent processes, including DNA replication, DNA repair, 
transcription, pre-mRNA splicing and mRNA stabilization (Eliseeva et al., 
2011). The overexpression of YB-1 in various cancers, such as breast cancer, 
gastric cancer, prostate tumor and rectal cancer, has been associated with poor 
prognosis (Janz et al., 2002; Huang et al., 2004b; Yasen et al., 2005; Habibi et 
al., 2008; Kosnopfel et al., 2014; Zhang et al., 2015). YB-1 has been reported 
to promote cell proliferation and metastatic potential in cancer cells. In 
addition, the nuclear translocation of YB-1 has been shown to be an early 
marker of multidrug resistance in tumor cells (Eliseeva et al., 2011).  
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Previous studies have shown that C1QBP interacts with YB-1 
(Matsumoto et al., 2005; Wang et al., 2015). Matsumoto et al. (2005) showed 
that C1QBP relieves the mRNA translational repression of YB-1. In renal 
carcinoma cells, C1QBP seemed to repress functions of YB-1, by inhibiting 
phosphorylation and nuclear translocation of YB-1 (Wang et al., 2015). In the 
current study, the interaction of YB-1 and C1QBP was studied, in terms of cell 
proliferation, migration and invasion. In breast cancer cell lines and tissue 
samples, a positive correlation was observed between the gene expression of 
C1QBP and YB-1. C1QBP was found to co-localize with YB-1 in the 
mitochondria of MDA-MB-231 cells overexpressing C1QBP. Double 
knockdown of C1QBP and YB-1 did not show synergistic decrease for cell 
proliferation, migration and invasion. When C1QBP was diminished in YB-1-
overexpressing cells, there was a decrease in cell proliferation, migration and 
invasion, but it did not return to the basal levels. Taken together, the 
interaction of C1QBP with YB-1 alone was not sufficient to induce cell 
proliferation, migration or invasion, implying that perhaps there are other 
factors which may also influence these functions.  
4.4 Conclusion 
In this study, the role of C1QBP in breast carcinogenesis has been 
explored, by a series of different functional analyses in breast cancer cell lines 
and breast cancer tissue samples. In breast cancer cell lines, C1QBP was 
shown to promote cell proliferation and survival, mainly by regulating the G1 
to S transition in the cell cycle process through Cyclin D1 and CDK4/6. 
Accordingly, the expression of C1QBP was highly correlated with tumor size 
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at both the mRNA and protein levels in breast cancer TMAs. Furthermore, the 
expression of C1QBP independently predicted tumor size in PR-positive 
breast cancer patients, as observed by multivariate analysis.  
High expression of C1QBP at the gene and protein level in breast cancer 
tissue samples, were associated with lymph node spread, although on further 
analysis, it was revealed that the expression of C1QBP was not independently 
associated with lymph node spread. Nonetheless, knockdown or 
overexpression of C1QBP in MDA-MB-231 breast cancer cell line, indicated 
a role of C1QBP in cell migration and invasion.  
Gene microarray, Pathscan® Intracellular Array and interactome studies 
done after manipulating C1QBP expression have provided clues on the 
signalling pathways that were affected. From the gene microarray analysis, 
RASGRP1 and MAP3K8 were identified as potential regulators of the ERK1/2 
pathway. In agreement with this, the antibody array used revealed a significant 
up-regulation of ERK1/2 activity after overexpression of C1QBP. Further 
investigations showed that C1QBP overexpression affected the expression of 
p-ERK1/2 and p-MEK1/2, both of which are important regulators of the 
ERK1/2 signalling pathway. Since the ERK1/2 signalling pathway has a 
widely established role in various cell functions, it can be postulated that 
C1QBP could mediate its functions in tumorigenesis through this pathway.  
The analysis of gene microarray data also identified IL15RA and IL23A, 
both of which are involved in the JAK/STAT signalling pathway. In addition, 
antibody signalling array showed an increase of STAT3 (Y705) activation in 
C1QBP-overexpressing cells. Thereafter, the expression of downstream 
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targets of STAT3 was elucidated. Indeed, C1QBP was found to promote 
STAT3 (Y705) activity, which also enhanced the expression of Mcl1 and Bcl2 
and reduced the expression of p53. This could account for the increased cell 
survival capability observed in C1QBP-overexpressing cells. Additionally, the 
survival-promoting property of the cells could contribute to increased 
Doxorubicin hydrochloride chemoresistance, observed in C1QBP-
overexpressing cells. Apart from cell survival, phosphorylation of STAT3 
(Y705) has also been shown to promote cell migration and invasion by various 
ways, including regulation of MMPs. In this study, gene microarray analysis 
also showed a decrease of MMP23B, after down-regulation of C1QBP. 
Although a direct link of p-STAT3 and MMP23B has not been reported, a 
previous study showed that STAT3 activation could lead to increased 
expression of MMP23B, and eventually promote cell invasion (Suman et al., 
2012). 
Additionally, Pathscan® Intracellular Signaling array has also revealed 
an up-regulation of p-Akt (Ser473), p-GSK3β (Ser9) and p-S6 ribosomal 
protein (Ser235/236), which are proteins involved in the Akt signalling 
pathway. This signalling pathway encompasses many cell processes, including 
cell growth and proliferation. The increase of p-S6 ribosomal protein has been 
known to increase cell proliferation. In addition, inhibition of GSK3β activity 
has also been shown to increase cell survival and proliferation, by preventing 
degradation of proteins, such as Cyclin D1 and Mcl1. However, the role of 
C1QBP in this pathway needs to be validated. 
Together with the Akt signalling pathway, ERK1/2 signalling pathway 
and STAT3 signalling pathway have also been extensively associated to cell 
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proliferation, especially in promoting Cyclin D1 expression. Hence, it can also 
be proposed that these pathways influence the expression of Cyclin D1. In 
cooperation with CDK4/6, the accumulation of Cyclin D1 will increase cell 
proliferation.  
Studies done using SILAC-immunoprecipitation quantitative 
proteomics, identified interacting partners with functions which are generally 
associated with DNA and RNA binding. A protein of interest, YB-1, a cold 
shock domain protein with prominent roles in DNA and RNA binding, was 
selected for further investigation on the role of its interaction with C1QBP, on 
functions such as, cell proliferation, migration and invasion. A correlation of 
C1QBP and YB-1 in breast cancer cell lines and tissue samples was observed 
at the gene level. In C1QBP-overexpressing cells, YB-1 and C1QBP seemed 
to be co-localized at the mitochondria. Although a synergistic effect was not 
observed upon double knockdown of C1QBP and YB-1, the knockdown of 
C1QBP in YB-1 overexpressing cells decreased cell proliferation, migration 
and invasion. However, this was not sufficient to reduce cell proliferation, 
migration and invasion to its original level. Hence, the role of C1QBP in these 
processes was only partially mediated by YB-1 and perhaps, other interacting 
partners were needed. Altogether, C1QBP could mediate cell proliferation, 
metastasis and chemoresistance, through ERK1/2, STAT3 and Akt signalling 
pathways. These cell processes could also be partially mediated through YB-1. 
The potential signalling pathways that C1QBP could be involved in is 




Figure 4.5. Potential signalling pathways mediated by C1QBP. 
Given the multifunctional roles of C1QBP in breast cancer progression, 
particularly cell proliferation, migration and invasion, and its involvement in 
major cancer signalling pathways, such as the ERK1/2 and STAT3 pathways, 
C1QBP appears to be a promising molecular target for breast cancer. In fact, a 
monoclonal antibody, which targets C1QBP on cell surfaces has been shown 
to consistently block cell proliferation in lymphoma cell lines (Peerschke and 
Ghebrehiwet, 2014), paving the way for C1QBP as a therapeutic target in 
cancer.  
4.5 Future studies 
Since C1QBP has great potential as a molecular target in cancer, 
additional investigations on C1QBP could ensure its future development as a 
therapeutic target. Firstly, although this study has shown that C1QBP was 
involved in the ERK1/2 pathway and STAT3 pathway, specific targets of this 
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pathway was not verified. For instance, the role of MMP23B in C1QBP-
mediated activation of STAT3 could be further investigated. In addition, 
Pathscan® Intracellular Signalling array has also shown that p-Akt (Ser473), 
p-GSK3β (Ser9) and p-S6 ribosomal protein (Ser235/236) were increased in 
C1QBP-overexpressing cells. Thus, the involvement of C1QBP in the Akt 
signalling pathway should be validated.  
Apart from up-regulation of the anti-apoptotic Bcl2 family, the 
mechanism in which C1QBP induces chemoresistance should also be 
investigated. It would be interesting to determine the cancer stem cell-like 
properties of C1QBP-overexpressing cells as cancer stem cells have been 
shown to play key roles in recurrence following chemotherapy (Abdullah and 
Chow, 2013). In addition, the role of ATP-binding cassette (ABC) transporters 
should also be taken into account in C1QBP-mediated Doxorubicin resistance. 
As reported, co-localization of YB-1 and C1QBP was detected in the 
mitochondria. The unique localization of YB-1 in the mitochondria warrants 
further investigation. YB-1 bound to nuclear-encoded mitochondrial oxidative 
phosphorylation mRNAs has been shown to be present at the outer membrane 
of mitochondria (Matsumoto et al., 2012). A more prominent mitochondrial 
localization of YB-1 has also been reported to significantly contribute to 
mitochondrial DNA mismatch-binding and mismatch-repair (de Souza-Pinto 
et al., 2009). Hence, it would be worthwhile to determine whether interaction 
of C1QBP and YB-1 could affect this activity, as disruption of mitochondrial 
DNA mismatch repair has been linked to DNA microsatellite instability and 
mitochondrial DNA instability, which has been implicated in cancer and aging 
(de Souza-Pinto et al., 2009).  
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Finally, the study of C1QBP’s interactome has revealed interactions of 
proteins which have not been reported previously. Therefore, a deeper insight 
on C1QBP’s functions could be attained by further exploring the interaction of 
















Abdullah, L.N., and Chow, E.K. (2013). Mechanisms of chemoresistance in 
cancer stem cells. Clin Transl Med 2, 3. 
Agarwal, S., Jain, R., Rusia, U., and Gupta, R.L. (1997). Proliferating cell 
nuclear antigen immunostaining in breast carcinoma and its relationship to 
clinical and pathological variables. Indian J Pathol Microbiol 40, 11-16. 
Albanese, C., Johnson, J., Watanabe, G., Eklund, N., Vu, D., Arnold, A., and 
Pestell, R.G. (1995). Transforming p21ras mutants and c-Ets-2 activate the 
cyclin D1 promoter through distinguishable regions. J Biol Chem 270, 23589-
23597. 
Albrecht, J.H., Poon, R.Y., Ahonen, C.L., Rieland, B.M., Deng, C., and Crary, 
G.S. (1998). Involvement of p21 and p27 in the regulation of CDK activity 
and cell cycle progression in the regenerating liver. Oncogene 16, 2141-2150. 
Amamoto, R., Yagi, M., Song, Y., Oda, Y., Tsuneyoshi, M., Naito, S., 
Yokomizo, A., Kuroiwa, K., Tokunaga, S., Kato, S., et al. (2011). 
Mitochondrial p32/C1QBP is highly expressed in prostate cancer and is 
associated with shorter prostate-specific antigen relapse time after radical 
prostatectomy. Cancer Sci 102, 639-647. 
Anderson, D.M., Kumaki, S., Ahdieh, M., Bertles, J., Tometsko, M., Loomis, 
A., Giri, J., Copeland, N.G., Gilbert, D.J., Jenkins, N.A., et al. (1995). 
Functional characterization of the human interleukin-15 receptor alpha chain 
and close linkage of IL15RA and IL2RA genes. J Biol Chem 270, 29862-
29869. 
Anderson, K.N., Schwab, R.B., and Martinez, M.E. (2014). Reproductive risk 
factors and breast cancer subtypes: a review of the literature. Breast Cancer 
Res Treat 144, 1-10. 
Austreid, E., Lonning, P.E., and Eikesdal, H.P. (2014). The emergence of 
targeted drugs in breast cancer to prevent resistance to endocrine treatment 
and chemotherapy. Expert Opin Pharmacother 15, 681-700. 
Balmanno, K., and Cook, S.J. (1999). Sustained MAP kinase activation is 
required for the expression of cyclin D1, p21Cip1 and a subset of AP-1 
proteins in CCL39 cells. Oncogene 18, 3085-3097. 
Bardia, A., and Baselga, J. (2014). Preoperative chemotherapy for operable 
breast cancer. In Diseases of the breast, J.R. Harris, M.E. Lipman, M. Morrow, 
and C.K. Osborne, eds. (Philadelphia: Wolters Kluwer/Lippincott Williams & 
Wilkins Health), pp. 743-753. 
Becker, T.M., Boyd, S.C., Mijatov, B., Gowrishankar, K., Snoyman, S., Pupo, 
G.M., Scolyer, R.A., Mann, G.J., Kefford, R.F., Zhang, X.D., et al. (2014). 
Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription 
factor. Oncogene 33, 1158-1166. 
187 
 
Bellacosa, A., Kumar, C.C., Di Cristofano, A., and Testa, J.R. (2005). 
Activation of AKT kinases in cancer: implications for therapeutic targeting. 
Adv Cancer Res 94, 29-86. 
Benson, J.R. (2013). The biological basis for breast cancer screening and its 
relevance to treatment. In Early breast cancer from screening to 
multidisciplinary management, J.R. Benson, G. Gui, and T.M. Tuttle, eds. 
(Boca Raton: CRC Press Taylor & Francis Group), pp. 50-66. 
Berg, W.A., Madsen, K.S., Schilling, K., Tartar, M., Pisano, E.D., Larsen, 
L.H., Narayanan, D., Ozonoff, A., Miller, J.P., and Kalinyak, J.E. (2011). 
Breast cancer: comparative effectiveness of positron emission mammography 
and MR imaging in presurgical planning for the ipsilateral breast. Radiology 
258, 59-72. 
Bhattacharya, S., Ray, R.M., and Johnson, L.R. (2005). STAT3-mediated 
transcription of Bcl-2, Mcl-1 and c-IAP2 prevents apoptosis in polyamine-
depleted cells. Biochem J 392, 335-344. 
Bleicher, R.J. (2014). Management of the palpable breast mass. In Diseases of 
the breast, J.R. Harris, M.E. Lipman, M. Morrow, and C.K. Osborne, eds. 
(Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins Health), pp. 
29-37. 
Bombonati, A., and Sgroi, D.C. (2011). The molecular pathology of breast 
cancer progression. J Pathol 223, 307-317. 
Bosetti, C., Bertuccio, P., Levi, F., Chatenoud, L., Negri, E., and La Vecchia, 
C. (2012). The decline in breast cancer mortality in Europe: an update (to 
2009). Breast 21, 77-82. 
Brokstad, K.A., Kalland, K.H., Russell, W.C., and Matthews, D.A. (2001). 
Mitochondrial protein p32 can accumulate in the nucleus. Biochem Biophys 
Res Commun 281, 1161-1169. 
Brown, K.K., and Toker, A. (2015). The phosphoinositide 3-kinase pathway 
and therapy resistance in cancer. F1000Prime Rep 7, 13. 
Buchert, M., Burns, C.J., and Ernst, M. (2015). Targeting JAK kinase in solid 
tumors: emerging opportunities and challenges. Oncogene In Press. 
Burotto, M., Chiou, V.L., Lee, J.M., and Kohn, E.C. (2014). The MAPK 
pathway across different malignancies: a new perspective. Cancer 120, 3446-
3456. 
Cailleau, R., Young, R., Olive, M., and Reeves, W.J., Jr. (1974). Breast tumor 
cell lines from pleural effusions. J Natl Cancer Inst 53, 661-674. 
Cancer, C.G.o.H.F.i.B. (2012). Menarche, menopause, and breast cancer risk: 
individual participant meta-analysis, including 118 964 women with breast 
cancer from 117 epidemiological studies. Lancet Oncol 13, 1141-1151. 
Carey, L.A., Cheang, M.C.U., and Perou, C.M. (2014). Genomics, prognosis 
and therapeutic interventions. In Diseases of the breast, J.R. Harris, M.E. 
188 
 
Lipman, M. Morrow, and C.K. Osborne, eds. (Philadelphia: Wolters 
Kluwer/Lippincott Williams & Wilkins Health), pp. 452-472. 
Casimiro, M.C., Velasco-Velazquez, M., Aguirre-Alvarado, C., and Pestell, 
R.G. (2014). Overview of cyclins D1 function in cancer and the CDK inhibitor 
landscape: past and present. Expert Opin Investig Drugs 23, 295-304. 
Catlett-Falcone, R., Landowski, T.H., Oshiro, M.M., Turkson, J., Levitzki, A., 
Savino, R., Ciliberto, G., Moscinski, L., Fernandez-Luna, J.L., Nunez, G., et 
al. (1999). Constitutive activation of Stat3 signaling confers resistance to 
apoptosis in human U266 myeloma cells. Immunity 10, 105-115. 
Chakraborti, S., Mandal, M., Das, S., Mandal, A., and Chakraborti, T. (2003). 
Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem 253, 
269-285. 
Chambard, J.C., Lefloch, R., Pouyssegur, J., and Lenormand, P. (2007). ERK 
implication in cell cycle regulation. Biochim Biophys Acta 1773, 1299-1310. 
Chattopadhyay, C., Hawke, D., Kobayashi, R., and Maity, S.N. (2004). 
Human p32, interacts with B subunit of the CCAAT-binding factor, CBF/NF-
Y, and inhibits CBF-mediated transcription activation in vitro. Nucleic Acids 
Res 32, 3632-3641. 
Chen, H., Zhu, G., Li, Y., Padia, R.N., Dong, Z., Pan, Z.K., Liu, K., and 
Huang, S. (2009a). Extracellular signal-regulated kinase signaling pathway 
regulates breast cancer cell migration by maintaining slug expression. Cancer 
Res 69, 9228-9235. 
Chen, Y.B., Jiang, C.T., Zhang, G.Q., Wang, J.S., and Pang, D. (2009b). 
Increased expression of hyaluronic acid binding protein 1 is correlated with 
poor prognosis in patients with breast cancer. J Surg Oncol 100, 382-386. 
Chen, Z., Gibson, T.B., Robinson, F., Silvestro, L., Pearson, G., Xu, B., 
Wright, A., Vanderbilt, C., and Cobb, M.H. (2001). MAP kinases. Chem Rev 
101, 2449-2476. 
Cheng, M., Sexl, V., Sherr, C.J., and Roussel, M.F. (1998). Assembly of 
cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-
activated protein kinase kinase (MEK1). Proc Natl Acad Sci U S A 95, 1091-
1096. 
Cheung, M., and Testa, J.R. (2013). Diverse mechanisms of AKT pathway 
activation in human malignancy. Curr Cancer Drug Targets 13, 234-244. 
Chiarelli, A.M., Majpruz, V., Brown, P., Theriault, M., Shumak, R., and Mai, 
V. (2009). The contribution of clinical breast examination to the accuracy of 
breast screening. J Natl Cancer Inst 101, 1236-1243. 
Chowdhury, A.R., Ghosh, I., and Datta, K. (2008). Excessive reactive oxygen 
species induces apoptosis in fibroblasts: role of mitochondrially accumulated 




Clarke, M., Collins, R., Darby, S., Davies, C., Elphinstone, P., Evans, V., 
Godwin, J., Gray, R., Hicks, C., James, S., et al. (2005). Effects of 
radiotherapy and of differences in the extent of surgery for early breast cancer 
on local recurrence and 15-year survival: an overview of the randomised trials. 
Lancet 366, 2087-2106. 
Claus, E.B., Risch, N., and Thompson, W.D. (1994). Autosomal dominant 
inheritance of early-onset breast cancer. Implications for risk prediction. 
Cancer 73, 643-651. 
Colditz, G.A., Bohlke, K., and Berkey, C.S. (2014). Breast cancer risk 
accumulation starts early: prevention must also. Breast Cancer Res Treat 145, 
567-579. 
Cook, S.J., Aziz, N., and McMahon, M. (1999). The repertoire of fos and jun 
proteins expressed during the G1 phase of the cell cycle is determined by the 
duration of mitogen-activated protein kinase activation. Mol Cell Biol 19, 330-
341. 
Corn, P.G., and El-Deiry, W.S. (2002). Derangement of growth and 
differentiation control in oncogenesis. Bioessays 24, 83-90. 
Cox, J., and Mann, M. (2008). MaxQuant enables high peptide identification 
rates, individualized p.p.b.-range mass accuracies and proteome-wide protein 
quantification. Nat Biotechnol 26, 1367-1372. 
Daksis, J.I., Lu, R.Y., Facchini, L.M., Marhin, W.W., and Penn, L.J. (1994). 
Myc induces cyclin D1 expression in the absence of de novo protein synthesis 
and links mitogen-stimulated signal transduction to the cell cycle. Oncogene 9, 
3635-3645. 
Dang, C., and Hudis, C.A. (2014). Adjuvant systemic chemotherapy in early 
breast cancer. In Diseases of the breast, J.R. Harris, M.E. Lipman, M. Morrow, 
and C.K. Osborne, eds. (Philadelphia: Wolters Kluwer/Lippincott Williams & 
Wilkins Health), pp. 635-648. 
Dang, C.V. (2010). p32 (C1QBP) and cancer cell metabolism: is the Warburg 
effect a lot of hot air? Mol Cell Biol 30, 1300-1302. 
de Souza-Pinto, N.C., Mason, P.A., Hashiguchi, K., Weissman, L., Tian, J., 
Guay, D., Lebel, M., Stevnsner, T.V., Rasmussen, L.J., and Bohr, V.A. 
(2009). Novel DNA mismatch-repair activity involving YB-1 in human 
mitochondria. DNA Repair (Amst) 8, 704-719. 
Debidda, M., Wang, L., Zang, H., Poli, V., and Zheng, Y. (2005). A role of 
STAT3 in Rho GTPase-regulated cell migration and proliferation. J Biol 
Chem 280, 17275-17285. 
Dedio, J., Jahnen-Dechent, W., Bachmann, M., and Muller-Esterl, W. (1998). 
The multiligand-binding protein gC1qR, putative C1q receptor, is a 
mitochondrial protein. J Immunol 160, 3534-3542. 
190 
 
Dembitzer, F.R., Kinoshita, Y., Burstein, D., Phelps, R.G., Beasley, M.B., 
Garcia, R., Harpaz, N., Jaffer, S., Thung, S.N., Unger, P.D., et al. (2012). 
gC1qR expression in normal and pathologic human tissues: differential 
expression in tissues of epithelial and mesenchymal origin. J Histochem 
Cytochem 60, 467-474. 
Dhillon, A.S., Hagan, S., Rath, O., and Kolch, W. (2007). MAP kinase 
signalling pathways in cancer. Oncogene 26, 3279-3290. 
Dower, N.A., Stang, S.L., Bottorff, D.A., Ebinu, J.O., Dickie, P., Ostergaard, 
H.L., and Stone, J.C. (2000). RasGRP is essential for mouse thymocyte 
differentiation and TCR signaling. Nat Immunol 1, 317-321. 
Dufner, A., and Thomas, G. (1999). Ribosomal S6 kinase signaling and the 
control of translation. Exp Cell Res 253, 100-109. 
Dumalaon-Canaria, J.A., Hutchinson, A.D., Prichard, I., and Wilson, C. 
(2014). What causes breast cancer? A systematic review of causal attributions 
among breast cancer survivors and how these compare to expert-endorsed risk 
factors. Cancer Causes Control 25, 771-785. 
Eisner, A., and Luoh, S.W. (2011). Breast cancer medications and vision: 
effects of treatments for early-stage disease. Curr Eye Res 36, 867-885. 
Eliseeva, I.A., Kim, E.R., Guryanov, S.G., Ovchinnikov, L.P., and Lyabin, 
D.N. (2011). Y-box-binding protein 1 (YB-1) and its functions. Biochemistry 
(Mosc) 76, 1402-1433. 
Emmott, E., and Goodfellow, I. (2014). Identification of protein interaction 
partners in mammalian cells using SILAC-immunoprecipitation quantitative 
proteomics. J Vis Exp 89, 51656. 
Engel, L.W., Young, N.A., Tralka, T.S., Lippman, M.E., O'Brien, S.J., and 
Joyce, M.J. (1978). Establishment and characterization of three new 
continuous cell lines derived from human breast carcinomas. Cancer Res 38, 
3352-3364. 
Evans, D.G. (2013). Genetic predisposition and breast screening. In Early 
breast cancer, J.R. Benson, G. Gui, and T.M. Tuttle, eds. (Boca Raton: CRC 
Press Taylor and Francis Group), pp. 17-27. 
Evans, D.G., Shenton, A., Woodward, E., Lalloo, F., Howell, A., and Maher, 
E.R. (2008). Penetrance estimates for BRCA1 and BRCA2 based on genetic 
testing in a Clinical Cancer Genetics service setting: risks of breast/ovarian 
cancer quoted should reflect the cancer burden in the family. BMC Cancer 8, 
155. 
Ferlay, J., Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, 
Parkin DM, Forman D, Bray, F (2013). GLOBOCAN 2012 v1.0, Cancer 
Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet] 
(Lyon, France: International Agency for Research on Cancer). 
191 
 
Fogal, V., Richardson, A.D., Karmali, P.P., Scheffler, I.E., Smith, J.W., and 
Ruoslahti, E. (2010). Mitochondrial p32 protein is a critical regulator of tumor 
metabolism via maintenance of oxidative phosphorylation. Mol Cell Biol 30, 
1303-1318. 
Ghebrehiwet, B., Lim, B.L., Peerschke, E.I., Willis, A.C., and Reid, K.B. 
(1994). Isolation, cDNA cloning, and overexpression of a 33-kD cell surface 
glycoprotein that binds to the globular "heads" of C1q. J Exp Med 179, 1809-
1821. 
Ghebrehiwet, B., and Peerschke, E.I. (1998). Structure and function of gC1q-
R: a multiligand binding cellular protein. Immunobiology 199, 225-238. 
Giacinti, C., and Giordano, A. (2006). RB and cell cycle progression. 
Oncogene 25, 5220-5227. 
Goldhirsch, A., Ingle, J.N., Gelber, R.D., Coates, A.S., Thurlimann, B., and 
Senn, H.J. (2009). Thresholds for therapies: highlights of the St Gallen 
International Expert Consensus on the primary therapy of early breast cancer 
2009. Ann Oncol 20, 1319-1329. 
Graves, L.M., Guy, H.I., Kozlowski, P., Huang, M., Lazarowski, E., Pope, 
R.M., Collins, M.A., Dahlstrand, E.N., Earp, H.S., and Evans, D.R. (2000). 
Regulation of carbamoyl phosphate synthetase by MAP kinase. Nature 403, 
328-332. 
Gunaratne, J., Goh, M.X., Swa, H.L., Lee, F.Y., Sanford, E., Wong, L.M., 
Hogue, K.A., Blackstock, W.P., and Okumura, K. (2011). Protein interactions 
of phosphatase and tensin homologue (PTEN) and its cancer-associated G20E 
mutant compared by using stable isotope labeling by amino acids in cell 
culture-based parallel affinity purification. J Biol Chem 286, 18093-18103. 
Habibi, G., Leung, S., Law, J.H., Gelmon, K., Masoudi, H., Turbin, D., 
Pollak, M., Nielsen, T.O., Huntsman, D., and Dunn, S.E. (2008). Redefining 
prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse 
and disease-specific survival than estrogen receptor or HER-2 across all tumor 
subtypes. Breast Cancer Res 10, R86. 
Hanahan, D., and Weinberg, R.A. (2011). Hallmarks of cancer: the next 
generation. Cell 144, 646-674. 
Harris, J.R. (2014). Staging of breast cancer. In Diseases of the breast, J.R. 
Harris, M.E. Lipman, M. Morrow, and C.K. Osborne, eds. (Philadelphia: 
Wolters Kluwer/Lippincott Williams & Wilkins Health), pp. 495-503. 
Harris, J.R., and Morrow, M. (2014). Breast-conserving Therapy. In Diseases 
of the breast, J.R. Harris, M.E. Lipman, M. Morrow, and C.K. Osborne, eds. 
(Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins Health), pp. 
514-535. 
Haura, E.B., Turkson, J., and Jove, R. (2005). Mechanisms of Disease: 
insights into the emerging role of signal transducers and activators of 
transcription in cancer. Nat Clin Prac Oncol 2, 315-324. 
192 
 
Heichman, K.A., and Roberts, J.M. (1994). Rules to replicate by. Cell 79, 557-
562. 
Herrmann, A., Kortylewski, M., Kujawski, M., Zhang, C., Reckamp, K., 
Armstrong, B., Wang, L., Kowolik, C., Deng, J., Figlin, R., et al. (2010). 
Targeting Stat3 in the myeloid compartment drastically improves the in vivo 
antitumor functions of adoptively transferred T cells. Cancer Res 70, 7455-
7464. 
Huang, C., Jacobson, K., and Schaller, M.D. (2004a). MAP kinases and cell 
migration. J Cell Sci 117, 4619-4628. 
Huang, X., Ushijima, K., Komai, K., Takemoto, Y., Motoshima, S., Kamura, 
T., and Kohno, K. (2004b). Co-expression of Y box-binding protein-1 and P-
glycoprotein as a prognostic marker for survival in epithelial ovarian cancer. 
Gynecol Oncol 93, 287-291. 
Itahana, K., and Zhang, Y. (2008). Mitochondrial p32 is a critical mediator of 
ARF-induced apoptosis. Cancer Cell 13, 542-553. 
Janz, M., Harbeck, N., Dettmar, P., Berger, U., Schmidt, A., Jurchott, K., 
Schmitt, M., and Royer, H.D. (2002). Y-box factor YB-1 predicts drug 
resistance and patient outcome in breast cancer independent of clinically 
relevant tumor biologic factors HER2, uPA and PAI-1. Int J Cancer 97, 278-
282. 
Jiang, J., Zhang, Y., Krainer, A.R., and Xu, R.M. (1999). Crystal structure of 
human p32, a doughnut-shaped acidic mitochondrial matrix protein. Proc Natl 
Acad Sci U S A 96, 3572-3577. 
Jochelson, M.S. (2014). New breast imaging techniques. In Diseases of the 
breast, J.R. Harris, M.E. Lipman, M. Morrow, and C.K. Osborne, eds. 
(Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins Health), pp. 
149-160. 
Kamproh, S., and Fungpong, S. (2008). Effects of breast self-examination 
(BSE) program for detection early stage of breast cancer. J Med Assoc Thai 91 
Suppl 3, S147-151. 
Kamran, M.Z., Patil, P., and Gude, R.P. (2013). Role of STAT3 in cancer 
metastasis and translational advances. Biomed Res Int 2013, 421821. 
Kao, J., Salari, K., Bocanegra, M., Choi, Y.L., Girard, L., Gandhi, J., Kwei, 
K.A., Hernandez-Boussard, T., Wang, P., Gazdar, A.F., et al. (2009). 
Molecular profiling of breast cancer cell lines defines relevant tumor models 
and provides a resource for cancer gene discovery. PLoS One 4, e6146. 
Katz, M., Amit, I., and Yarden, Y. (2007). Regulation of MAPKs by growth 
factors and receptor tyrosine kinases. Biochim Biophys Acta 1773, 1161-1176. 
Kaul, R., Saha, P., Saradhi, M., Prasad, R.L., Chatterjee, S., Ghosh, I., Tyagi, 
R.K., and Datta, K. (2012). Overexpression of hyaluronan-binding protein 1 
(HABP1/p32/gC1qR) in HepG2 cells leads to increased hyaluronan synthesis 
193 
 
and cell proliferation by up-regulation of cyclin D1 in AKT-dependent 
pathway. J Biol Chem 287, 19750-19764. 
Kawada, M., Yamagoe, S., Murakami, Y., Suzuki, K., Mizuno, S., and 
Uehara, Y. (1997). Induction of p27Kip1 degradation and anchorage 
independence by Ras through the MAP kinase signaling pathway. Oncogene 
15, 629-637. 
Keydar, I., Chen, L., Karby, S., Weiss, F.R., Delarea, J., Radu, M., Chaitcik, 
S., and Brenner, H.J. (1979). Establishment and characterization of a cell line 
of human breast carcinoma origin. Eur J Cancer 15, 659-670. 
Khan, A., and Haffty, B.G. (2014). Postmastectomy radiation therapy. In 
Diseases of the breast, J.R. Harris, M.E. Lipman, M. Morrow, and C.K. 
Osborne, eds. (Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins 
Health), pp. 604-617. 
Kim, E.K., and Choi, E.J. (2010). Pathological roles of MAPK signaling 
pathways in human diseases. Biochim Biophys Acta 1802, 396-405. 
Kim, E.K., and Choi, E.J. (2015). Compromised MAPK signaling in human 
diseases: an update. Arch Toxicol 89, 867-882. 
Kim, K.B., Yi, J.S., Nguyen, N., Lee, J.H., Kwon, Y.C., Ahn, B.Y., Cho, H., 
Kim, Y.K., Yoo, H.J., Lee, J.S., et al. (2011). Cell-surface receptor for 
complement component C1q (gC1qR) is a key regulator for lamellipodia 
formation and cancer metastasis. J Biol Chem 286, 23093-23101. 
Kiuchi, N., Nakajima, K., Ichiba, M., Fukada, T., Narimatsu, M., Mizuno, K., 
Hibi, M., and Hirano, T. (1999). STAT3 is required for the gp130-mediated 
full activation of the c-myc gene. J Exp Med 189, 63-73. 
Kortylewski, M., Xin, H., Kujawski, M., Lee, H., Liu, Y., Harris, T., Drake, 
C., Pardoll, D., and Yu, H. (2009). Regulation of the IL-23 and IL-12 balance 
by Stat3 signaling in the tumor microenvironment. Cancer Cell 15, 114-123. 
Kortylewski, M., and Yu, H. (2008). Role of Stat3 in suppressing anti-tumor 
immunity. Curr Opin Immunol 20, 228-233. 
Koskela, H.L., Eldfors, S., Ellonen, P., van Adrichem, A.J., Kuusanmaki, H., 
Andersson, E.I., Lagstrom, S., Clemente, M.J., Olson, T., Jalkanen, S.E., et al. 
(2012). Somatic STAT3 mutations in large granular lymphocytic leukemia. N 
Engl J Med 366, 1905-1913. 
Kosnopfel, C., Sinnberg, T., and Schittek, B. (2014). Y-box binding protein 1-
a prognostic marker and target in tumour therapy. Eur J Cell Biol 93, 61-70. 
Ksionda, O., Limnander, A., and Roose, J.P. (2013). RasGRP Ras guanine 
nucleotide exchange factors in cancer. Front Biol (Beijing) 8, 508-532. 
Kyriakis, J.M., and Avruch, J. (2001). Mammalian mitogen-activated protein 
kinase signal transduction pathways activated by stress and inflammation. 
Physiol Rev 81, 807-869. 
194 
 
Langowski, J.L., Zhang, X., Wu, L., Mattson, J.D., Chen, T., Smith, K., 
Basham, B., McClanahan, T., Kastelein, R.A., and Oft, M. (2006). IL-23 
promotes tumour incidence and growth. Nature 442, 461-465. 
Lauchle, J.O., Kim, D., Le, D.T., Akagi, K., Crone, M., Krisman, K., Warner, 
K., Bonifas, J.M., Li, Q., Coakley, K.M., et al. (2009). Response and 
resistance to MEK inhibition in leukaemias initiated by hyperactive Ras. 
Nature 461, 411-414. 
Lavoie, J.N., L'Allemain, G., Brunet, A., Muller, R., and Pouyssegur, J. 
(1996). Cyclin D1 expression is regulated positively by the p42/p44MAPK 
and negatively by the p38/HOGMAPK pathway. J Biol Chem 271, 20608-
20616. 
Lee, C.I., and Elmore, J.G. (2014). Breast cancer screening. In Diseases of the 
breast, J.R. Harris, M.E. Lipman, M. Morrow, and C.K. Osborne, eds. 
(Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins Health), pp. 
90-105. 
Lewin, J.M. (2011). Radiologic techniques for early detection and diagnosis. 
In Early diagnosis and treatment of cancer series: breast cancer, L.J.A. 
Finlayson, ed. (Saint Louis: W.B. Saunders), pp. 125-139. 
Li, H., Huang, C., Huang, K., Wu, W., Jiang, T., Cao, J., Feng, Z., and Qiu, Z. 
(2011). STAT3 knockdown reduces pancreatic cancer cell invasiveness and 
matrix metalloproteinase-7 expression in nude mice. PLoS One 6, e25941. 
Li, T., Guo, H., Song, Y., Zhao, X., Shi, Y., Lu, Y., Hu, S., Nie, Y., Fan, D., 
and Wu, K. (2014). Loss of vinculin and membrane-bound beta-catenin 
promotes metastasis and predicts poor prognosis in colorectal cancer. Mol 
Cancer 13, 263. 
Li, W.X. (2008). Canonical and non-canonical JAK-STAT signaling. Trends 
Cell Biol 18, 545-551. 
Lim, C.P., and Cao, X. (2006). Structure, function, and regulation of STAT 
proteins. Mol Biosyst 2, 536-550. 
Lin, J.X., Migone, T.S., Tseng, M., Friedmann, M., Weatherbee, J.A., Zhou, 
L., Yamauchi, A., Bloom, E.T., Mietz, J., John, S., et al. (1995). The role of 
shared receptor motifs and common stat proteins in the generation of cytokine 
pleiotropy and redundancy by IL-2, IL-4, IL-7, IL-13, and IL-15. Immunity 2, 
331-339. 
Liu, H., Tekle, C., Chen, Y.W., Kristian, A., Zhao, Y., Zhou, M., Liu, Z., 
Ding, Y., Wang, B., Maelandsmo, G.M., et al. (2011). B7-H3 silencing 
increases paclitaxel sensitivity by abrogating Jak2/Stat3 phosphorylation. Mol 
Cancer Ther 10, 960-971. 
Lumachi, F., Luisetto, G., Basso, S.M., Basso, U., Brunello, A., and Camozzi, 
V. (2011). Endocrine therapy of breast cancer. Curr Med Chem 18, 513-522. 
195 
 
Lutas, A., Wahlmark, C.J., Acharjee, S., and Kawasaki, F. (2012). Genetic 
analysis in Drosophila reveals a role for the mitochondrial protein p32 in 
synaptic transmission. G3 (Bethesda) 2, 59-69. 
Manning, B.D., and Cantley, L.C. (2007). AKT/PKB signaling: navigating 
downstream. Cell 129, 1261-1274. 
Marieb, E.N., Wilhelm, P.B., and Mallatt, J.B. (2014). Human anatomy, 7th 
edn (Edinburg Gate, Harlow, Essex: Pearson Education Limited). 
Marra, P., Mathew, S., Grigoriadis, A., Wu, Y., Kyle-Cezar, F., Watkins, J., 
Rashid, M., De Rinaldis, E., Hessey, S., Gazinska, P., et al. (2014). IL15RA 
drives antagonistic mechanisms of cancer development and immune control in 
lymphocyte-enriched triple-negative breast cancers. Cancer Res 74, 4908-
4921. 
Maruti, S.S., Willett, W.C., Feskanich, D., Rosner, B., and Colditz, G.A. 
(2008). A prospective study of age-specific physical activity and 
premenopausal breast cancer. J Natl Cancer Inst 100, 728-737. 
Mathew, J., and Cheung, K. (2013). Clinical assessment of symptomatic 
patients. In Early breast cancer from screening to multidisciplinary 
management, J.R. Benson, G. Gui, and T.M. Tuttle, eds. (Boca Raton: CRC 
Press Taylor & Francis Group), pp. 119-128. 
Matos, P., Horn, J.A., Beards, F., Lui, S., Desforges, M., and Harris, L.K. 
(2014). A role for the mitochondrial-associated protein p32 in regulation of 
trophoblast proliferation. Mol Hum Reprod 20, 745-755. 
Matsumoto, K., Tanaka, K.J., and Tsujimoto, M. (2005). An acidic protein, 
YBAP1, mediates the release of YB-1 from mRNA and relieves the 
translational repression activity of YB-1. Mol Cell Biol 25, 1779-1792. 
Matsumoto, S., Uchiumi, T., Saito, T., Yagi, M., Takazaki, S., Kanki, T., and 
Kang, D. (2012). Localization of mRNAs encoding human mitochondrial 
oxidative phosphorylation proteins. Mitochondrion 12, 391-398. 
Maughan, K.L., Lutterbie, M.A., and Ham, P.S. (2010). Treatment of breast 
cancer. Am Fam Physician 81, 1339-1346. 
Maurer, U., Charvet, C., Wagman, A.S., Dejardin, E., and Green, D.R. (2006). 
Glycogen synthase kinase-3 regulates mitochondrial outer membrane 
permeabilization and apoptosis by destabilization of MCL-1. Mol Cell 21, 
749-760. 
McCubrey, J.A., Steelman, L.S., Bertrand, F.E., Davis, N.M., Sokolosky, M., 
Abrams, S.L., Montalto, G., D'Assoro, A.B., Libra, M., Nicoletti, F., et al. 
(2014). GSK-3 as potential target for therapeutic intervention in cancer. 
Oncotarget 5, 2881-2911. 
McGee, A.M., and Baines, C.P. (2011). Complement 1q-binding protein 
inhibits the mitochondrial permeability transition pore and protects against 
oxidative stress-induced death. Biochem J 433, 119-125. 
196 
 
McGee, A.M., Douglas, D.L., Liang, Y., Hyder, S.M., and Baines, C.P. 
(2011). The mitochondrial protein C1qbp promotes cell proliferation, 
migration and resistance to cell death. Cell Cycle 10, 4119-4127. 
Meenakshi, J., Anupama, Goswami, S.K., and Datta, K. (2003). Constitutive 
expression of hyaluronan binding protein 1 (HABP1/p32/gC1qR) in normal 
fibroblast cells perturbs its growth characteristics and induces apoptosis. 
Biochem Biophys Res Commun 300, 686-693. 
Meloche, S., and Pouyssegur, J. (2007). The ERK1/2 mitogen-activated 
protein kinase pathway as a master regulator of the G1- to S-phase transition. 
Oncogene 26, 3227-3239. 
Miyazaki, T., Liu, Z.J., Kawahara, A., Minami, Y., Yamada, K., Tsujimoto, 
Y., Barsoumian, E.L., Perlmutter, R.M., and Taniguchi, T. (1995). Three 
distinct IL-2 signaling pathways mediated by bcl-2, c-myc, and lck cooperate 
in hematopoietic cell proliferation. Cell 81, 223-231. 
Mohr, A., Chatain, N., Domoszlai, T., Rinis, N., Sommerauer, M., Vogt, M., 
and Muller-Newen, G. (2012). Dynamics and non-canonical aspects of 
JAK/STAT signalling. Eur J Cell Biol 91, 524-532. 
Morrow, M. (2014). Physical examination of the breast. In Diseases of the 
breast, J.R. Harris, M.E. Lipman, M. Morrow, and C.K. Osborne, eds. 
(Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins Health), pp. 
25-28. 
Morrow, M., and Golshan, M. (2014). Mastectomy. In Diseases of the breast, 
J.R. Harris, M.E. Lipman, M. Morrow, and C.K. Osborne, eds. (Philadelphia: 
Wolters Kluwer/Lippincott Williams & Wilkins Health), pp. 504-510. 
Munagala, R., Aqil, F., and Gupta, R.C. (2011). Promising molecular targeted 
therapies in breast cancer. Indian J Pharmacol 43, 236-245. 
Muta, T., Kang, D., Kitajima, S., Fujiwara, T., and Hamasaki, N. (1997). p32 
protein, a splicing factor 2-associated protein, is localized in mitochondrial 
matrix and is functionally important in maintaining oxidative phosphorylation. 
J Biol Chem 272, 24363-24370. 
NBOCC (2009). Breast cancer risk factors: A review of the evidence, 
N.B.O.C. Centre, ed. (Surry Hills, NSW). 
Nilsson, C., Koliadi, A., Johansson, I., Ahlin, C., Thorstenson, S., Bergkvist, 
L., Hedenfalk, I., and Fjallskog, M.L. (2013). High proliferation is associated 
with inferior outcome in male breast cancer patients. Mod Pathol 26, 87-94. 
NRDO (2015). Singapore Cancer Registry Interim Annual Report. Trends in 
cancer incidence in Singapore 2010-2014 (Singapore: Ministry of Health). 
Odle, T.G. (2014). Adverse effects of breast cancer treatment. Radiol Technol 
85, 297M-319M; quiz 320M-323M. 
Oppmann, B., Lesley, R., Blom, B., Timans, J.C., Xu, Y., Hunte, B., Vega, F., 
Yu, N., Wang, J., Singh, K., et al. (2000). Novel p19 protein engages IL-
197 
 
12p40 to form a cytokine, IL-23, with biological activities similar as well as 
distinct from IL-12. Immunity 13, 715-725. 
Pages, G., Lenormand, P., L'Allemain, G., Chambard, J.C., Meloche, S., and 
Pouyssegur, J. (1993). Mitogen-activated protein kinases p42mapk and 
p44mapk are required for fibroblast proliferation. Proc Natl Acad Sci U S A 
90, 8319-8323. 
Peerschke, E.I., and Ghebrehiwet, B. (2007). The contribution of gC1qR/p33 
in infection and inflammation. Immunobiology 212, 333-342. 
Peerschke, E.I., and Ghebrehiwet, B. (2014). cC1qR/CR and gC1qR/p33: 
observations in cancer. Mol Immunol 61, 100-109. 
Peerschke, E.I., Minta, J.O., Zhou, S.Z., Bini, A., Gotlieb, A., Colman, R.W., 
and Ghebrehiwet, B. (2004). Expression of gC1q-R/p33 and its major ligands 
in human atherosclerotic lesions. Mol Immunol 41, 759-766. 
Pestell, R.G. (2013). New roles of cyclin D1. Am J Pathol 183, 3-9. 
Petersen-Mahrt, S.K., Estmer, C., Ohrmalm, C., Matthews, D.A., Russell, 
W.C., and Akusjarvi, G. (1999). The splicing factor-associated protein, p32, 
regulates RNA splicing by inhibiting ASF/SF2 RNA binding and 
phosphorylation. EMBO J 18, 1014-1024. 
Pilati, C., Amessou, M., Bihl, M.P., Balabaud, C., Nhieu, J.T., Paradis, V., 
Nault, J.C., Izard, T., Bioulac-Sage, P., Couchy, G., et al. (2011). Somatic 
mutations activating STAT3 in human inflammatory hepatocellular adenomas. 
J Exp Med 208, 1359-1366. 
Plotnikov, A., Zehorai, E., Procaccia, S., and Seger, R. (2011). The MAPK 
cascades: signaling components, nuclear roles and mechanisms of nuclear 
translocation. Biochim Biophys Acta 1813, 1619-1633. 
Pointon, L.J., and Down, S.K. (2013). An introduction to screening for breast 
cancer. In Early breast cancer, J.R. Benson, G. Gui, and T.M. Tuttle, eds. 
(Boca Raton: CRC Press Taylor and Francis Group), pp. 1-12. 
Polivka, J., Jr., and Janku, F. (2014). Molecular targets for cancer therapy in 
the PI3K/AKT/mTOR pathway. Pharmacol Ther 142, 164-175. 
Pozarowski, P., and Darzynkiewicz, Z. (2004). Analysis of cell cycle by flow 
cytometry. Methods Mol Biol 281, 301-311. 
Prakash, M., Kale, S., Ghosh, I., Kundu, G.C., and Datta, K. (2011). 
Hyaluronan-binding protein 1 (HABP1/p32/gC1qR) induces melanoma cell 
migration and tumor growth by NF-kappa B dependent MMP-2 activation 
through integrin alpha(v)beta(3) interaction. Cell Signal 23, 1563-1577. 
Prier, E. (2011). Surgical biopsy. In Early diagnosis and treatment of cancer 




Rahaman, S.O., Harbor, P.C., Chernova, O., Barnett, G.H., Vogelbaum, M.A., 
and Haque, S.J. (2002). Inhibition of constitutively active Stat3 suppresses 
proliferation and induces apoptosis in glioblastoma multiforme cells. 
Oncogene 21, 8404-8413. 
Real, P.J., Sierra, A., De Juan, A., Segovia, J.C., Lopez-Vega, J.M., and 
Fernandez-Luna, J.L. (2002). Resistance to chemotherapy via Stat3-dependent 
overexpression of Bcl-2 in metastatic breast cancer cells. Oncogene 21, 7611-
7618. 
Rimawi, M.F., and Osborne, C.K. (2014). Adjuvant systemic therapy: 
endocrine therapy. In Diseases of the breast, J.R. Harris, M.E. Lipman, M. 
Morrow, and C.K. Osborne, eds. (Philadelphia: Wolters Kluwer/Lippincott 
Williams & Wilkins Health), pp. 618-634. 
Robinson, M.J., and Cobb, M.H. (1997). Mitogen-activated protein kinase 
pathways. Curr Opin Cell Biol 9, 180-186. 
Roskoski, R., Jr. (2012). ERK1/2 MAP kinases: structure, function, and 
regulation. Pharmacol Res 66, 105-143. 
Rossi, R.E., Pericleous, M., Mandair, D., Whyand, T., and Caplin, M.E. 
(2014). The role of dietary factors in prevention and progression of breast 
cancer. Anticancer Res 34, 6861-6875. 
Rozanov, D.V., Ghebrehiwet, B., Ratnikov, B., Monosov, E.Z., Deryugina, 
E.I., and Strongin, A.Y. (2002). The cytoplasmic tail peptide sequence of 
membrane type-1 matrix metalloproteinase (MT1-MMP) directly binds to 
gC1qR, a compartment-specific chaperone-like regulatory protein. FEBS Lett 
527, 51-57. 
Rubinstein, D.B., Stortchevoi, A., Boosalis, M., Ashfaq, R., Ghebrehiwet, B., 
Peerschke, E.I., Calvo, F., and Guillaume, T. (2004). Receptor for the globular 
heads of C1q (gC1q-R, p33, hyaluronan-binding protein) is preferentially 
expressed by adenocarcinoma cells. Int J Cancer 110, 741-750. 
Rue, P., and Martinez Arias, A. (2015). Cell dynamics and gene expression 
control in tissue homeostasis and development. Mol Syst Biol 11, 792. 
Samatar, A.A., and Poulikakos, P.I. (2014). Targeting RAS-ERK signalling in 
cancer: promises and challenges. Nat Rev Drug Discov 13, 928-942. 
Sansone, P., and Bromberg, J. (2012). Targeting the interleukin-6/Jak/Stat 
pathway in human malignancies. J Clin Oncol 30, 1005-1014. 
Sap, K.A., and Demmers, J.A.A. (2012). Labeling methods in mass 
spectrometry based quantitative proteomics. In Integrative Proteomics, H.-
C.E. Leung, ed. (Rijeka: InTech), pp. 111-132. 
Schaeffer, H.J., and Weber, M.J. (1999). Mitogen-activated protein kinases: 
specific messages from ubiquitous messengers. Mol Cell Biol 19, 2435-2444. 
199 
 
Schaerer, M.T., Kannenberg, K., Hunziker, P., Baumann, S.W., and Sigel, E. 
(2001). Interaction between GABA(A) receptor beta subunits and the 
multifunctional protein gC1q-R. J Biol Chem 276, 26597-26604. 
Schnitt, S.J. (2010). Classification and prognosis of invasive breast cancer: 
from morphology to molecular taxonomy. Mod Pathol 23, S60-S64. 
Sedgwick, E.L. (2014). Imaging analysis: ultrasonography. In Diseases of the 
breast, J.R. Harris, M.E. Lipman, M. Morrow, and C.K. Osborne, eds. 
(Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins Health), pp. 
123-132. 
Seger, R., and Krebs, E.G. (1995). The MAPK signaling cascade. FASEB J 9, 
726-735. 
Seger, R., Seger, D., Reszka, A.A., Munar, E.S., Eldar-Finkelman, H., 
Dobrowolska, G., Jensen, A.M., Campbell, J.S., Fischer, E.H., and Krebs, 
E.G. (1994). Overexpression of mitogen-activated protein kinase kinase 
(MAPKK) and its mutants in NIH 3T3 cells. Evidence that MAPKK 
involvement in cellular proliferation is regulated by phosphorylation of serine 
residues in its kinase subdomains VII and VIII. J Biol Chem 269, 25699-
25709. 
Sellier, H., Rebillard, A., Guette, C., Barre, B., and Coqueret, O. (2013). How 
should we define STAT3 as an oncogene and as a potential target for therapy? 
JAKSTAT 2, e24716. 
Seth, A., Alvarez, E., Gupta, S., and Davis, R.J. (1991). A phosphorylation 
site located in the NH2-terminal domain of c-Myc increases transactivation of 
gene expression. J Biol Chem 266, 23521-23524. 
Sever, R., and Brugge, J.S. (2015). Signal transduction in cancer. Cold Spring 
Harb Perspect Med 5, pii: a006098. 
Sherr, C.J. (1994). G1 phase progression: cycling on cue. Cell 79, 551-555. 
Sherr, C.J. (1996). Cancer cell cycles. Science 274, 1672-1677. 
Sherr, C.J., and Roberts, J.M. (1999). CDK inhibitors: positive and negative 
regulators of G1-phase progression. Genes Dev 13, 1501-1512. 
Shevchenko, A., Tomas, H., Havlis, J., Olsen, J.V., and Mann, M. (2006). In-
gel digestion for mass spectrometric characterization of proteins and 
proteomes. Nat Protoc 1, 2856-2860. 
Simos, G., and Georgatos, S.D. (1994). The lamin B receptor-associated 
protein p34 shares sequence homology and antigenic determinants with the 
splicing factor 2-associated protein p32. FEBS Lett 346, 225-228. 
Simpson, P.T., Reis-Filho, J.S., Gale, T., and Lakhani, S.R. (2005). Molecular 
evolution of breast cancer. J Pathol 205, 248-254. 
Sinibaldi, D., Wharton, W., Turkson, J., Bowman, T., Pledger, W.J., and Jove, 
R. (2000). Induction of p21WAF1/CIP1 and cyclin D1 expression by the Src 
200 
 
oncoprotein in mouse fibroblasts: role of activated STAT3 signaling. 
Oncogene 19, 5419-5427. 
Sinn, H.P., and Kreipe, H. (2013). A Brief Overview of the WHO 
Classification of Breast Tumors, 4th Edition, Focusing on Issues and Updates 
from the 3rd Edition. Breast Care (Basel) 8, 149-154. 
Soltys, B.J., Kang, D., and Gupta, R.S. (2000). Localization of P32 protein 
(gC1q-R) in mitochondria and at specific extramitochondrial locations in 
normal tissues. Histochem Cell Biol 114, 245-255. 
Sonnenblick, A., Fumagalli, D., Sotiriou, C., and Piccart, M. (2014). Is the 
differentiation into molecular subtypes of breast cancer important for staging, 
local and systemic therapy, and follow up? Cancer Treat Rev 40, 1089-1095. 
Soule, H.D., Vazguez, J., Long, A., Albert, S., and Brennan, M. (1973). A 
human cell line from a pleural effusion derived from a breast carcinoma. J 
Natl Cancer Inst 51, 1409-1416. 
Spitzner, M., Ebner, R., Wolff, H.A., Ghadimi, B.M., Wienands, J., and 
Grade, M. (2014). STAT3: a novel molecular mediator of resistance to 
chemoradiotherapy. Cancers (Basel) 6, 1986-2011. 
Stone, J.C. (2011). Regulation and function of the RasGRP family of Ras 
activators in blood cells. Genes Cancer 2, 320-334. 
Storz, P., Hausser, A., Link, G., Dedio, J., Ghebrehiwet, B., Pfizenmaier, K., 
and Johannes, F.J. (2000). Protein kinase C [micro] is regulated by the 
multifunctional chaperon protein p32. J Biol Chem 275, 24601-24607. 
Suman, P., Godbole, G., Thakur, R., Morales-Prieto, D.M., Modi, D.N., 
Markert, U.R., and Gupta, S.K. (2012). AP-1 transcription factors, mucin-type 
molecules and MMPs regulate the IL-11 mediated invasiveness of JEG-3 and 
HTR-8/SVneo trophoblastic cells. PLoS One 7, e29745. 
Sung, J.S., and Comstock, C.E. (2014). Image-guided biopsy of nonpalpable 
breast lesions. In Diseases of the breast, J.R. Harris, M.E. Lipman, M. 
Morrow, and C.K. Osborne, eds. (Philadelphia: Wolters Kluwer/Lippincott 
Williams & Wilkins Health), pp. 161-172. 
Tagaya, Y., Bamford, R.N., DeFilippis, A.P., and Waldmann, T.A. (1996). IL-
15: a pleiotropic cytokine with diverse receptor/signaling pathways whose 
expression is controlled at multiple levels. Immunity 4, 329-336. 
Tai, S.K., Tan, O.J., Chow, V.T., Jin, R., Jones, J.L., Tan, P.H., Jayasurya, A., 
and Bay, B.H. (2003). Differential expression of metallothionein 1 and 2 
isoforms in breast cancer lines with different invasive potential: identification 
of a novel nonsilent metallothionein-1H mutant variant. Am J Pathol 163, 
2009-2019. 
Takahashi-Yanaga, F. (2013). Activator or inhibitor? GSK-3 as a new drug 
target. Biochem Pharmacol 86, 191-199. 
201 
 
Teng, T.S., Lin, B., Manser, E., Ng, D.C., and Cao, X. (2009). Stat3 promotes 
directional cell migration by regulating Rac1 activity via its activator betaPIX. 
J Cell Sci 122, 4150-4159. 
Teng, Y., Ross, J.L., and Cowell, J.K. (2014). The involvement of JAK-
STAT3 in cell motility, invasion, and metastasis. JAKSTAT 3, e28086. 
Tindall, E.A., and Hayes, V.M. (2010). Comprehensive sequence analysis of 
the human IL23A gene defines new variation content and high rate of 
evolutionary conservation. DNA Res 17, 117-122. 
Toker, A., and Marmiroli, S. (2014). Signaling specificity in the Akt pathway 
in biology and disease. Adv Biol Regul 55, 28-38. 
Torre, L.A., Bray, F., Siegel, R.L., Ferlay, J., Lortet-Tieulent, J., and Jemal, A. 
(2015). Global cancer statistics, 2012. CA Cancer J Clin 65, 87-108. 
Trinkle-Mulcahy, L. (2012). Resolving protein interactions and complexes by 
affinity purification followed by label-based quantitative mass spectrometry. 
Proteomics 12, 1623-1638. 
Tye, A.J., Ghebrehiwet, B., Guo, N., Sastry, K.N., Chow, B.K., Peerschke, 
E.I., and Lim, B.L. (2001). The human gC1qR/p32 gene, C1qBP. Genomic 
organization and promoter analysis. J Biol Chem 276, 17069-17075. 
Vainchenker, W., and Constantinescu, S.N. (2013). JAK/STAT signaling in 
hematological malignancies. Oncogene 32, 2601-2613. 
Vallenius, T. (2013). Actin stress fibre subtypes in mesenchymal-migrating 
cells. Open Biol 3, 130001. 
Viala, E., and Pouyssegur, J. (2004). Regulation of tumor cell motility by ERK 
mitogen-activated protein kinases. Ann N Y Acad Sci 1030, 208-218. 
Viale, G. (2012). The current state of breast cancer classification. Ann Oncol 
23 Suppl 10, x207-210. 
Vougioukalaki, M., Kanellis, D.C., Gkouskou, K., and Eliopoulos, A.G. 
(2011). Tpl2 kinase signal transduction in inflammation and cancer. Cancer 
Lett 304, 80-89. 
Wang, Y., Yue, D., Xiao, M., Qi, C., Chen, Y., Sun, D., Zhang, N., and Chen, 
R. (2015). C1QBP negatively regulates the activation of oncoprotein YBX1 in 
the renal cell carcinoma as revealed by interactomics analysis. J Proteome Res 
14, 804-813. 
Weinstein, S.P., and Roth, S.O. (2014). Imaging analysis: magnetic resonance 
imaging. In Diseases of the breast, J.R. Harris, M.E. Lipman, M. Morrow, and 
C.K. Osborne, eds. (Philadelphia: Wolters Kluwer/Lippincott Williams & 
Wilkins Health), pp. 133-148. 
Wendt, M.K., Balanis, N., Carlin, C.R., and Schiemann, W.P. (2014). STAT3 
and epithelial-mesenchymal transitions in carcinomas. JAKSTAT 3, e28975. 
202 
 
Xie, T.X., Wei, D., Liu, M., Gao, A.C., Ali-Osman, F., Sawaya, R., and 
Huang, S. (2004). Stat3 activation regulates the expression of matrix 
metalloproteinase-2 and tumor invasion and metastasis. Oncogene 23, 3550-
3560. 
Yagi, M., Uchiumi, T., Takazaki, S., Okuno, B., Nomura, M., Yoshida, S., 
Kanki, T., and Kang, D. (2012). p32/gC1qR is indispensable for fetal 
development and mitochondrial translation: importance of its RNA-binding 
ability. Nucleic Acids Res 40, 9717-9737. 
Yalcin, B. (2013). Staging, risk assessment and screening of breast cancer. 
Exp Oncol 35, 238-245. 
Yano, T., Ferlito, M., Aponte, A., Kuno, A., Miura, T., Murphy, E., and 
Steenbergen, C. (2014). Pivotal role of mTORC2 and involvement of 
ribosomal protein S6 in cardioprotective signaling. Circ Res 114, 1268-1280. 
Yao, Z.Q., Eisen-Vandervelde, A., Ray, S., and Hahn, Y.S. (2003). HCV 
core/gC1qR interaction arrests T cell cycle progression through stabilization 
of the cell cycle inhibitor p27Kip1. Virology 314, 271-282. 
Yasen, M., Kajino, K., Kano, S., Tobita, H., Yamamoto, J., Uchiumi, T., Kon, 
S., Maeda, M., Obulhasim, G., Arii, S., et al. (2005). The up-regulation of Y-
box binding proteins (DNA binding protein A and Y-box binding protein-1) as 
prognostic markers of hepatocellular carcinoma. Clin Cancer Res 11, 7354-
7361. 
Yoshikawa, H., Komatsu, W., Hayano, T., Miura, Y., Homma, K., Izumikawa, 
K., Ishikawa, H., Miyazawa, N., Tachikawa, H., Yamauchi, Y., et al. (2011). 
Splicing factor 2-associated protein p32 participates in ribosome biogenesis by 
regulating the binding of Nop52 and fibrillarin to preribosome particles. Mol 
Cell Proteomics 10, M110 006148. 
Youlden, D.R., Cramb, S.M., Dunn, N.A., Muller, J.M., Pyke, C.M., and 
Baade, P.D. (2012). The descriptive epidemiology of female breast cancer: an 
international comparison of screening, incidence, survival and mortality. 
Cancer Epidemiol 36, 237-248. 
Yu, G., and Wang, J. (2013). Significance of hyaluronan binding protein 
(HABP1/P32/gC1qR) expression in advanced serous ovarian cancer patients. 
Exp Mol Pathol 94, 210-215. 
Yu, H., and Jove, R. (2004). The STATs of cancer-new molecular targets 
come of age. Nat Rev Cancer 4, 97-105. 
Yu, H., Lee, H., Herrmann, A., Buettner, R., and Jove, R. (2014). Revisiting 
STAT3 signalling in cancer: new and unexpected biological functions. Nat 
Rev Cancer 14, 736-746. 
Yu, H., Liu, Q., Xin, T., Xing, L., Dong, G., Jiang, Q., Lv, Y., Song, X., Teng, 
C., Huang, D., et al. (2013). Elevated expression of hyaluronic acid binding 
protein 1 (HABP1)/P32/C1QBP is a novel indicator for lymph node and 
203 
 
peritoneal metastasis of epithelial ovarian cancer patients. Tumour Biol 34, 
3981-3987. 
Yu, L., Loewenstein, P.M., Zhang, Z., and Green, M. (1995). In vitro 
interaction of the human immunodeficiency virus type 1 Tat transactivator and 
the general transcription factor TFIIB with the cellular protein TAP. J Virol 
69, 3017-3023. 
Yu, Y.N. (2010). Functional studies of Y-box binding protein 1 in breast 
cancer. Dissertation. (Singapore: Department of Anatomy, National University 
of Singapore). 
Zhang, X., Zhang, F., Guo, L., Wang, Y., Zhang, P., Wang, R., Zhang, N., and 
Chen, R. (2013). Interactome analysis reveals that C1QBP (complement 
component 1, q subcomponent binding protein) is associated with cancer cell 
chemotaxis and metastasis. Mol Cell Proteomics 12, 3199-3209. 
Zhang, Y., Zhao, P.W., Feng, G., Xie, G., Wang, A.Q., Yang, Y.H., Wang, D., 
and Du, X.B. (2015). The expression level and prognostic value of Y-box 
binding protein-1 in rectal cancer. PLoS One 10, e0119385. 
Zhao, J., Liu, T., Yu, G., and Wang, J. (2015). Overexpression of HABP1 
correlated with clinicopathological characteristics and unfavorable prognosis 
in endometrial cancer. Tumour Biol 36, 1299-1306. 
Ziauddin, M.F., Hua, D., and Tang, S.C. (2014). Emerging strategies to 
overcome resistance to endocrine therapy for breast cancer. Cancer Metastasis 
Rev 33, 791-807. 
Zushi, S., Shinomura, Y., Kiyohara, T., Miyazaki, Y., Kondo, S., Sugimachi, 
M., Higashimoto, Y., Kanayama, S., and Matsuzawa, Y. (1998). STAT3 
mediates the survival signal in oncogenic ras-transfected intestinal epithelial 





















Supplementary Table 1 
Transcript 
ID 
Gene Symbol Gene name RefSeq p-value 
(Attribute) 
p-value   
(siybap1 vs. nt) 
Ratio  
(siybap1 vs. nt) 
Fold-Change 
(siybap1 vs. nt) 
F(Attribute) SS(Attribute) SS(Error) F(Error) 
16761518 TAS2R31 Taste receptor, type 2, 
member 31 
NM_176885 0.0130177 0.0130177 2.43929 2.43929 18.1771 2.48248 0.546288 1 
16820947 HPR Haptoglobin-related protein NM_020995 0.0352038 0.0352038 2.26608 2.26608 9.79348 2.08931 0.853347 1 
16924149 TPTE Transmembrane phosphatase 
with tensin homology 
ENST00000415664 0.0136987 0.0136987 2.16776 2.16776 17.6378 1.86888 0.423834 1 
16801028 RNA5SP395 RNA, 5S ribosomal 
pseudogene 395 
ENST00000516567 0.0499184 0.0499184 2.14439 2.14439 7.71751 1.81688 0.941693 1 
16992195 MIR378E MicroRNA 378e NR_039609 0.0479144 0.0479144 2.13078 2.13078 7.94241 1.78666 0.899809 1 
17051439 RNU7-73P RNA, U7 small nuclear 73 
pseudogene 
ENST00000458743 0.0105224 0.0105224 2.06486 2.06486 20.5829 1.64131 0.318966 1 
17008025 RAB44 RAB44, member RAS 
oncogene family 
NM_001257357 0.00393404 0.00393404 2.05404 2.05404 35.742 1.61761 0.181032 1 
16721212 OR51F2 Olfactory receptor, family 
51, subfamily F, member 2 
ENST00000322110 0.0268037 0.0268037 1.95385 1.95385 11.6899 1.40067 0.479277 1 
16898567 GKN2 Gastrokine 2 NM_182536 0.0357134 0.0357134 1.93535 1.93535 9.70058 1.36115 0.561265 1 
17091932 CBWD1 COBW domain containing 1 NM_018491 0.00996034 0.00996034 1.89753 1.89753 21.2463 1.28101 0.241173 1 
16979330 FLJ14186 Uncharacterized LOC401149  NR_037596 0.00903048 0.00903048 1.89212 1.89212 22.4772 1.26961 0.225938 1 
16810972 SNORD18B Small nucleolar RNA, C/D 
box 18B  
NR_002442 0.0054852 0.0054852 1.88865 1.88865 29.7664 1.2623 0.169627 1 
17118419 CDC14B Cell division cycle 14B  ENST00000481149 0.00759399 0.00759399 1.86621 1.86621 24.8066 1.2153 0.195963 1 
17046586 SNORA22 Small nucleolar RNA, 
H/ACA box 22 
NR_002961 0.0327419 0.0327419 1.86355 1.86355 10.2726 1.20974 0.471057 1 
16774764 RNY3P2 RNA, Ro-associated Y3 
pseudogene 2 
ENST00000362918 0.00917447 0.00917447 1.8395 1.8395 22.2744 1.15979 0.208274 1 
16888454 FSIP2 Fibrous sheath interacting 
protein 2  
NM_173651 0.0274427 0.0274427 1.8231 1.8231 11.5154 1.12595 0.39111 1 
17093018 EQTN Equatorin, sperm acrosome 
associated 
NM_020641 0.00143389 0.00143389 1.81232 1.81232 61.367 1.10383 0.071949 1 
16761514 TAS2R19 Taste receptor, type 2, 
member 19  






16760825 CLEC4C C-type lectin domain family 
4, member C  
BC114338 0.0122955 0.0122955 1.7908 1.7908 18.7974 1.05992 0.225547 1 
17111801 IGBP1-AS1 IGBP1 antisense RNA 1  ENST00000366397 0.0423266 0.0423266 1.76075 1.76075 8.65231 0.99924 0.461953 1 
16665507 FOXD3 Forkhead box D3  NM_012183 0.00367629 0.00367629 1.75292 1.75292 37.087 0.98356 0.106081 1 
17115154 TREX2 Three prime repair 
exonuclease 2 
NM_080701 0.0422422 0.0422422 1.73375 1.73375 8.66412 0.945401 0.436467 1 
16942369 SNTN Sentan, cilia apical structure 
protein  
ENST00000343837 0.0333035 0.0333035 1.72339 1.72339 10.1586 0.92493 0.364197 1 
17117114 BCORP1 BCL6 corepressor 
pseudogene 1  
NR_033732 0.0163674 0.0163674 1.72119 1.72119 15.86 0.920585 0.232177 1 
16788669 SNORD114-17 Small nucleolar RNA, C/D 
box 114-17  
NR_003210 0.0290858 0.0290858 1.71756 1.71756 11.0938 0.91344 0.329352 1 
16830343 SLC2A4 Solute carrier family 2 
(facilitated glucose 
transporter), member 
NM_001042 0.00487364 0.00487364 1.71049 1.71049 31.7786 0.899565 0.113229 1 
17112362 MIR4328 MicroRNA 4328  NR_036258 0.0301389 0.0301389 1.70784 1.70784 10.8419 0.89438 0.329971 1 
16865060 MIR517A MicroRNA 517a NR_030201 0.00189589 0.00189589 1.702 1.702 52.9378 0.882966 0.066717 1 
16755223 KRT19P2 Keratin 19 pseudogene 2  NR_036685 0.0430275 0.0430275 1.66399 1.66399 8.5557 0.80955 0.378485 1 
17108740 P2RY8 Purinergic receptor P2Y, G-
protein coupled, 8 
ENST00000460672 0.0237277 0.0237277 1.66232 1.66232 12.6261 0.806379 0.255464 1 
17046422 ZNF735 Zinc finger protein 735  NM_001159524 0.010731 0.010731 1.65518 1.65518 20.3501 0.792771 0.155827 1 
16803618 MIR184 MicroRNA 184  NR_029705 0.0196718 0.0196718 1.65475 1.65475 14.183 0.791958 0.223354 1 
16878888 MIR558 MicroRNA 558 NR_030285 0.025101 0.025101 1.65445 1.65445 12.1868 0.791372 0.259747 1 
16814628 TPSD1 Tryptase delta 1  NM_012217 0.0319127 0.0319127 1.65202 1.65202 10.4463 0.786757 0.301258 1 
16941704 ITIH1 Inter-alpha-trypsin inhibitor 
heavy chain 1 
NM_001166434 0.0102624 0.0102624 1.65014 1.65014 20.883 0.7832 0.150017 1 
16812373 LOC100133746 Uncharacterized 
LOC100133746 
ENST00000548231 0.0197171 0.0197171 1.64507 1.64507 14.163 0.773611 0.218488 1 
16934881 SOX10 SRY (sex determining region 
Y)-box 10  
NM_006941 0.039498 0.039498 1.64284 1.64284 9.06821 0.769392 0.33938 1 
17005790 HIST2H4B Histone cluster 2, H4b ENST00000354348 0.0095927 0.0095927 1.64185 1.64185 21.7115 0.76753 0.141405 1 
16731054 MIR34B MicroRNA 34b NR_029839 0.0384154 0.0384154 1.63941 1.63941 9.23947 0.762938 0.330295 1 
16831527 CCDC144A Coiled-coil domain 
containing 144A 
ENST00000443444 0.0402288 0.0402288 1.63901 1.63901 8.95654 0.762174 0.340388 1 






16659794 CLCNKA Chloride channel, voltage-
sensitive Ka 
NM_004070 0.031585 0.031585 1.62784 1.62784 10.5169 0.741219 0.281916 1 
16705992 MIR4676 MicroRNA 4676 NR_039823 0.034681 0.034681 1.61913 1.61913 9.89091 0.725003 0.2932 1 
17107371 SRD5A1P1 Steroid-5-alpha-reductase, 
alpha polypeptide 1 
pseudogene 1 
NR_028597 0.0458398 0.0458398 1.6169 1.6169 8.19069 0.720845 0.352031 1 
16703659 MAP3K8 Mitogen-activated protein 
kinase kinase kinase 8 
AB209539 0.00793012 0.00793012 1.59747 1.59747 24.2051 0.68504 0.113206 1 
16747917 FAM66C Family with sequence 
similarity 66, member C 
NR_026788 0.0333728 0.0333728 1.59684 1.59684 10.1447 0.683887 0.269653 1 
17095020 NMRK1 Nicotinamide riboside kinase 
1 
NR_023352 0.0252456 0.0252456 1.58741 1.58741 12.1426 0.666679 0.219616 1 
16785083 HIF1A Hypoxia inducible factor 1, 
alpha subunit (basic helix-
loop 
ENST00000554177 0.0329583 0.0329583 1.58611 1.58611 10.2283 0.664318 0.259796 1 
16927749 IGLV1-44 Immunoglobulin lambda 
variable 1-44 
ENST00000390297 0.023334 0.023334 1.58288 1.58288 12.7592 0.658459 0.206427 1 
16909760 ASB18 Ankyrin repeat and SOCS 
box containing 18  
NM_212556 0.0360273 0.0360273 1.579 1.579 9.64435 0.651438 0.270184 1 
16852921 LOC284294 Uncharacterized LOC284294 NR_033881 0.00617287 0.00617287 1.57756 1.57756 27.8715 0.648843 0.093119 1 
16748275 CLEC9A C-type lectin domain family 
9, member A 
NM_207345 0.0166945 0.0166945 1.57568 1.57568 15.672 0.645455 0.164741 1 
16862815 ZNF575 Zinc finger protein 575 NM_174945 0.0448975 0.0448975 1.57563 1.57563 8.30913 0.645356 0.310673 1 
16969155 MIR3684 MicroRNA 3684 NR_037455 0.0330968 0.0330968 1.56999 1.56999 10.2002 0.635232 0.249106 1 
16873160 ZFP112 Zinc finger protein 112 
homolog  
NM_001083335 0.03461 0.03461 1.56926 1.56926 9.90432 0.633923 0.256018 1 
16678946 LOC100506810 Uncharacterized 
LOC100506810 
NR_038856 0.00234529 0.00234529 1.5632 1.5632 47.2635 0.623077 0.052732 1 
17014798 SMOC2 SPARC related modular 
calcium binding 2 
NM_022138 0.0471266 0.0471266 1.56271 1.56271 8.03474 0.622195 0.309753 1 
16811577 LOC283731 Uncharacterized LOC283731 NR_027073 0.0212716 0.0212716 1.56145 1.56145 13.5157 0.619947 0.183474 1 
16803469 DNAJA4 DnaJ (Hsp40) homolog, 
subfamily A, member 4  
NM_018602 0.0271638 0.0271638 1.56123 1.56123 11.5908 0.619556 0.213809 1 
16701634 OR14I1 Olfactory receptor, family 
14, subfamily I, member 1 






16954705 LINC00696 Long intergenic non-protein 
coding RNA 696 
NR_027331 0.0190837 0.0190837 1.55961 1.55961 14.4492 0.616686 0.170718 1 
16958638 KLF15 Kruppel-like factor 15 NM_014079 0.00203996 0.00203996 1.55624 1.55624 50.9155 0.610687 0.047977 1 
16697272 LOC100288079 Microtubule-associated 
protein 1 light chain 3 beta 
pseudo 
NR_038424 0.039607 0.039607 1.55339 1.55339 9.05136 0.605634 0.267644 1 
16673341 RNA5SP65 RNA, 5S ribosomal 
pseudogene 65 
ENST00000363166 0.042946 0.042946 1.54523 1.54523 8.56681 0.591249 0.276065 1 
16778677 LINC00330 Long intergenic non-protein 
coding RNA 330 
AK056732 0.0313837 0.0313837 1.54379 1.54379 10.5608 0.588709 0.22298 1 
16809123 USP50 Ubiquitin specific peptidase 
50  
NM_203494 0.0100706 0.0100706 1.54204 1.54204 21.1119 0.585633 0.110958 1 
16679799 OR2T4 Olfactory receptor, family 2, 
subfamily T, member 4 
NM_001004696 0.0318457 0.0318457 1.54202 1.54202 10.4606 0.585598 0.223924 1 
16799776 OIP5-AS1 OIP5 antisense RNA 1 ENST00000558945 0.0347324 0.0347324 1.53624 1.53624 9.88123 0.575486 0.232961 1 
16927742 IGLV7-46 Immunoglobulin lambda 
variable 7-46 
(gene/pseudogene)  
ENST00000390295 0.0340871 0.0340871 1.53516 1.53516 10.0043 0.573606 0.229344 1 
16788731 MIR1193 MicroRNA 1193 NR_036132 0.0164339 0.0164339 1.52923 1.52923 15.8214 0.563296 0.142414 1 
16804062 TM6SF1 Transmembrane 6 
superfamily member 1 
NM_023003 0.00223439 0.00223439 1.52746 1.52746 48.503 0.560234 0.046202 1 
16704027 ZNF37A Zinc finger protein 37A NM_001007094 0.0152454 0.0152454 1.52651 1.52651 16.5503 0.558585 0.135003 1 
16849597 C1QTNF1-AS1 C1QTNF1 antisense RNA 1 NR_040018 0.0433442 0.0433442 1.52573 1.52573 8.51281 0.557226 0.26183 1 
16667481 DPYD-AS1 DPYD antisense RNA 1 NR_046590 0.0116713 0.0116713 1.52374 1.52374 19.3792 0.553798 0.114307 1 
16725084 OR5A1 Olfactory receptor, family 5, 
subfamily A, member 1  
ENST00000302030 0.00858497 0.00858497 1.52101 1.52101 23.1366 0.549097 0.094931 1 
16926043 TFF1 Trefoil factor 1 ENST00000291527 0.0368823 0.0368823 1.51829 1.51829 9.49486 0.544416 0.229352 1 
16865498 KIR3DL1 Killer cell immunoglobulin-
like receptor, three domains, 
long c 
NM_013289 0.040739 0.040739 1.51015 1.51015 8.88038 0.530494 0.238951 1 
16858756 GCDH Glutaryl-CoA dehydrogenase NM_000159 0.0393276 0.0393276 0.666147 -1.50117 9.09469 0.51525 0.226616 1 
16826619 LOC100132339 Uncharacterized 
LOC100132339 
ENST00000559802 0.0432994 0.0432994 0.665876 -1.50178 8.51885 0.516279 0.242417 1 
16657895 MMP23B Matrix metallopeptidase 23B NM_006983 0.00553606 0.00553606 0.665351 -1.50297 29.6143 0.518284 0.070005 1 






17069141 LOC286177 Uncharacterized LOC286177 NR_038874 0.0109349 0.0109349 0.662864 -1.5086 20.1289 0.527856 0.104895 1 
16848692 HID1 HID1 domain containing NM_030630 0.0300424 0.0300424 0.661961 -1.51066 10.8644 0.531363 0.195634 1 
17042805 GET4 Golgi to ER traffic protein 4 
homolog (S. cerevisiae) 
NM_015949 0.0420725 0.0420725 0.659264 -1.51684 8.68794 0.541931 0.24951 1 
16686376 ZSWIM5 Zinc finger, SWIM-type 
containing 5 
NM_020883 0.00694559 0.00694559 0.657235 -1.52153 26.0879 0.54998 0.084327 1 
17008529 TOMM6 Translocase of outer 
mitochondrial membrane 6 
homolog (yeast) 
AJ420506 0.0161474 0.0161474 0.656565 -1.52308 15.9897 0.552657 0.138253 1 
16942389 THOC7-AS1 THOC7 antisense RNA 1  ENST00000468961 0.0496952 0.0496952 0.65602 -1.52434 7.74189 0.554838 0.286668 1 
16659881 NECAP2 NECAP endocytosis 
associated 2 
NM_018090 0.0152683 0.0152683 0.6554 -1.52579 16.5354 0.557332 0.134821 1 
16703758 RNU7-22P RNA, U7 small nuclear 22 
pseudogene 
ENST00000516673 0.0441043 0.0441043 0.655306 -1.526 8.4118 0.55771 0.265204 1 
17068782 MCM4 Minichromosome 
maintenance complex 
component 4 
NM_005914 0.0380317 0.0380317 0.650849 -1.53646 9.30193 0.575867 0.247633 1 
16920876 LOC100128310 Uncharacterized 
LOC100128310  
AK097866 0.0298676 0.0298676 0.650784 -1.53661 10.9055 0.576132 0.211318 1 
16916158 MIR941-1 MicroRNA 941-1 NR_030637 0.0324546 0.0324546 0.649299 -1.54012 10.332 0.582276 0.225427 1 
16910854 EBF4 Early B-cell factor 4 NM_001110514 0.0363486 0.0363486 0.648818 -1.54126 9.58756 0.584278 0.243765 1 
16780268 LOC100652869 Uncharacterized 
LOC100652869 
XR_171060 0.00617201 0.00617201 0.648237 -1.54265 27.8737 0.586701 0.084194 1 
17063975 CTAGE6 CTAGE family, member 6 NM_178561 0.0381603 0.0381603 0.64822 -1.54269 9.2809 0.586772 0.252895 1 
16708061 ZFYVE27 Zinc finger, FYVE domain 
containing 27 
NM_144588 0.0459347 0.0459347 0.647782 -1.54373 8.17896 0.588601 0.287861 1 
16914117 PABPC1L Poly(A) binding protein, 
cytoplasmic 1-like  
NM_001124756 0.0426532 0.0426532 0.646879 -1.54588 8.60699 0.592391 0.275307 1 
17057897 VOPP1 Vesicular, overexpressed in 
cancer, prosurvival protein 1 
NM_030796 0.0118575 0.0118575 0.64688 -1.54588 19.2008 0.592387 0.123409 1 
16671049 LCE2A Late cornified envelope 2A NM_178428 0.0158713 0.0158713 0.646083 -1.54779 16.1562 0.595745 0.147496 1 
16681127 HES2 Hairy and enhancer of split 2  NM_019089 0.0345635 0.0345635 0.646077 -1.5478 9.91312 0.595768 0.240396 1 
16728141 GAL Galanin/GMAP 
prepropeptide 






16928428 ADRBK2 Adrenergic, beta, receptor 
kinase 2 
NM_005160 0.0292868 0.0292868 0.644519 -1.55154 11.0446 0.602373 0.21816 1 
16664438 LINC00853 Long intergenic non-protein 
coding RNA 853 
NR_047498 0.00392191 0.00392191 0.644396 -1.55184 35.8023 0.602895 0.067358 1 
17092187 RLN1 Relaxin 1 NM_006911 0.00601878 0.00601878 0.641863 -1.55797 28.2677 0.613754 0.086849 1 
16798951 GREM1 Gremlin 1, DAN family 
BMP antagonist  
ENST00000300177 0.0467654 0.0467654 0.641705 -1.55835 8.07785 0.614435 0.304256 1 
17118281 LOC100506458 Putative uncharacterized 
protein LOC65996-like 
AK097034 0.039974 0.039974 0.640889 -1.56033 8.99512 0.617963 0.274799 1 
16822548 NARFL Nuclear prelamin A 
recognition factor-like 
NM_022493 0.0279976 0.0279976 0.640866 -1.56039 11.3689 0.618064 0.217458 1 
17016363 HIST1H3B Histone cluster 1, H3b NM_003537 0.0075093 0.0075093 0.63827 -1.56673 24.9645 0.62939 0.100846 1 
16932782 PI4KAP2 Phosphatidylinositol 4-
kinase, catalytic, alpha 
pseudogene 2 
NR_003700 0.0100812 0.0100812 0.637439 -1.56878 21.099 0.633052 0.120015 1 
17049667 TRIM56 Tripartite motif containing 
56 
ENST00000306085 0.0303044 0.0303044 0.636306 -1.57157 10.8035 0.638063 0.236242 1 
17004339 PSMG4 Proteasome (prosome, 
macropain) assembly 
chaperone 4  
AK096543 0.0496349 0.0496349 0.635179 -1.57436 7.7485 0.643074 0.331973 1 
16858263 QTRT1 Queuine tRNA-
ribosyltransferase 1  
NM_031209 0.0424447 0.0424447 0.634868 -1.57513 8.63587 0.644462 0.298505 1 
16739317 MTA2 Metastasis associated 1 
family, member 2 
NM_004739 0.0435419 0.0435419 0.634777 -1.57536 8.48628 0.644872 0.30396 1 
17101605 TCEANC Transcription elongation 
factor A (SII) N-terminal and 
central d 
NM_152634 0.0225791 0.0225791 0.633589 -1.57831 13.024 0.650197 0.199692 1 
17081850 GPR20 G protein-coupled receptor 
20 
NM_005293 0.0215886 0.0215886 0.633532 -1.57845 13.3924 0.650454 0.194276 1 
17117486 LOC387720 Uncharacterized LOC387720 AK127642 0.0166138 0.0166138 0.632389 -1.58131 15.7179 0.655612 0.166844 1 
16910645 FAM110A Family with sequence 
similarity 110, member A 
ENST00000381941 0.0166047 0.0166047 0.631965 -1.58237 15.7231 0.657532 0.167278 1 
17104947 SLC16A2 Solute carrier family 16, 
member 2 (thyroid hormone 
transporter 






17073290 GPIHBP1 Glycosylphosphatidylinositol 
anchored high density 
lipoprotein  
NM_178172 0.00588708 0.00588708 0.630145 -1.58694 28.6186 0.66582 0.093061 1 
16864084 CCDC155 Coiled-coil domain 
containing 155 
NM_144688 0.0240895 0.0240895 0.62944 -1.58871 12.5067 0.669053 0.213982 1 
16822801 NME3 NME/NM23 nucleoside 
diphosphate kinase 3 
ENST00000219302 0.0194712 0.0194712 0.627934 -1.59252 14.2725 0.675997 0.189455 1 
16857242 LOC100131094 Uncharacterized 
LOC100131094 
NM_001242901 0.0406088 0.0406088 0.626812 -1.59537 8.89968 0.6812 0.306168 1 
16757873 SIRT4 Sirtuin 4 NM_012240 0.0206501 0.0206501 0.625628 -1.59839 13.7657 0.686728 0.199547 1 
16753962 MIR3913-1 MicroRNA 3913-1 NR_037475 0.0485542 0.0485542 0.623832 -1.603 7.86908 0.695175 0.353371 1 
17013520 SASH1 SAM and SH3 domain 
containing 1 
NM_015278 0.049728 0.049728 0.621149 -1.60992 7.7383 0.707932 0.365937 1 
16806538 GOLGA8R Golgin A8 family, member R  ENST00000544495 0.032288 0.032288 0.621122 -1.60999 10.3668 0.708062 0.273203 1 
16729290 TSKU Tsukushi, small leucine rich 
proteoglycan  
NM_001258210 0.00953557 0.00953557 0.618969 -1.61559 21.7862 0.718422 0.131904 1 
16990146 WDR55 WD repeat domain 55 ENST00000358337 0.0256844 0.0256844 0.61618 -1.6229 12.011 0.732015 0.243782 1 
16715223 C10orf105 Chromosome 10 open 
reading frame 105 
NM_001164375 0.0457697 0.0457697 0.615783 -1.62395 8.19937 0.733965 0.358059 1 
17110700 KCND1 Potassium voltage-gated 
channel, Shal-related 
subfamily, member 1 
NM_004979 0.00600062 0.00600062 0.613899 -1.62893 28.3154 0.74327 0.104999 1 
16857630 PNPLA6 Patatin-like phospholipase 
domain containing 6 
NM_001166111 0.00386235 0.00386235 0.613384 -1.6303 36.1026 0.74583 0.082635 1 
16774623 LRCH1 Leucine-rich repeats and 
calponin homology (CH) 
domain cont 
ENST00000311191 0.00434677 0.00434677 0.613272 -1.6306 33.8429 0.746387 0.088218 1 
16795755 TTC7B Tetratricopeptide repeat 
domain 7B 
NM_001010854 0.0133899 0.0133899 0.61314 -1.63095 17.8772 0.747042 0.16715 1 
17033279 MICA MHC class I polypeptide-
related sequence A  
NR_036523 0.0103894 0.0103894 0.610552 -1.63786 20.735 0.76002 0.146616 1 
16855673 BCL2 B-cell CLL/lymphoma 2  ENST00000398117 0.0204666 0.0204666 0.60862 -1.64306 13.8417 0.769815 0.222462 1 
17060983 POLR2J Polymerase (RNA) II (DNA 
directed) polypeptide J, 
13.3kDa 






16741549 ALG1L9P Asparagine-linked 
glycosylation 1-like 9, 
pseudogene 
NR_073388 0.0140843 0.0140843 0.60178 -1.66174 17.35 0.805255 0.18565 1 
16807195 RASGRP1 RAS guanyl releasing 
protein 1 (calcium and DAG-
regulated) 
NM_005739 0.0479793 0.0479793 0.598616 -1.67052 7.9349 0.822058 0.414401 1 
16662108 TSSK3 Testis-specific serine kinase 
3 
NM_052841 0.021244 0.021244 0.59463 -1.68172 13.5266 0.843605 0.249466 1 
17003077 RNF44 Ring finger protein 44 NM_014901 4.37E-05 4.37E-05 0.592431 -1.68796 367.338 0.855672 0.009318 1 
17049702 ZNHIT1 Zinc finger, HIT-type 
containing 1  
NM_006349 0.0394297 0.0394297 0.592168 -1.68871 9.0788 0.857124 0.377638 1 
16797285 BRF1 RNA polymerase III 
transcription initiation factor 
90 
ENST00000546474 0.0421155 0.0421155 0.590962 -1.69216 8.6819 0.86381 0.397982 1 
16867657 PSPN Persephin NM_004158 0.0382368 0.0382368 0.589907 -1.69518 9.26843 0.869686 0.375333 1 
17041421 ZBTB9  Zinc finger and BTB 
domain containing 9 
ENST00000395064 0.0438848 0.0438848 0.587237 -1.70289 8.44069 0.884702 0.419256 1 
17032957 HLA-L Major histocompatibility 
complex, class I, L 
(pseudogene) 
ENST00000491405 0.0169509 0.0169509 0.585126 -1.70903 15.5285 0.896712 0.230984 1 
16842070 TOP3A Topoisomerase (DNA) III 
alpha  
NM_004618 0.0292841 0.0292841 0.584694 -1.7103 11.0453 0.899185 0.325635 1 
16795567 KCNK10 Potassium channel, 
subfamily K, member 10  
NM_021161 0.00668772 0.00668772 0.581317 -1.72023 26.6486 0.918699 0.137898 1 
16946016 PCCB Propionyl CoA carboxylase, 
beta polypeptide 
NM_000532 0.0413342 0.0413342 0.580743 -1.72193 8.79333 0.922048 0.419431 1 
16817212 RNA5SP405 RNA, 5S ribosomal 
pseudogene 405 
ENST00000363059 0.0341409 0.0341409 0.578528 -1.72853 9.99393 0.935064 0.374253 1 
16848961 TRIM65 Tripartite motif containing 
65  
NM_173547 0.0321262 0.0321262 0.578186 -1.72955 10.4009 0.937083 0.360384 1 
16748304 GABARAPL1 GABA(A) receptor-
associated protein like 1 
ENST00000266458 0.0218829 0.0218829 0.576816 -1.73365 13.2803 0.945216 0.284697 1 
16995888 LOC648987 Uncharacterized LOC648987 ENST00000503152 0.03522 0.03522 0.576709 -1.73398 9.7905 0.945855 0.386438 1 
16859874 UPF1 UPF1 regulator of nonsense 
transcripts homolog  






17057813 COBL Cordon-bleu WH2 repeat 
protein 
NM_015198 0.0257134 0.0257134 0.571697 -1.74918 12.0024 0.976094 0.325301 1 
16916221 TCEA2 Transcription elongation 
factor A (SII), 2  
BC098585 0.00983256 0.00983256 0.569842 -1.75487 21.4051 0.987474 0.184531 1 
16814619 TPSAB1 Tryptase alpha/beta 1  NM_003294 0.0458649 0.0458649 0.567337 -1.76262 8.18758 1.003 0.490012 1 
16902679 LOC389033 Placenta-specific 9 
pseudogene 
NR_026740 0.0474685 0.0474685 0.566148 -1.76632 7.99438 1.01044 0.505577 1 
16894824 OSR1 Odd-skipped related 1 NM_145260 0.00987536 0.00987536 0.558694 -1.78989 21.3516 1.05807 0.19822 1 
17111464 FGD1 FYVE, RhoGEF and PH 
domain containing 1 
NM_004463 0.0119947 0.0119947 0.558614 -1.79014 19.0721 1.05859 0.222019 1 
16865693 NAT14 N-acetyltransferase 14 
(GCN5-related, putative) 
NM_020378 0.0282187 0.0282187 0.557613 -1.79336 11.3117 1.06512 0.376645 1 
16843376 NLE1 Notchless homolog 1 
(Drosophila)  
NM_001014445 0.0354797 0.0354797 0.552428 -1.81019 9.74294 1.09947 0.45139 1 
16723100 MIR610 MicroRNA 610  NR_030341 0.00238537 0.00238537 0.552107 -1.81124 46.8369 1.10162 0.094082 1 
16722295 RNA5SP332 RNA, 5S ribosomal 
pseudogene 332 
ENST00000391063 0.0278526 0.0278526 0.546166 -1.83095 11.4068 1.14212 0.400505 1 
16711484 IL15RA Interleukin 15 receptor, 
alpha 
NM_001243539 0.0291015 0.0291015 0.545693 -1.83253 11.0899 1.14539 0.413128 1 
16808340 CATSPER2P1 Cation channel, sperm 
associated 2 pseudogene 1  
NR_002318 0.040096 0.040096 0.544994 -1.83488 8.9766 1.15024 0.512551 1 
17000121 LOC340073 Uncharacterized LOC340073 NR_037895 0.00807635 0.00807635 0.544351 -1.83705 23.9553 1.15472 0.192813 1 
16758186 PSMD9 Proteasome (prosome, 
macropain) 26S subunit, 
non-ATPase, 9 
NM_002813 0.0448884 0.0448884 0.534256 -1.87176 8.31029 1.2269 0.590545 1 
16717706 POLL Polymerase (DNA directed), 
lambda 
NM_001174084 0.0241437 0.0241437 0.533809 -1.87333 12.4891 1.23018 0.394001 1 
16855049 TCEB3C Transcription elongation 
factor B polypeptide 3C 
(elongin A3) 
NM_145653 0.020991 0.020991 0.53241 -1.87825 13.6272 1.24048 0.364119 1 
17047138 GTF2IRD1 GTF2I repeat domain 
containing 1  
NM_016328 0.0474343 0.0474343 0.531654 -1.88092 7.99839 1.24609 0.623169 1 
16891225 TUBA4B Tubulin, alpha 4b 
(pseudogene) 






16673883 C1orf105 Chromosome 1 open reading 
frame 105 
ENST00000367727 0.00242651 0.00242651 0.522491 -1.91391 46.4101 1.31561 0.11339 1 
16952244 ACAA1 Acetyl-CoA acyltransferase 
1  
NM_001607 0.0418213 0.0418213 0.514133 -1.94502 8.72349 1.38179 0.633593 1 
16812083 LOC91450 Uncharacterized LOC91450 NR_026998 0.00067377 0.00067377 0.490577 -2.03842 91.0427 1.58348 0.069571 1 
17056506 RP9P Retinitis pigmentosa 9 
pseudogene 
NR_003500 0.00704435 0.00704435 0.489133 -2.04443 25.8814 1.59661 0.246759 1 
17046559 INTS4L2 Integrator complex subunit 
4-like 2 
NR_027392 0.0391764 0.0391764 0.483515 -2.06819 9.11834 1.64861 0.723206 1 
17035366 LOC100996357 Uncharacterized 
LOC100996357 
ENST00000436256 0.0047095 0.0047095 0.482577 -2.07221 32.3844 1.65744 0.20472 1 
17052679 IL23A Interleukin 23, alpha subunit 
p19  
AY532914 0.0291177 0.0291177 0.481004 -2.07899 11.0859 1.67232 0.603403 1 
17108719 ASMTL Acetylserotonin O-
methyltransferase-like 
ENST00000463763 0.00620783 0.00620783 0.480388 -2.08165 27.7837 1.67818 0.241606 1 
16782207 LRP10 Low density lipoprotein 
receptor-related protein 10  
ENST00000359591 0.0141519 0.0141519 0.477584 -2.09387 17.3007 1.70509 0.394225 1 
16862484 CCDC97 Coiled-coil domain 
containing 97  
NM_052848 0.0355213 0.0355213 0.457644 -2.18511 9.73536 1.90757 0.78377 1 
16789743 CRIP1 Cysteine-rich protein 1 
(intestinal)  
NM_001311 0.0413088 0.0413088 0.436936 -2.28866 8.79701 2.14027 0.973179 1 
16771801 HCAR3 Hydroxycarboxylic acid 
receptor 3 
NM_006018 0.0339516 0.0339516 0.429125 -2.33032 10.0306 2.23454 0.891089 1 
17051157 RNU7-27P RNA, U7 small nuclear 27 
pseudogene 
ENST00000459281 0.00793745 0.00793745 0.413836 -2.41642 24.1925 2.43029 0.401826 1 
16691129 AP4B1 Adaptor-related protein 
complex 4, beta 1 subunit 
NM_001253852 0.0497166 0.0497166 0.356928 -2.80168 7.73954 3.3136 1.71256 1 
16840284 C1QBP Complement component 1, q 
subcomponent binding 
protein 




Supplementary Table 2 
Pathway Name Enrichment 
Score 
Genes 
Fatty acid degradation 3.51594 ACAA1, GCDH 
Valine, leucine and isoleucine degradation 3.51594 ACAA1, PCCB 
Taste transduction 3.209 TAS2R19, TAS2R31 
Adipocytokine signaling pathway 2.67827 POMC, SLC2A4 
Non-homologous end-joining 2.56127 POLL 
Olfactory transduction 2.31763 ADRBK2, OR2T4, OR5A1, OR14I1, 
OR51F2 
mRNA surveillance pathway 2.22979 PABPC1L, UPF1 
Biosynthesis of unsaturated fatty acids 2.10542 ACAA1 
T cell receptor signaling pathway 2.01024 MAP3K8, RASGRP1 
Pyrimidine metabolism 1.99475 NME3, POLR2J 
Glyoxylate and dicarboxylate metabolism 1.98074 PCCB 
HIF-1 signaling pathway 1.97945 BCL2, HIF1A 
alpha-Linolenic acid metabolism 1.94286 ACAA1 
Nicotinate and nicotinamide metabolism 1.83835 NMRK1 
Homologous recombination 1.83835 TOP3A 
Cell cycle 1.73155 CDC14B, MCM4 
Propanoate metabolism 1.71654 PCCB 
RNA polymerase 1.71654 POLR2J 
Regulation of autophagy 1.66176 GABARAPL1 
African trypanosomiasis 1.66176 HPR 
Base excision repair 1.66176 POLL 
Natural killer cell mediated cytotoxicity 1.64724 KIR3DL1, MICA 
FoxO signaling pathway 1.62423 GABARAPL1, SLC2A4 
DNA replication 1.61043 MCM4 
Systemic lupus erythematosus 1.59054 HIST1H3B, HIST2H4B 
Tryptophan metabolism 1.5167 GCDH 
Graft-versus-host disease 1.45308 KIR3DL1 
Basal transcription factors 1.4134 GTF2IRD1 
Jak-STAT signaling pathway 1.37955 IL15RA, IL23A 
Fatty acid metabolism 1.35751 ACAA1 
Type II diabetes mellitus 1.35751 SLC2A4 
Lysine degradation 1.33977 GCDH 
Intestinal immune network for IgA production 1.33977 IL15RA 
RNA transport 1.30902 PABPC1L, UPF1 
Amyotrophic lateral sclerosis (ALS) 1.30551 BCL2 
Fanconi anemia pathway 1.27279 TOP3A 
Purine metabolism 1.26732 NME3, POLR2J 
Tuberculosis 1.19646 BCL2, IL23A 
Alcoholism 1.19646 HIST1H3B, HIST2H4B 
mTOR signaling pathway 1.16873 HIF1A 
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Herpes simplex infection 1.14479 C1QBP, GTF2IRD1 
Colorectal cancer 1.14163 BCL2 
Renal cell carcinoma 1.09045 HIF1A 
PPAR signaling pathway 1.06625 ACAA1 
Inflammatory bowel disease (IBD) 1.06625 IL23A 
Epstein-Barr virus infection 1.0367 BCL2, POLR2J 
RNA degradation 1.00939 PABPC1L 
Gastric acid secretion 0.987977 KCNK10 
Pertussis 0.977536 IL23A 
Antigen processing and presentation 0.977536 KIR3DL1 
Peroxisome 0.927797 ACAA1 
Apoptosis 0.881805 BCL2 
Small cell lung cancer 0.881805 BCL2 
GABAergic synapse 0.855826 GABARAPL1 
Prostate cancer 0.847418 BCL2 
Glycerophospholipid metabolism 0.839131 PNPLA6 
Morphine addiction 0.83096 ADRBK2 
NF-kappa B signaling pathway 0.83096 Bcl2 
Rheumatoid arthritis 0.83096 IL23A 
Carbon metabolism 0.776864 PCCB 
Melanogenesis 0.762334 POMC 
MAPK signaling pathway 0.743159 MAP3K8, RASGRP1 
Toll-like receptor signaling pathway 0.720971 MAP3K8 
Cytokine-cytokine receptor interaction 0.709588 IL15RA, IL23A 
TNF signaling pathway 0.701456 MAP3K8 
Cholinergic synapse 0.688846 BCL2 
Glutamatergic synapse 0.670505 ADRBK2 
Neurotrophin signaling pathway 0.641379 BCL2 
Toxoplasmosis 0.641379 BCL2 
Lysosome 0.630202 AP4B1 
MicroRNAs in cancer 0.615074 BCL2, MIR34B 
Insulin signaling pathway 0.535764 SLC2A4 
Hepatitis B 0.509766 BCL2 
Adrenergic signaling in cardiomyocytes 0.501455 BCL2 
Pathways in cancer 0.499403 BCL2, HIF1A 
Protein processing in endoplasmic reticulum 0.433732 BCL2 
Transcriptional misregulation in cancer 0.394724 HIST1H3B 
Huntington's disease 0.388639 POLR2J 
Chemokine signaling pathway 0.368195 ADRBK2 
Endocytosis 0.328479 ADRBK2 
Focal adhesion 0.323569 BCL2 
Viral carcinogenesis 0.321145 HIST2H4B 
Regulation of actin cytoskeleton 0.30475 FGD1 
Proteoglycans in cancer 0.282953 HIF1A 
 217 
 
Ras signaling pathway 0.276762 RASGRP1 
HTLV-I infection 0.213123 IL15RA 
Neuroactive ligand-receptor interaction 0.191498 P2RY8 
Metabolic pathways 0.135322 ACAA1, GCDH, NME3, PCCB, 
POLR2J 






Supplementary Table 3 
Protein IDs Peptide counts 
(all) 










Q07021 8 Complement component 1 Q 
subcomponent-binding protein, 
mitochondrial 
C1QBP 51.4 31.362 282 67.376 
Q9H6W3;Q9H6W3-2 19;11 Bifunctional lysine-specific demethylase 
and histidyl-hydroxylase NO66 
NO66 44 71.085 641 59.393 
Q7Z7K6;Q7Z7K6-3;Q7Z7K6-2 7;6;5 Centromere protein V CENPV 37.1 29.946 275 51.369 
P56182;D6RE82 6;2 Ribosomal RNA processing protein 1 
homolog A 
RRP1 14.8 52.839 461 45.853 
Q8NFW8;Q8NFW8-
2;F5H296;F5GYM0 
15;8;3;3 N-acylneuraminate cytidylyltransferase CMAS 42.6 48.379 434 45.504 
Q86V81;E9PB61 7;6 THO complex subunit 4 ALYREF 34.2 26.888 257 40.451 
Q8TDD1;Q8TDD1-
2;F8VRX4;H0YHH7 








Melanoma-associated antigen D2 MAGED2 31.8 64.953 606 33.31 
Q9Y6H1;Q5T1J5 3;2 Coiled-coil-helix-coiled-coil-helix domain-
containing protein 2, 
mitochondrial;Putative coiled-coil-helix-




31.1 15.512 151 24.503 
P67809;A0A087X1S2;H0Y449;C9J5V
9;Q9Y2T7 
13;10;9;6;4 Nuclease-sensitive element-binding protein 
1 
YBX1 51.2 35.924 324 20.563 
Q9BX40;Q5TBQ0;Q9BX40-
2;Q5TBQ1;Q5TBP9;Q9BX40-3 






Q96JP5;Q96JP5-2;H3BTR0 8;7;5 E3 ubiquitin-protein ligase ZFP91 ZFP91;ZFP91-
CNTF 
17 63.444 570 20.072 
P62081;B5MCP9 8;6 40S ribosomal protein S7 RPS7 40.7 22.127 194 19.184 
P0CW22;P08708;H0YN88;A0A075B7
16;H0YN73;H3BNC9 
8;8;7;7;5;2 40S ribosomal protein S17-like;40S 
ribosomal protein S17 




5;5;5;5;5;5;5;5 60S ribosomal protein L28 RPL28 59.4 7.888 69 15.03 
P51116;I3L1Z2 12;2 Fragile X mental retardation syndrome-
related protein 2 













Fragile X mental retardation syndrome-
related protein 1 
FXR1 31.6 69.72 621 13.774 
Q13724-2;Q13724;C9J8D4;C9JDQ1 6;6;3;1 Mannosyl-oligosaccharide glucosidase MOGS 11.2 80.702 731 11.476 
P48634-2;P48634-3;P48634;P48634-4 13;13;13;11 Protein PRRC2A PRRC2A 8.2 227.84 2144 10.753 
E9PLL6;P46776;E9PJD9;E9PLX7 4;4;3;1 60S ribosomal protein L27a RPL27A 38 12.201 108 10.532 
P62854;Q5JNZ5 3;2 40S ribosomal protein S26;Putative 40S 
ribosomal protein S26-like 1 
RPS26;RPS26P
11 
31.3 13.015 115 10.49 
Q8NC51-4;Q8NC51-3;Q8NC51-
2;Q8NC51 
9;9;9;9 Plasminogen activator inhibitor 1 RNA-
binding protein 
SERBP1 29.5 42.426 387 10.434 









Protein PRRC2C PRRC2C 5.5 301.57 2752 8.9975 








3;3;3;3;3;1 60S ribosomal protein L23a RPL23A 14.7 17.695 156 6.4511 
P62753;A2A3R7;A2A3R5 5;3;3 40S ribosomal protein S6 RPS6 25.7 28.68 249 5.649 
Q2NL82;I3L1Q5 8;3 Pre-rRNA-processing protein TSR1 
homolog 
TSR1 10.8 91.809 804 5.5874 
P62263;H0YB22;E5RH77 6;5;5 40S ribosomal protein S14 RPS14 37.7 16.273 151 4.9595 







ATP-dependent RNA helicase 




33.6 71.354 646 4.3595 












rRNA 2-O-methyltransferase fibrillarin FBL 34.9 33.784 321 3.4512 
P62829;C9JD32;J3KT29;B9ZVP7;J3K
TJ3;J3QQT9 
5;4;4;3;2;1 60S ribosomal protein L23 RPL23 44.3 14.865 140 3.0869 
Q00839-2;Q00839;Q5RI18 7;7;3 Heterogeneous nuclear ribonucleoprotein U HNRNPU 8.4 88.979 806 2.3757 
 
 
